<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25154027</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0852</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of cancer (Oxford, England : 1990)</Title>
                <ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0959-8049(14)00873-9</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.ejca.2014.07.021</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">SMIP-016, a new anti-tumour agent, is a mouse/human chimeric fusion protein built on the ADAPTIR??? (modular protein therapeutic) platform targeting human CD37. In this study, for the first time, we examined pro-apoptotic activity of SMIP-016 in combination with monoclonal anti-CD20 antibody, ofatumumab (HuMax-CD20) in de novo chronic lymphocytic leukaemia (CLL) cells and in different B-cell neoplasm-derived lines. In CLL cells SMIP-016 exerted significant cytotoxicity (versus control - p=0.01). In the in vitro models, SMIP-016 was also distinctly active against Raji line (Burkitt lymphoma; BL) (versus control - p=0.007), Riva-1 line (diffuse large B-cell lymphoma; DLBCL) (versus control - p=0.002) and RPMI 8226 line (multiple myeloma cells; MM) (versus control - p=0.03). In studies combining SMIP-016 and ofatumumab, the cytotoxicity against CLL cells was significantly higher than the agents used alone (p&lt;0.03). Remarkably enhanced cytotoxic activity of SMIP-016 and ofatumumab in combination was also observed in Raji and Riva-1 cell lines (p&lt;0.01 and p&lt;0.003, respectively). Importantly, both agents induced cytotoxicity at very low concentrations which suggests that potential side-effects may be decreased in clinical practice. The mechanism responsible for cytotoxicity of SMIP-016 in all the examined models was connected with caspase-dependent apoptosis. In majority of cell types SMIP-016 induced overexpression of Bax protein, as well as downregulation of Bcl-2, cIAP1 (p&lt;0.03) and Smac/DIABLO (p&lt;0.003) apoptosis-regulating proteins. In conclusion, our study demonstrated high pro-apoptotic activity of SMIP-016, especially in combination with ofatumumab, against ex vivo CLL cells, and BL or DLBCL in vitro cell lines. Thus, further preclinical studies in in vivo models are warranted, as this combination may be a promising therapeutic concept for treatment of those malignancies.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Smolewski</LastName>
                    <ForeName>Piotr</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Experimental Hematology, Medical University of Lodz, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Robak</LastName>
                    <ForeName>Pawel</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Experimental Hematology, Medical University of Lodz, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cebula-Obrzut</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Experimental Hematology, Medical University of Lodz, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Misiewicz</LastName>
                    <ForeName>Ma??gorzata</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Hematology, Medical University of Lodz, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>M??dra</LastName>
                    <ForeName>Aleksandra</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Experimental Hematology, Medical University of Lodz, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Majchrzak</LastName>
                    <ForeName>Agata</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Experimental Hematology, Medical University of Lodz, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Witkowska</LastName>
                    <ForeName>Magdalena</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Experimental Hematology, Medical University of Lodz, Poland; Department of Hematology, Medical University of Lodz, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Stromatt</LastName>
                    <ForeName>Scott</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Emergent Biosolutions, Seattle, WA, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Robak</LastName>
                    <ForeName>Tadeusz</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Hematology, Medical University of Lodz, Poland.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Eur J Cancer</MedlineTA>
            <NlmUniqueID>9005373</NlmUniqueID>
            <ISSNLinking>0959-8049</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">B-cell malignancies</Keyword>
            <Keyword MajorTopicYN="N">Chronic lymphocytic leukaemia</Keyword>
            <Keyword MajorTopicYN="N">Ofatumumab</Keyword>
            <Keyword MajorTopicYN="N">SMIP-016</Keyword>
            <Keyword MajorTopicYN="N">TRU-016</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0959-8049(14)00873-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejca.2014.07.021</ArticleId>
            <ArticleId IdType="pubmed">25154027</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153994</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tau Overexpression Impacts a Neuroinflammation Gene Expression Network Perturbed in Alzheimer's Disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e106050</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0106050</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Filamentous inclusions of the microtubule-associated protein, tau, define a variety of neurodegenerative diseases known as tauopathies, including Alzheimer's disease (AD). To better understand the role of tau-mediated effects on pathophysiology and global central nervous system function, we extensively characterized gene expression, pathology and behavior of the rTg4510 mouse model, which overexpresses a mutant form of human tau that causes Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). We found that the most predominantly altered gene expression pathways in rTg4510 mice were in inflammatory processes. These results closely matched the causal immune function and microglial gene-regulatory network recently identified in AD. We identified additional gene expression changes by laser microdissecting specific regions of the hippocampus, which highlighted alterations in neuronal network activity. Expression of inflammatory genes and markers of neuronal activity changed as a function of age in rTg4510 mice and coincided with behavioral deficits. Inflammatory changes were tau-dependent, as they were reversed by suppression of the tau transgene. Our results suggest that the alterations in microglial phenotypes that appear to contribute to the pathogenesis of Alzheimer's disease may be driven by tau dysfunction, in addition to the direct effects of beta-amyloid.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Wes</LastName>
                    <ForeName>Paul D</ForeName>
                    <Initials>PD</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Easton</LastName>
                    <ForeName>Amy</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Corradi</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Applied Genomics, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Barten</LastName>
                    <ForeName>Donna M</ForeName>
                    <Initials>DM</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Devidze</LastName>
                    <ForeName>Nino</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>DeCarr</LastName>
                    <ForeName>Lynn B</ForeName>
                    <Initials>LB</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Truong</LastName>
                    <ForeName>Amy</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Applied Genomics, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>He</LastName>
                    <ForeName>Aiqing</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Applied Genomics, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Barrezueta</LastName>
                    <ForeName>Nestor X</ForeName>
                    <Initials>NX</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Polson</LastName>
                    <ForeName>Craig</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bourin</LastName>
                    <ForeName>Clotilde</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Flynn</LastName>
                    <ForeName>Marianne E</ForeName>
                    <Initials>ME</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Keenan</LastName>
                    <ForeName>Stefanie</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lidge</LastName>
                    <ForeName>Regina</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Meredith</LastName>
                    <ForeName>Jere</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Natale</LastName>
                    <ForeName>Joanne</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sankaranarayanan</LastName>
                    <ForeName>Sethu</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cadelina</LastName>
                    <ForeName>Greg W</ForeName>
                    <Initials>GW</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Albright</LastName>
                    <ForeName>Charlie F</ForeName>
                    <Initials>CF</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cacace</LastName>
                    <ForeName>Angela M</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>Department of Neuroscience, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0106050</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-02606</ArticleId>
            <ArticleId IdType="pubmed">25153994</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153991</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Impact of Age-Dependent Adventitia Inflammation on Structural Alteration of Abdominal Aorta in Hyperlipidemic Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105739</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0105739</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The adventitia is suggested to contribute to vascular remodeling; however, the site-selective inflammatory responses in association with the development of atherosclerosis remain to be elucidated.</AbstractText>
                <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Wild-type or apolipoprotein E knockout male C57BL/6J background mice were fed standard chow for 16, 32, and 52 weeks, and the morphology of the aortic arch, descending aorta, and abdominal aorta was compared. Atheromatous plaque formation progressed with age, particularly in the aortic arch and abdominal aorta but not in the descending aorta. In addition, we found that the numbers of macrophages, T-lymphocytes, and microvessels, assessed by anti-F4/80, CD3, and CD31 antibodies, were higher in the adventitia of the abdominal aorta at 52 weeks. These numbers were positively correlated with plaque formation, but negatively correlated with elastin content, resulting in the enlargement of the total vessel area. In aortic tissues, interleukin-6 levels increased in the atheromatous plaque with age, whereas the level of regulated on activation, normal T cell expressed and secreted (RANTES) increased with age, and compared with other sites, it was particularly distributed in inflammatory cells in the adventitia of the abdominal aorta.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study suggests that adventitial inflammation contributes to the age-dependent structural alterations, and that the activation/inactivation of cytokines/chemokines is involved in the process.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sakamoto</LastName>
                    <ForeName>Sumiharu</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tsuruda</LastName>
                    <ForeName>Toshihiro</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hatakeyama</LastName>
                    <ForeName>Kinta</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Imamura</LastName>
                    <ForeName>Takuroh</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Internal Medicine, Koga General Hospital, Miyazaki, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Asada</LastName>
                    <ForeName>Yujiro</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kitamura</LastName>
                    <ForeName>Kazuo</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105739</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-00962</ArticleId>
            <ArticleId IdType="pubmed">25153991</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153903</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2139</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Brain, behavior, and immunity</Title>
                <ISOAbbreviation>Brain Behav. Immun.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0889-1591(14)00419-X</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbi.2014.08.002</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Interleukin-33 (IL-33) is a member of the interleukin-1 cytokine family and highly expressed in the na??ve mouse brain and spinal cord. Despite the fact that IL-33 is known to be inducible by various inflammatory stimuli, its cellular localization in the central nervous system and role in pathological conditions is controversial. Administration of recombinant IL-33 has been shown to attenuate experimental autoimmune encephalomyelitis progression in one study, yet contradictory reports also exist. Here we investigated for the first time the pattern of IL-33 expression in the contused mouse spinal cord and demonstrated that after spinal cord injury (SCI) IL-33 was up-regulated and exhibited a nuclear localization predominantly in astrocytes. Importantly, we found that treatment with recombinant IL-33 alleviated secondary damage by significantly decreasing tissue loss, demyelination and astrogliosis in the contused mouse spinal cord, resulting in dramatically improved functional recovery. We identified both central and peripheral mechanisms of IL-33 action. In spinal cord, IL-33 treatment reduced the expression of pro-inflammatory tumor necrosis factor-alpha and promoted the activation of anti-inflammatory arginase-1 positive M2 microglia/macrophages, which chronically persisted in the injured spinal cord for up to at least 42 days after the treatment. In addition, IL-33 treatment showed a tendency towards reduced T-cell infiltration into the spinal cord. In the periphery, IL-33 treatment induced a shift towards the Th2 type cytokine profile and reduced the percentage and absolute number of cytotoxic, tumor necrosis factor-alpha expressing CD4+ cells in the spleen. Additionally, IL-33 treatment increased expression of T-regulatory cell marker FoxP3 and reduced expression of M1 marker iNOS in the spleen. Taken together, these results provide the first evidence that IL-33 administration is beneficial after CNS trauma. Treatment with IL33 may offer a novel therapeutic strategy for patients with acute contusion SCI.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Pomeshchik</LastName>
                    <ForeName>Yuriy</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Neurobiology, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kidin</LastName>
                    <ForeName>Iurii</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Department of Neurobiology, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Korhonen</LastName>
                    <ForeName>Paula</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Neurobiology, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Savchenko</LastName>
                    <ForeName>Ekaterina</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Neurobiology, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wojciechowski</LastName>
                    <ForeName>Sara</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Neurobiology, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kanninen</LastName>
                    <ForeName>Katja</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Neurobiology, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Koistinaho</LastName>
                    <ForeName>Jari</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Neurobiology, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland. Electronic address: jari.koistinaho@uef.fi.</Affiliation>
                </Author>
                <Author>
                    <LastName>Malm</LastName>
                    <ForeName>Tarja</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Neurobiology, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Brain Behav Immun</MedlineTA>
            <NlmUniqueID>8800478</NlmUniqueID>
            <ISSNLinking>0889-1591</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Astrocytes</Keyword>
            <Keyword MajorTopicYN="N">Cytokines</Keyword>
            <Keyword MajorTopicYN="N">IL-33</Keyword>
            <Keyword MajorTopicYN="N">Macrophages</Keyword>
            <Keyword MajorTopicYN="N">Neuroinflammation</Keyword>
            <Keyword MajorTopicYN="N">SCI</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0889-1591(14)00419-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbi.2014.08.002</ArticleId>
            <ArticleId IdType="pubmed">25153903</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153888</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Rhythmic Ganglion Cell Activity in Bleached and Blind Adult Mouse Retinas.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e106047</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0106047</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">In retinitis pigmentosa - a degenerative disease which often leads to incurable blindness- the loss of photoreceptors deprives the retina from a continuous excitatory input, the so-called dark current. In rodent models of this disease this deprivation leads to oscillatory electrical activity in the remaining circuitry, which is reflected in the rhythmic spiking of retinal ganglion cells (RGCs). It remained unclear, however, if the rhythmic RGC activity is attributed to circuit alterations occurring during photoreceptor degeneration or if rhythmic activity is an intrinsic property of healthy retinal circuitry which is masked by the photoreceptor's dark current. Here we tested these hypotheses by inducing and analysing oscillatory activity in adult healthy (C57/Bl6) and blind mouse retinas (rd10 and rd1). Rhythmic RGC activity in healthy retinas was detected upon partial photoreceptor bleaching using an extracellular high-density multi-transistor-array. The mean fundamental spiking frequency in bleached retinas was 4.3 Hz; close to the RGC rhythm detected in blind rd10 mouse retinas (6.5 Hz). Crosscorrelation analysis of neighbouring wild-type and rd10 RGCs (separation distance &lt;200 ??m) reveals synchrony among homologous RGC types and a constant phase shift (???70 msec) among heterologous cell types (ON versus OFF). The rhythmic RGC spiking in these retinas is driven by a network of presynaptic neurons. The inhibition of glutamatergic ganglion cell input or the inhibition of gap junctional coupling abolished the rhythmic pattern. In rd10 and rd1 retinas the presynaptic network leads to local field potentials, whereas in bleached retinas additional pharmacological disinhibition is required to achieve detectable field potentials. Our results demonstrate that photoreceptor bleaching unmasks oscillatory activity in healthy retinas which shares many features with the functional phenotype detected in rd10 retinas. The quantitative physiological differences advance the understanding of the degeneration process and may guide future rescue strategies.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Menzler</LastName>
                    <ForeName>Jacob</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Neurochip Research Group, Natural and Medical Sciences Institute at the University T??bingen, Reutlingen, Germany; Helmholtz Zentrum M??nchen, Deutsches Forschungszentrum f??r Gesundheit und Umwelt, Neuherberg, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Channappa</LastName>
                    <ForeName>Lakshmi</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Neurochip Research Group, Natural and Medical Sciences Institute at the University T??bingen, Reutlingen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zeck</LastName>
                    <ForeName>Guenther</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Neurochip Research Group, Natural and Medical Sciences Institute at the University T??bingen, Reutlingen, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0106047</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-14547</ArticleId>
            <ArticleId IdType="pubmed">25153888</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153885</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hsp70 Regulates Immune Response in Experimental Autoimmune Encephalomyelitis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105737</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0105737</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Heat shock protein (Hsp)70 is one of the most important stress-inducible proteins. Intracellular Hsp70 not only mediates chaperone-cytoprotective functions but can also block multiple steps in the apoptosis pathway. In addition, Hsp70 is actively released into the extracellular milieu, thereby promoting innate and adaptive immune responses. Thus, Hsp70 may be a critical molecule in multiple sclerosis (MS) pathogenesis and a potential target in this disease due to its immunological and cytoprotective functions. To investigate the role of Hsp70 in MS pathogenesis, we examined its immune and cytoprotective roles using both in vitro and in vivo experimental procedures. We found that Hsp70.1-deficient mice were more resistant to developing experimental autoimmune encephalomyelitis (EAE) compared with their wild-type (WT) littermates, suggesting that Hsp70.1 plays a critical role in promoting an effective myelin oligodendrocyte glycoprotein (MOG)-specific T cell response. Conversely, Hsp70.1-deficient mice that developed EAE showed an increased level of autoreactive T cells to achieve the same production of cytokines compared with the WT mice. Although a neuroprotective role of HSP70 has been suggested, Hsp70.1-deficient mice that developed EAE did not exhibit increased demyelination compared with the control mice. Accordingly, Hsp70 deficiency did not influence the vulnerability to apoptosis of oligodendrocyte precursor cells (OPCs) in culture. Thus, the immunological role of Hsp70 may be relevant in EAE, and specific therapies down-regulating Hsp70 expression may be a promising approach to reduce the early autoimmune response in MS patients.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Mansilla</LastName>
                    <ForeName>M Jos??</ForeName>
                    <Initials>MJ</Initials>
                    <Affiliation>Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi M??ltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain; Universitat Aut??noma de Barcelona, Bellaterra, Cerdanyola del Vall??s, Barcelona, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Costa</LastName>
                    <ForeName>Carme</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi M??ltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain; Universitat Aut??noma de Barcelona, Bellaterra, Cerdanyola del Vall??s, Barcelona, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Eixarch</LastName>
                    <ForeName>Herena</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi M??ltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain; Universitat Aut??noma de Barcelona, Bellaterra, Cerdanyola del Vall??s, Barcelona, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tepavcevic</LastName>
                    <ForeName>Vanja</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Sorbonne Universit??s UPMC Univ Paris 06, UM-75, ICM-GH Piti??-Salp??tri??re, Paris, France, Inserm, U1127, Paris, France, CNRS, UMR 7225, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Castillo</LastName>
                    <ForeName>Mireia</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi M??ltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain; Universitat Aut??noma de Barcelona, Bellaterra, Cerdanyola del Vall??s, Barcelona, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Martin</LastName>
                    <ForeName>Roland</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Neuroimmunology and Multiple Sclerosis Research, Neurology Clinic, University Hospital Z??rich, Z??rich, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lubetzki</LastName>
                    <ForeName>Catherine</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Sorbonne Universit??s UPMC Univ Paris 06, UM-75, ICM-GH Piti??-Salp??tri??re, Paris, France, Inserm, U1127, Paris, France, CNRS, UMR 7225, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Aigrot</LastName>
                    <ForeName>Marie-St??phane</ForeName>
                    <Initials>MS</Initials>
                    <Affiliation>Sorbonne Universit??s UPMC Univ Paris 06, UM-75, ICM-GH Piti??-Salp??tri??re, Paris, France, Inserm, U1127, Paris, France, CNRS, UMR 7225, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Montalban</LastName>
                    <ForeName>Xavier</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi M??ltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain; Universitat Aut??noma de Barcelona, Bellaterra, Cerdanyola del Vall??s, Barcelona, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Espejo</LastName>
                    <ForeName>Carmen</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi M??ltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain; Universitat Aut??noma de Barcelona, Bellaterra, Cerdanyola del Vall??s, Barcelona, Spain.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105737</ArticleId>
            <ArticleId IdType="pii">PONE-D-13-52389</ArticleId>
            <ArticleId IdType="pubmed">25153885</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153880</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1420-3049</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>19</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Molecules (Basel, Switzerland)</Title>
                <ISOAbbreviation>Molecules</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Copaiba Oil Suppresses Inflammatory Cytokines in Splenocytes of C57Bl/6 Mice Induced with Experimental Autoimmune Encephalomyelitis (EAE).</ArticleTitle>
            <Pagination>
                <MedlinePgn>12814-12826</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Experimental autoimmune encephalomyelitis (EAE) is a murine autoimmune disease used to study multiple sclerosis. We have investigated the immunomodulatory effects of copaiba oil (100, 50 and 25 ??g/mL) on NO, H2O2, TNF-??, IFN-?? and IL-17 production in cultured cells from EAE-mice. Copaiba oil (100 ??g/mL) inhibited H2O2, NO, IFN-?? TNF-?? and IL-17 production spontaneously or after ConA and MOG35-55 stimulation. It is suggested that copaiba oil acts on the mechanism of development of EAE by IFN-??, IL-17 and TNF-?? inhibition, modulating the immune response on both Th1 and Th17 cells.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Dias</LastName>
                    <ForeName>D??bora S</ForeName>
                    <Initials>DS</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences, Faculty of Pharmacy, Federal University of Juiz de Fora, Juiz de Fora, R. Jos?? Louren??o Kelmer s/n, Campus Universit??rio, 36036-900 Juiz de Fora, MG, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fontes</LastName>
                    <ForeName>L??via B A</ForeName>
                    <Initials>LB</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences, Faculty of Pharmacy, Federal University of Juiz de Fora, Juiz de Fora, R. Jos?? Louren??o Kelmer s/n, Campus Universit??rio, 36036-900 Juiz de Fora, MG, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Crotti</LastName>
                    <ForeName>Ant??nio E M</ForeName>
                    <Initials>AE</Initials>
                    <Affiliation>Departamento de Qu??mica, Faculdade de Filosofia, Ci??ncias e Letras de Ribeir??o Preto, Universidade de S??o Paulo, 14040-901 Ribeir??o Preto, SP, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Aarestrup</LastName>
                    <ForeName>Beatriz J V</ForeName>
                    <Initials>BJ</Initials>
                    <Affiliation>Laboratory of Experimental Imunology and Patology, CBR, Federal University of Juiz de Fora, Juiz de Fora, R. Jos?? Louren??o Kelmer s/n, Campus Universit??rio, 36036-900 Juiz de Fora, MG, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Aarestrup</LastName>
                    <ForeName>Fernando M</ForeName>
                    <Initials>FM</Initials>
                    <Affiliation>Laboratory of Experimental Imunology and Patology, CBR, Federal University of Juiz de Fora, Juiz de Fora, R. Jos?? Louren??o Kelmer s/n, Campus Universit??rio, 36036-900 Juiz de Fora, MG, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>da Silva Filho</LastName>
                    <ForeName>Ademar A</ForeName>
                    <Initials>AA</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences, Faculty of Pharmacy, Federal University of Juiz de Fora, Juiz de Fora, R. Jos?? Louren??o Kelmer s/n, Campus Universit??rio, 36036-900 Juiz de Fora, MG, Brazil. ademar.alves@ufjf.edu.br.</Affiliation>
                </Author>
                <Author>
                    <LastName>Corr??a</LastName>
                    <ForeName>Jos?? O A</ForeName>
                    <Initials>JO</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences, Faculty of Pharmacy, Federal University of Juiz de Fora, Juiz de Fora, R. Jos?? Louren??o Kelmer s/n, Campus Universit??rio, 36036-900 Juiz de Fora, MG, Brazil. joacorrea@gmail.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Molecules</MedlineTA>
            <NlmUniqueID>100964009</NlmUniqueID>
            <ISSNLinking>1420-3049</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">molecules190812814</ArticleId>
            <ArticleId IdType="doi">10.3390/molecules190812814</ArticleId>
            <ArticleId IdType="pubmed">25153880</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153878</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1420-3049</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>19</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Molecules (Basel, Switzerland)</Title>
                <ISOAbbreviation>Molecules</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Anti-Inflammatory Effect of Momordica Charantia in Sepsis Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>12777-12788</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Wild bitter gourd (Momordica charantia L. var. abbreviate Seringe), a common vegetable in Asia, is used in traditional medicine to treat various diseases, including inflammation. Extant literature indicates that wild bitter gourds have components that activate PPAR?? and PPAR??. This research probed the influence of adding wild bitter gourd to diets on inflammation responses in mice with sepsis induced by intraperitoneal injection of LPS. Male BALB/c mice were divided normal, sepsis, positive control, and three experimental groups. The latter ate diets with low (1%), moderate (2%), and high (10%) ratios of wild bitter gourd lyophilized powder. Before mice were sacrificed, with the exception of the normal group, intraperitoneal injection of LPS induced sepsis in each group; positive control group was injected with LPS after PDTC. This experiment revealed starkly lower weights in groups with added wild bitter gourd than those of the remaining groups. Blood lipids (TG, cholesterol, and NEFA) were also lower in comparison to the sepsis group, and blood glucose concentrations recovered and approached normal levels. Blood biochemistry values related to inflammation reactions indicated GOT, GPT, C-RP, and NO concentrations of groups with added wild bitter gourd were all lower than those of the sepsis group. Secretion levels of the spleen pro-inflammatory cytokines IL-1, IL-6, and TNF-?? tallied significantly lower in comparison to the sepsis group, whereas secretion levels of IL-10 anti-inflammatory cytokine increased. Expression level of proteins NF-??B, iNOS, and COX-2 were significantly inhibited. Results indicate wild bitter gourd in diets promoted lipid metabolism, reducing fat accumulation, and improving low blood glucose in sepsis. Addition of wild bitter gourd can reduce inflammation biochemical markers or indicators and pro-inflammatory cytokines in the body, hence improving the inflammation responses in mice with sepsis.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chao</LastName>
                    <ForeName>Che-Yi</ForeName>
                    <Initials>CY</Initials>
                    <Affiliation>Department of Health and Nutrition Biotechnology, Asia University, Taichung, 41354, Taiwan. cychao@asia.edu.tw.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sung</LastName>
                    <ForeName>Ping-Jyun</ForeName>
                    <Initials>PJ</Initials>
                    <Affiliation>Graduate Institute of Marine Biotechnology and Department of Life Science and Institute of Biotechnology, National Dong Hwa University, Pingtung 94450, Taiwan. whw@mail.nsysu.edu.tw.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Wei-Hsien</ForeName>
                    <Initials>WH</Initials>
                    <Affiliation>National Museum of Marine Biology and Aquarium, Pingtung 94450, Taiwan. whw@mail.nsysu.edu.tw.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kuo</LastName>
                    <ForeName>Yueh-Hsiung</ForeName>
                    <Initials>YH</Initials>
                    <Affiliation>Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 40402, Taiwan. kuoyh@mail.cmu.edu.tw.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Molecules</MedlineTA>
            <NlmUniqueID>100964009</NlmUniqueID>
            <ISSNLinking>1420-3049</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">molecules190812777</ArticleId>
            <ArticleId IdType="doi">10.3390/molecules190812777</ArticleId>
            <ArticleId IdType="pubmed">25153878</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153837</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>ALKBH4 Depletion in Mice Leads to Spermatogenic Defects.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105113</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0105113</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">ALKBH4, an AlkB homologue in the 2-oxoglutarate and Fe2+ dependent hydroxylase family, has previously been shown to regulate the level of monomethylated lysine-84 in actin and thereby indirectly influences the ability of non-muscular myosin II to bind actin filaments. ALKBH4 modulates fundamental processes including cytokinesis and cell motility, and its depletion is lethal during early preimplantation embryo stage. The aim of this study was to investigate the effect of ALKBH4 deficiency in a physiological context, using inducible Alkbh4 knockout mice. Here, we report that ALKBH4 is essential for the development of spermatocytes during the prophase of meiosis, and that ALKBH4 depletion leads to insufficient establishment of the synaptonemal complex. We also show that ALKBH4 is localized in nucleolar structures of Sertoli cells, spermatogonia and primary spermatocytes.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Nilsen</LastName>
                    <ForeName>Anja</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Institute of Medical Microbiology, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fusser</LastName>
                    <ForeName>Markus</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Institute of Medical Microbiology, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
                <Author>
                    <LastName>Greggains</LastName>
                    <ForeName>Gareth</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Section for Reproductive Medicine, Department of Gynecology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fedorcsak</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Section for Reproductive Medicine, Department of Gynecology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.</Affiliation>
                </Author>
                <Author>
                    <LastName>Klungland</LastName>
                    <ForeName>Arne</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Institute of Medical Microbiology, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway; Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105113</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-11458</ArticleId>
            <ArticleId IdType="pubmed">25153837</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153823</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Corepressor Tle4 Is a Novel Regulator of Murine Hematopoiesis and Bone Development.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105557</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0105557</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Hematopoiesis is a complex process that relies on various cell types, signaling pathways, transcription factors and a specific niche. The integration of these various components is of critical importance to normal blood development, as deregulation of these may lead to bone marrow failure or malignancy. Tle4, a transcriptional corepressor, acts as a tumor suppressor gene in a subset of acute myeloid leukemia, yet little is known about its function in normal and malignant hematopoiesis or in mammalian development. We report here that Tle4 knockout mice are runted and die at around four weeks with defects in bone development and BM aplasia. By two weeks of age, Tle4 knockout mice exhibit leukocytopenia, B cell lymphopenia, and significant reductions in hematopoietic stem and progenitor cells. Tle4 deficient hematopoietic stem cells are intrinsically defective in B lymphopoiesis and exhaust upon stress, such as serial transplantation. In the absence of Tle4 there is a profound decrease in bone mineralization. In addition, Tle4 knockout stromal cells are defective at maintaining wild-type hematopoietic stem cell function in vitro. In summary, we illustrate a novel and essential role for Tle4 in the extrinsic and intrinsic regulation of hematopoiesis and in bone development.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Wheat</LastName>
                    <ForeName>Justin C</ForeName>
                    <Initials>JC</Initials>
                    <Affiliation>Department of Pediatrics, Divisions of Pediatric Hematology/Oncology and Medical Genetics, Massachusetts General Hospital, Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Krause</LastName>
                    <ForeName>Daniela S</ForeName>
                    <Initials>DS</Initials>
                    <Affiliation>Center for Regenerative Medicine and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shin</LastName>
                    <ForeName>Thomas H</ForeName>
                    <Initials>TH</Initials>
                    <Affiliation>Department of Pediatrics, Divisions of Pediatric Hematology/Oncology and Medical Genetics, Massachusetts General Hospital, Boston, Massachusetts, United States of America; Department of Molecular and Translational Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Xi</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Pediatrics, Divisions of Pediatric Hematology/Oncology and Medical Genetics, Massachusetts General Hospital, Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Jianfeng</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Pediatrics, Divisions of Pediatric Hematology/Oncology and Medical Genetics, Massachusetts General Hospital, Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ding</LastName>
                    <ForeName>Dacheng</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Pediatrics, Divisions of Pediatric Hematology/Oncology and Medical Genetics, Massachusetts General Hospital, Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yamin</LastName>
                    <ForeName>Rae'e</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Pediatrics, Divisions of Pediatric Hematology/Oncology and Medical Genetics, Massachusetts General Hospital, Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sweetser</LastName>
                    <ForeName>David A</ForeName>
                    <Initials>DA</Initials>
                    <Affiliation>Department of Pediatrics, Divisions of Pediatric Hematology/Oncology and Medical Genetics, Massachusetts General Hospital, Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105557</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-17254</ArticleId>
            <ArticleId IdType="pubmed">25153823</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153787</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Correction: Characterization of Subtle Brain Abnormalities in a Mouse Model of Hedgehog Pathway Antagonist-Induced Cleft Lip and Palate.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e106607</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0106607</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">[This corrects the article DOI: 10.1371/journal.pone.0102603.].</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <CollectiveName>The PLOS ONE Staff</CollectiveName>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0106607</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-36086</ArticleId>
            <ArticleId IdType="pubmed">25153787</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153780</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1878-7568</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Acta biomaterialia</Title>
                <ISOAbbreviation>Acta Biomater</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Staphylococcus epidermidis originating from titanium implants infects surrounding tissue and immune cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1742-7061(14)00348-1</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.actbio.2014.08.012</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Infection is a major cause of failure of inserted or implanted biomedical devices (biomaterials). During surgery bacteria may adhere to the implant initiating biofilm formation. Bacteria also are observed in and recultured from the tissue surrounding implants, and may even reside inside host cells. Whether these bacteria originate from biofilms is not known. Therefore, we investigated the fate of Staphylococcus epidermidis inoculated on the surface of implants as adherent planktonic cells or as a biofilm in mouse experimental biomaterial-associated infection. In order to discriminate the challenge strain from potential contaminating mouse microflora, we constructed a fully virulent green fluorescent S. epidermidis strain. S. epidermidis injected along subcutaneous titanium implants, pre-seeded on the implants or pre-grown as biofilm, were retrieved from the implants as well as the surrounding tissue in all cases after 4 days, and in histology bacteria were observed in the tissue co-localizing with macrophages. Thus, bacteria adherent to, or in a biofilm on the implant are a potential source of infection of the surrounding tissue and antimicrobial strategies should prevent both biofilm formation and tissue colonization.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Riool</LastName>
                    <ForeName>Martijn</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Medical Microbiology, Center of Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>de Boer</LastName>
                    <ForeName>Leonie</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Medical Microbiology, Center of Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jaspers</LastName>
                    <ForeName>Valery</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Department of Medical Microbiology, Center of Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>van der Loos</LastName>
                    <ForeName>Chris M</ForeName>
                    <Initials>CM</Initials>
                    <Affiliation>Department of Pathology, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>van Wamel</LastName>
                    <ForeName>Willem J B</ForeName>
                    <Initials>WJ</Initials>
                    <Affiliation>Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Centre, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Gang</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Oral Implantology and Prosthetic Dentistry, Academic Center for Dentistry Amsterdam, VU University and University of Amsterdam, Gustav Mahlerlaan 3004, 1081 LA, Amsterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kwakman</LastName>
                    <ForeName>Paulus H S</ForeName>
                    <Initials>PH</Initials>
                    <Affiliation>Department of Medical Microbiology, Center of Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zaat</LastName>
                    <ForeName>Sebastian A J</ForeName>
                    <Initials>SA</Initials>
                    <Affiliation>Department of Medical Microbiology, Center of Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands. Electronic address: s.a.zaat@amc.uva.nl.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Acta Biomater</MedlineTA>
            <NlmUniqueID>101233144</NlmUniqueID>
            <ISSNLinking>1742-7061</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Biofilm</Keyword>
            <Keyword MajorTopicYN="N">Biomaterial-associated infection</Keyword>
            <Keyword MajorTopicYN="N">Intracellular survival</Keyword>
            <Keyword MajorTopicYN="N">Staphylococcus epidermidis</Keyword>
            <Keyword MajorTopicYN="N">Titanium</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1742-7061(14)00348-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.actbio.2014.08.012</ArticleId>
            <ArticleId IdType="pubmed">25153780</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153747</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0031-5125</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>119</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Perceptual and motor skills</Title>
                <ISOAbbreviation>Percept Mot Skills</ISOAbbreviation>
            </Journal>
            <ArticleTitle>VISUOMOTOR CONTROL IN CONTINUOUS RESPONSE TIME TASKS ACROSS DIFFERENT AGE GROUPS.</ArticleTitle>
            <Pagination>
                <MedlinePgn>169-182</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Summary.-The goal was to examine whether visuomotor control and choice response time shared age-related developmental trajectories, and if prior computer experience played an important role in control processes. Children (6-7, 8-9, 10-11 yr.), younger adults (24 yr.) and older adults (76 yr.) performed the cursor pointing and choice response time (CRT) tasks with a computer mouse. Participants moved the mouse cursor back and forth to click two targets on the screen as fast and accurately as possible. In the CRT, based on visual stimuli, participants moved and clicked one of the three targets on the screen as fast and accurately as possible; the time between stimulus onset and clicking the correct target was recorded as the choice response time. Visuomotor performance increased with age to younger adulthood but was worse in the older adult group. CRT performance was also positively related to age among the groups of children, with scores leveling off in the young adult group. Computer experience was statistically significantly related only to visuomotor control, but not to CRT. Optimal CRT performance required only sub-optimal visuomotor control. Cognitive and sensory age declines may be related to the poorer CRT performance in the oldest age group.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Guanmin</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>1 Department of Psychology Tsinghua University, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chan</LastName>
                    <ForeName>John S Y</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>David D</ForeName>
                    <Initials>DD</Initials>
                </Author>
                <Author>
                    <LastName>Peng</LastName>
                    <ForeName>Kaiping</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Qin</LastName>
                    <ForeName>Chunbo</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Yan</LastName>
                    <ForeName>Jin H</ForeName>
                    <Initials>JH</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Percept Mot Skills</MedlineTA>
            <NlmUniqueID>0401131</NlmUniqueID>
            <ISSNLinking>0031-5125</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.2466/25.10.PMS.119c13z8</ArticleId>
            <ArticleId IdType="pubmed">25153747</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153728</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <Issue>15</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1?? and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6540-6551</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Recently, we found that sMEK1 effectively regulates pro-apoptotic activity when combined with a traditional chemotherapeutic drug. Therefore, combinational therapeutic strategies targeting critical molecular and cellular mechanisms are urgently required. In this present work, we evaluated whether sMEK1 enhanced the pro-apoptotic activity of chemotherapeutic drugs in ovarian carcinoma cells. Combined with a chemotherapeutic drug, sMEK1 showed an additive effect on the suppression of ovarian cancer cell growth by inducing cell cycle arrest and apoptosis and regulating related gene expression levels or protein activities. In addition, the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway was strongly inhibited by the combined treatment, showing de-repression of the tuberous sclerosis complex (TSC) and suppression of ras homolog enriched in the brain (Rheb) and mTOR and raptor in aggressive ovarian carcinoma cells and mouse xenograft models. Treatment with sMEK1 and paclitaxel reduced phosphorylation of ribosomal S6 kinase (S6K) and 4E-binding protein (4E-BP), two critical downstream targets of the mTOR-signaling pathway. Furthermore, both sMEK1 and paclitaxel significantly inhibited the expression of signaling components downstream of S6K/4E-BP, such as hypoxia-inducible factor-1?? (HIF-1??) and vascular endothelial growth factor (VEGF), both in vitro and in vivo. Therefore, our data suggest that the combination of sMEK1 and paclitaxel is a promising and effective targeted therapy for chemotherapy-resistant or recurrent ovarian cancers.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Boh-Ram</ForeName>
                    <Initials>BR</Initials>
                    <Affiliation>Research Institute, National Cancer Center, 323, Ilsan-ro, Ilsandong-gu, Goyang-si Gyeonggi-do, Republic of Korea; These Authors contributed equally to this work.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yoon</LastName>
                    <ForeName>Kyungsil</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Research Institute, National Cancer Center, 323, Ilsan-ro, Ilsandong-gu, Goyang-si Gyeonggi-do, Republic of Korea; These Authors contributed equally to this work.</Affiliation>
                </Author>
                <Author>
                    <LastName>Byun</LastName>
                    <ForeName>Hyun-Jung</ForeName>
                    <Initials>HJ</Initials>
                    <Affiliation>Research Institute, National Cancer Center, 323, Ilsan-ro, Ilsandong-gu, Goyang-si Gyeonggi-do, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Seo</LastName>
                    <ForeName>Seung Hee</ForeName>
                    <Initials>SH</Initials>
                    <Affiliation>Research Institute, National Cancer Center, 323, Ilsan-ro, Ilsandong-gu, Goyang-si Gyeonggi-do, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Seung-Hoon</ForeName>
                    <Initials>SH</Initials>
                    <Affiliation>Department of Life Science, Yong In University, 470, Samga-dong, Cheoin-gu, Yongin-si Gyeonggi-do, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rho</LastName>
                    <ForeName>Seung Bae</ForeName>
                    <Initials>SB</Initials>
                    <Affiliation>Research Institute, National Cancer Center, 323, Ilsan-ro, Ilsandong-gu, Goyang-si Gyeonggi-do, Republic of Korea.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2119</ArticleId>
            <ArticleId IdType="pubmed">25153728</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153727</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <Issue>15</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Treatment of osteosarcoma with microwave thermal ablation to induce immunogenic cell death.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6526-6539</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Microwave ablation (MWA) has been used as a classical hyperthermic ablation method for decades with the intention to induce direct killing of tumor cells or modulation of tumor architecture. The purpose of this study was to explore whether MWA induced tumor cell death could generate an immunogenic source of tumor antigens and elicit tumor-specific immune responses, taking an alternative antitumor effects. Three kinds of osteosarcoma cell lines, respectively derived from mice, rats and human, were selected as ablation models. In vitro and in situ tumor ablation were both performed to detect the &quot;damage-associated molecular patterns&quot; (DAMPs) exposure level. Active ablated products vaccination resulted in complete protection in both mouse and rat tumor-bearing models, which was mediated primarily by vaccine-elicited CD8+ T cells. These effector cells functioned by releasing IFN-?? and TNF-?? in the presence of target cells, which may trigger FasL-directed cell apoptosis. These data suggest that MWA-processed osteosarcoma cells could be applied to generate specific antitumor effects, especially for in situ ablation. Hence, MWA could be used in combination with immunotherapy, especially for patients who have failed chemotherapy or who have limited treatment options.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Yu</LastName>
                    <ForeName>Zhe</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Center of Orthopedic Surgery, Orthopedics Oncology Institute of Chinese PLA, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, P. R. China; These authors contributed equally to this work.</Affiliation>
                </Author>
                <Author>
                    <LastName>Geng</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Medical Department of Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, P. R. China; These authors contributed equally to this work.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Minghua</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Center of Orthopedic Surgery, Orthopedics Oncology Institute of Chinese PLA, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, P. R. China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Yong</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Center of Orthopedic Surgery, Orthopedics Oncology Institute of Chinese PLA, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, P. R. China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fan</LastName>
                    <ForeName>Qingyu</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Center of Orthopedic Surgery, Orthopedics Oncology Institute of Chinese PLA, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, P. R. China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Jingyuan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Faculty of Military Preventive Medicine, Fourth Military Medical University, Xi'an, Shaanxi P. R. China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2310</ArticleId>
            <ArticleId IdType="pubmed">25153727</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153726</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <Issue>15</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Multifunctional targeting daunorubicin plus quinacrine liposomes, modified by wheat germ agglutinin and tamoxifen, for treating brain glioma and glioma stem cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6497-6511</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Most anticancer drugs are not able to cross the blood-brain barrier (BBB) effectively while surgery and radiation therapy cannot eradicate brain glioma cells and glioma stem cells (GSCs), hence resulting in poor prognosis with high recurrence rates. In the present study, a kind of multifunctional targeting daunorubicin plus quinacrine liposomes was developed for treating brain glioma and GSCs. Evaluations were performed on in-vitro BBB model, murine glioma cells, GSCs, and GSCs bearing mice. Results showed that the multifunctional targeting daunorubicin plus quinacrine liposomes exhibited evident capabilities in crossing the BBB, in killing glioma cells and GSCs and in diminishing brain glioma in mice. Action mechanism studies indicated that the enhanced efficacy of the multifunctional targeting drugs-loaded liposomes could be due to the following aspects: evading the rapid elimination from blood circulation; crossing the BBB effectively; improving drug uptake by glioma cells and GSCs; down-regulating the overexpressed ABC transporters; inducing apoptosis of GSCs via up-regulating apoptotic receptor/ligand (Fas/Fasl), activating apoptotic enzymes (caspases 8, 9 and 3), activating pro-apoptotic proteins (Bax and Bok), activating tumor suppressor protein (P53) and suppressing anti-apoptotic proteins (Bcl-2 and Mcl-1). In conclusion, the multifunctional targeting daunorubicin plus quinacrine liposomes could be used as a potential therapy for treating brain glioma and GSCs.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Xue-Tao</ForeName>
                    <Initials>XT</Initials>
                    <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China; School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ju</LastName>
                    <ForeName>Rui-Jun</ForeName>
                    <Initials>RJ</Initials>
                    <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Xiu-Ying</ForeName>
                    <Initials>XY</Initials>
                    <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zeng</LastName>
                    <ForeName>Fan</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shi</LastName>
                    <ForeName>Ji-Feng</ForeName>
                    <Initials>JF</Initials>
                    <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Cheng-Xiang</ForeName>
                    <Initials>CX</Initials>
                    <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sun</LastName>
                    <ForeName>Meng-Ge</ForeName>
                    <Initials>MG</Initials>
                    <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lou</LastName>
                    <ForeName>Jin-Ning</ForeName>
                    <Initials>JN</Initials>
                    <Affiliation>Institute of Clinical Medical Sciences, Chia-Japan Friendship Hospital, The Ministry of Health, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lu</LastName>
                    <ForeName>Wan-Liang</ForeName>
                    <Initials>WL</Initials>
                    <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2267</ArticleId>
            <ArticleId IdType="pubmed">25153726</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153719</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <Issue>15</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5934-5949</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The role of HER4 in breast cancer is controversial and its role in relation to trastuzumab resistance remains unclear. We showed that trastuzumab treatment and its acquired resistance induced HER4 upregulation, cleavage and nuclear translocation. However, knockdown of HER4 by specific siRNAs increased trastuzumab sensitivity and reversed its resistance in HER2 positive breast cancer cells. Preventing HER4 cleavage by a ??-secretase inhibitor and inhibiting HER4 tyrosine kinase activity by neratinib decreased trastuzumab-induced HER4 nuclear translocation and enhanced trastuzumab response. There was also increased nuclear HER4 staining in the tumours from BT474 xenograft mice and human patients treated with trastuzumab. Furthermore, nuclear HER4 predicted poor clinical response to trastuzumab monotherapy in patients undergoing a window study and was shown to be an independent poor prognostic factor in HER2 positive breast cancer. Our data suggest that HER4 plays a key role in relation to trastuzumab resistance in HER2 positive breast cancer. Therefore, our study provides novel findings that HER4 activation, cleavage and nuclear translocation influence trastuzumab sensitivity and resistance in HER2 positive breast cancer. Nuclear HER4 could be a potential prognostic and predictive biomarker and understanding the role of HER4 may provide strategies to overcome trastuzumab resistance in HER2 positive breast cancer.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Mohd Nafi</LastName>
                    <ForeName>Siti Norasikin</ForeName>
                    <Initials>SN</Initials>
                    <Affiliation>Human Epidermal Growth Factor Group, Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Generali</LastName>
                    <ForeName>Daniele</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>U.O. Multidisciplinare di Patologia Mammaria, U.S Terapia Molecolare e Farmacogenomica, A.O. Instituti Ospitalieri di Cremona, Viale Concordia 1, Cremona, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kramer-Marek</LastName>
                    <ForeName>Gabriela</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Institute of Cancer Research, Division of Radiotherapy and Imaging, 15 Cotswold Road, Belmont, Sutton, Surrey, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gijsen</LastName>
                    <ForeName>Merel</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Human Epidermal Growth Factor Group, Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Strina</LastName>
                    <ForeName>Carla</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>U.O. Multidisciplinare di Patologia Mammaria, U.S Terapia Molecolare e Farmacogenomica, A.O. Instituti Ospitalieri di Cremona, Viale Concordia 1, Cremona, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cappelletti</LastName>
                    <ForeName>Mariarosa</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>U.O. Multidisciplinare di Patologia Mammaria, U.S Terapia Molecolare e Farmacogenomica, A.O. Instituti Ospitalieri di Cremona, Viale Concordia 1, Cremona, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Andreis</LastName>
                    <ForeName>Daniele</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>U.O. Multidisciplinare di Patologia Mammaria, U.S Terapia Molecolare e Farmacogenomica, A.O. Instituti Ospitalieri di Cremona, Viale Concordia 1, Cremona, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Haider</LastName>
                    <ForeName>Syed</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Growth Factor Group, Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Ji-Liang</ForeName>
                    <Initials>JL</Initials>
                    <Affiliation>Growth Factor Group, Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bridges</LastName>
                    <ForeName>Esther</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Growth Factor Group, Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Capala</LastName>
                    <ForeName>Jacek</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>National Institutes of Health, Radiation Oncology Branch, Bethesda MD, US.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ioannis</LastName>
                    <ForeName>Roxanis</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Cellular Pathology, Oxford University Hospitals and Oxford Biomedical Research Centre, Oxford, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Harris</LastName>
                    <ForeName>Adrian L</ForeName>
                    <Initials>AL</Initials>
                    <Affiliation>Growth Factor Group, Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kong</LastName>
                    <ForeName>Anthony</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Human Epidermal Growth Factor Group, Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1904</ArticleId>
            <ArticleId IdType="pubmed">25153719</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153718</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <Issue>15</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>SPHK1 regulates proliferation and survival responses in triple-negative breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5920-5933</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Triple-negative breast cancer (TNBC) is characterized by unique aggressive behavior and lack of targeted therapies. Among the various molecular subtypes of breast cancer, it was observed that TNBCs express elevated levels of sphingosine kinase 1 (SPHK1) compared to other breast tumor subtypes. High levels of SPHK1 gene expression correlated with poor overall and progression- free survival, as well as poor response to Doxorubicin-based treatment. Inhibition of SPHK1 was found to attenuate ERK1/2 and AKT signaling and reduce growth of TNBC cells in vitro and in a xenograft SCID mouse model. Moreover, SPHK1 inhibition by siRNA knockdown or treatment with SKI-5C sensitizes TNBCs to chemotherapeutic drugs. Our findings suggest that SPHK1 inhibition, which effectively counteracts oncogenic signaling through ERK1/2 and AKT pathways, is a potentially important anti-tumor strategy in TNBC. A combination of SPHK1 inhibitors with chemotherapeutic agents may be effective against this aggressive subtype of breast cancer.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Datta</LastName>
                    <ForeName>Arpita</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Loo</LastName>
                    <ForeName>Ser Yue</ForeName>
                    <Initials>SY</Initials>
                    <Affiliation>Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore; Cancer Science Institute of Singapore, National University of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Baohua</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wong</LastName>
                    <ForeName>Lingkai</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Chemistry, National University of Singapore, Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tan</LastName>
                    <ForeName>Sheryl S L</ForeName>
                    <Initials>SS</Initials>
                    <Affiliation>Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tan</LastName>
                    <ForeName>Tuan Zea</ForeName>
                    <Initials>TZ</Initials>
                    <Affiliation>Cancer Science Institute of Singapore, National University of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Soo-Chin</ForeName>
                    <Initials>SC</Initials>
                    <Affiliation>Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Hospital, Singapore; National University Cancer Institute, Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Thiery</LastName>
                    <ForeName>Jean Paul</ForeName>
                    <Initials>JP</Initials>
                    <Affiliation>Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore; Cancer Science Institute of Singapore, National University of Singapore; National University Cancer Institute, Singapore; Institute of Molecular and Cell Biology (IMCB), A*STAR, Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lim</LastName>
                    <ForeName>Yaw Chyn</ForeName>
                    <Initials>YC</Initials>
                    <Affiliation>Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore; Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yong</LastName>
                    <ForeName>Wei Peng</ForeName>
                    <Initials>WP</Initials>
                    <Affiliation>Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Hospital, Singapore; National University Cancer Institute, Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lam</LastName>
                    <ForeName>Yulin</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Chemistry, National University of Singapore, Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kumar</LastName>
                    <ForeName>Alan Prem</ForeName>
                    <Initials>AP</Initials>
                    <Affiliation>Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Cancer Science Institute of Singapore, National University of Singapore; National University Cancer Institute, Singapore; School of Biomedical Sciences, Faculty of Health Sciences, Curtin University, Western Australia; Department of Biological Sciences, University of North Texas, Denton, Texas, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yap</LastName>
                    <ForeName>Celestial T</ForeName>
                    <Initials>CT</Initials>
                    <Affiliation>Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore; National University Cancer Institute, Singapore.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1874</ArticleId>
            <ArticleId IdType="pubmed">25153718</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153709</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dysbalance of Astrocyte Calcium under Hyperammonemic Conditions.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105832</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0105832</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Increased brain ammonium (NH4+/NH3) plays a central role in the manifestation of hepatic encephalopathy (HE), a complex syndrome associated with neurological and psychiatric alterations, which is primarily a disorder of astrocytes. Here, we analysed the influence of NH4+/NH3 on the calcium concentration of astrocytes in situ and studied the underlying mechanisms of NH4+/NH3-evoked calcium changes, employing fluorescence imaging with Fura-2 in acute tissue slices derived from different regions of the mouse brain. In the hippocampal stratum radiatum, perfusion with 5 mM NH4+/NH3 for 30 minutes caused a transient calcium increase in about 40% of astrocytes lasting about 10 minutes. Furthermore, the vast majority of astrocytes (???90%) experienced a persistent calcium increase by ???50 nM. This persistent increase was already evoked at concentrations of 1-2 mM NH4+/NH3, developed within 10-20 minutes and was maintained as long as the NH4+/NH3 was present. Qualitatively similar changes were observed in astrocytes of different neocortical regions as well as in cerebellar Bergmann glia. Inhibition of glutamine synthetase resulted in significantly larger calcium increases in response to NH4+/NH3, indicating that glutamine accumulation was not a primary cause. Calcium increases were not mimicked by changes in intracellular pH. Pharmacological inhibition of voltage-gated sodium channels, sodium-potassium-chloride-cotransporters (NKCC), the reverse mode of sodium/calcium exchange (NCX), AMPA- or mGluR5-receptors did not dampen NH4+/NH3-induced calcium increases. They were, however, significantly reduced by inhibition of NMDA receptors and depletion of intracellular calcium stores. Taken together, our measurements show that sustained exposure to NH4+/NH3 causes a sustained increase in intracellular calcium in astrocytes in situ, which is partly dependent on NMDA receptor activation and on release of calcium from intracellular stores. Our study furthermore suggests that dysbalance of astrocyte calcium homeostasis under hyperammonemic conditions is a widespread phenomenon, which might contribute to the disturbance of neurotransmission during HE.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Haack</LastName>
                    <ForeName>Nicole</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Institute of Neurobiology, Faculty of Mathematics and Natural Sciences, Heinrich Heine University, Duesseldorf, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dublin</LastName>
                    <ForeName>Pavel</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Institute of Neurobiology, Faculty of Mathematics and Natural Sciences, Heinrich Heine University, Duesseldorf, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rose</LastName>
                    <ForeName>Christine R</ForeName>
                    <Initials>CR</Initials>
                    <Affiliation>Institute of Neurobiology, Faculty of Mathematics and Natural Sciences, Heinrich Heine University, Duesseldorf, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105832</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-21140</ArticleId>
            <ArticleId IdType="pubmed">25153709</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153704</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-8305</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nutritional neuroscience</Title>
                <ISOAbbreviation>Nutr Neurosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Standardized Bacopa monnieri extract ameliorates acute paraquat-induced oxidative stress, and neurotoxicity in prepubertal mice brain.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Objectives Bacopa monnieri (BM), an ayurvedic medicinal plant, has attracted considerable interest owing to its diverse neuropharmacological properties. Epidemiological studies have shown significant correlation between paraquat (PQ) exposure and increased risk for Parkinson's disease in humans. In this study, we examined the propensity of standardized extract of BM to attenuate acute PQ-induced oxidative stress, mitochondrial dysfunctions, and neurotoxicity in the different brain regions of prepubertal mice. Methods To test this hypothesis, prepubertal mice provided orally with standardized BM extract (200??mg/kg body weight/day for 4 weeks) were challenged with an acute dose (15??mg/kg body weight, intraperitoneally) of PQ after 3 hours of last dose of extract. Mice were sacrificed after 48 hours of PQ injection, and different brain regions were isolated and subjected to biochemical determinations/quantification of central monoamine (dopamine, DA) levels (by high-performance liquid chromatography). Results Oral supplementation of BM for 4 weeks resulted in significant reduction in the basal levels of oxidative markers such as reactive oxygen species (ROS), malondialdehyde (MDA), and hydroperoxides (HP) in various brain regions. PQ at the administered dose elicited marked oxidative stress within 48 hours in various brain regions of mice. However, BM prophylaxis significantly improved oxidative homeostasis by restoring PQ-induced ROS, MDA, and HP levels and also by attenuating mitochondrial dysfunction. Interestingly, BM supplementation restored the activities of cholinergic enzymes along with the restoration of striatal DA levels among the PQ-treated mice. Discussion Based on these findings, we infer that BM prophylaxis renders the brain resistant to PQ-mediated oxidative perturbations and thus may be better exploited as a preventive approach to protect against oxidative-mediated neuronal dysfunctions.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hosamani</LastName>
                    <ForeName>Ravikumar</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Krishna</LastName>
                    <ForeName>Gokul</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author>
                    <LastName>Muralidhara</LastName>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Nutr Neurosci</MedlineTA>
            <NlmUniqueID>100892202</NlmUniqueID>
            <ISSNLinking>1028-415X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Bacopa monnieri</Keyword>
            <Keyword MajorTopicYN="N">Mice</Keyword>
            <Keyword MajorTopicYN="N">Mitochondrial dysfunctions</Keyword>
            <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
            <Keyword MajorTopicYN="N">Paraquat</Keyword>
            <Keyword MajorTopicYN="N">Parkinson's disease</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1179/1476830514Y.0000000149</ArticleId>
            <ArticleId IdType="pubmed">25153704</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153701</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A Small Molecule p75NTR Ligand, LM11A-31, Reverses Cholinergic Neurite Dystrophy in Alzheimer's Disease Mouse Models with Mid- to Late-Stage Disease Progression.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e102136</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0102136</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Degeneration of basal forebrain cholinergic neurons contributes significantly to the cognitive deficits associated with Alzheimer's disease (AD) and has been attributed to aberrant signaling through the neurotrophin receptor p75 (p75NTR). Thus, modulating p75NTR signaling is considered a promising therapeutic strategy for AD. Accordingly, our laboratory has developed small molecule p75NTR ligands that increase survival signaling and inhibit amyloid-??-induced degenerative signaling in in vitro studies. Previous work found that a lead p75NTR ligand, LM11A-31, prevents degeneration of cholinergic neurites when given to an AD mouse model in the early stages of disease pathology. To extend its potential clinical applications, we sought to determine whether LM11A-31 could reverse cholinergic neurite atrophy when treatment begins in AD mouse models having mid- to late stages of pathology. Reversing pathology may have particular clinical relevance as most AD studies involve patients that are at an advanced pathological stage. In this study, LM11A-31 (50 or 75 mg/kg) was administered orally to two AD mouse models, Thy-1 hAPPLond/Swe (APPL/S) and Tg2576, at age ranges during which marked AD-like pathology manifests. In mid-stage male APPL/S mice, LM11A-31 administered for 3 months starting at 6-8 months of age prevented and/or reversed atrophy of basal forebrain cholinergic neurites and cortical dystrophic neurites. Importantly, a 1 month LM11A-31 treatment given to male APPL/S mice (12-13 months old) with late-stage pathology reversed the degeneration of cholinergic neurites in basal forebrain, ameliorated cortical dystrophic neurites, and normalized increased basal forebrain levels of p75NTR. Similar results were seen in female Tg2576 mice. These findings suggest that LM11A-31 can reduce and/or reverse fundamental AD pathologies in late-stage AD mice. Thus, targeting p75NTR is a promising approach to reducing AD-related degenerative processes that have progressed beyond early stages.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Simmons</LastName>
                    <ForeName>Danielle A</ForeName>
                    <Initials>DA</Initials>
                    <Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Knowles</LastName>
                    <ForeName>Juliet K</ForeName>
                    <Initials>JK</Initials>
                    <Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California, United States of America; Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Belichenko</LastName>
                    <ForeName>Nadia P</ForeName>
                    <Initials>NP</Initials>
                    <Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Banerjee</LastName>
                    <ForeName>Gargi</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Finkle</LastName>
                    <ForeName>Carly</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Massa</LastName>
                    <ForeName>Stephen M</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Department of Neurology and Laboratory for Computational Neurochemistry and Drug Discovery, San Francisco Veterans Affairs Medical Center, and Department of Neurology, University of California San Francisco, San Francisco, California, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Longo</LastName>
                    <ForeName>Frank M</ForeName>
                    <Initials>FM</Initials>
                    <Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California, United States of America; Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0102136</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-12451</ArticleId>
            <ArticleId IdType="pubmed">25153701</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153696</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Multiple Regulatory Roles of the Mouse Transmembrane Adaptor Protein NTAL in Gene Transcription and Mast Cell Physiology.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105539</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0105539</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Non-T cell activation linker (NTAL; also called LAB or LAT2) is a transmembrane adaptor protein that is expressed in a subset of hematopoietic cells, including mast cells. There are conflicting reports on the role of NTAL in the high affinity immunoglobulin E receptor (Fc??RI) signaling. Studies carried out on mast cells derived from mice with NTAL knock out (KO) and wild type mice suggested that NTAL is a negative regulator of Fc??RI signaling, while experiments with RNAi-mediated NTAL knockdown (KD) in human mast cells and rat basophilic leukemia cells suggested its positive regulatory role. To determine whether different methodologies of NTAL ablation (KO vs KD) have different physiological consequences, we compared under well defined conditions Fc??RI-mediated signaling events in mouse bone marrow-derived mast cells (BMMCs) with NTAL KO or KD. BMMCs with both NTAL KO and KD exhibited enhanced degranulation, calcium mobilization, chemotaxis, tyrosine phosphorylation of LAT and ERK, and depolymerization of filamentous actin. These data provide clear evidence that NTAL is a negative regulator of Fc??RI activation events in murine BMMCs, independently of possible compensatory developmental alterations. To gain further insight into the role of NTAL in mast cells, we examined the transcriptome profiles of resting and antigen-activated NTAL KO, NTAL KD, and corresponding control BMMCs. Through this analysis we identified several genes that were differentially regulated in nonactivated and antigen-activated NTAL-deficient cells, when compared to the corresponding control cells. Some of the genes seem to be involved in regulation of cholesterol-dependent events in antigen-mediated chemotaxis. The combined data indicate multiple regulatory roles of NTAL in gene expression and mast cell physiology.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Polakovicova</LastName>
                    <ForeName>Iva</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Department of Signal Transduction, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic.</Affiliation>
                </Author>
                <Author>
                    <LastName>Draberova</LastName>
                    <ForeName>Lubica</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Signal Transduction, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic.</Affiliation>
                </Author>
                <Author>
                    <LastName>Simicek</LastName>
                    <ForeName>Michal</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Signal Transduction, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic.</Affiliation>
                </Author>
                <Author>
                    <LastName>Draber</LastName>
                    <ForeName>Petr</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Signal Transduction, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105539</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-21036</ArticleId>
            <ArticleId IdType="pubmed">25153696</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153689</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1521-0499</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Experimental lung research</Title>
                <ISOAbbreviation>Exp. Lung Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Kinetics of the angiogenic response in lung endothelium following acute inflammatory injury with bleomycin.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">ABSTRACT Purpose/Aim: Angiogenesis is a central component of normal wound healing but it has not been fully characterized in lung repair following acute inflammatory injury. The current literature lacks vital information pertaining to the extent, timing, and location of this process. This information is necessary for examining mechanisms that drive normal lung repair in resolving acute inflammatory injury. The goal of our study was to formally characterize lung angiogenesis over a time course of bleomycin-induced lung injury. Materials and Methods: Female C57BL/6 mice age 8-12 weeks were treated with a single dose of intratracheal bleomycin. Total lung endothelial cells were quantified with flow cytometry 0, 7, 14, 21, and 28??days following bleomycin administration, and endothelial cell replication was assessed using bromodeoxyuridine (BrdU) incorporation. Results: Endothelial cell replication was maximal 14??days after bleomycin administration, while total lung endothelial cells peaked at day 21. Tissue analysis with stereology was performed to measure total lung vascular surface area in bleomycin at day 21 relative to controls and demonstrated a trend toward increased vasculature in the bleomycin group. Conclusions: Angiogenesis begins shortly after injury in the bleomycin model and leads to an expansion in the lung endothelial cell population that peaks at day 21. This study offers the first longitudinal examination of angiogenesis following acute inflammatory lung injury induced by bleomycin. Information provided in this study will be vital for further investigating mechanisms of angiogenesis in both normal and abnormal lung repair.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Yunt</LastName>
                    <ForeName>Zulma X</ForeName>
                    <Initials>ZX</Initials>
                    <Affiliation>1National Jewish Health, Denver, Colorado, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mohning</LastName>
                    <ForeName>Michael P</ForeName>
                    <Initials>MP</Initials>
                </Author>
                <Author>
                    <LastName>Barthel</LastName>
                    <ForeName>Lea</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Kearns</LastName>
                    <ForeName>Mark T</ForeName>
                    <Initials>MT</Initials>
                </Author>
                <Author>
                    <LastName>Tuder</LastName>
                    <ForeName>Rubin M</ForeName>
                    <Initials>RM</Initials>
                </Author>
                <Author>
                    <LastName>Hyde</LastName>
                    <ForeName>Dallas M</ForeName>
                    <Initials>DM</Initials>
                </Author>
                <Author>
                    <LastName>Henson</LastName>
                    <ForeName>Peter M</ForeName>
                    <Initials>PM</Initials>
                </Author>
                <Author>
                    <LastName>Janssen</LastName>
                    <ForeName>William J</ForeName>
                    <Initials>WJ</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Exp Lung Res</MedlineTA>
            <NlmUniqueID>8004944</NlmUniqueID>
            <ISSNLinking>0190-2148</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">angiogenesis</Keyword>
            <Keyword MajorTopicYN="N">bleomycin</Keyword>
            <Keyword MajorTopicYN="N">lung injury</Keyword>
            <Keyword MajorTopicYN="N">lung repair</Keyword>
            <Keyword MajorTopicYN="N">pulmonary endothelium</Keyword>
            <Keyword MajorTopicYN="N">stereology</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3109/01902148.2014.938202</ArticleId>
            <ArticleId IdType="pubmed">25153689</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153686</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1439-4286</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme</Title>
                <ISOAbbreviation>Horm. Metab. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>AHNAK KO Mice are Protected from Diet-Induced Obesity but are Glucose Intolerant.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">AHNAK is a 700 KD phosphoprotein primarily involved in calcium signaling in various cell types and regulating cytoskeletal organization and cell membrane architecture. AHNAK expression has also been associated with obesity. To investigate the role of AHNAK in regulating metabolic homeostasis, we studied whole body AHNAK knockout mice (KO) on either regular chow or high-fat diet (HFD). KO mice had a leaner phenotype and were resistant to high-fat diet-induced obesity (DIO), as reflected by a reduction in adipose tissue mass in conjunction with higher lean mass compared to wild-type controls (WT). However, KO mice exhibited higher fasting glucose levels, impaired glucose tolerance, and diminished serum insulin levels on either diet. Concomitantly, KO mice on HFD displayed defects in insulin signaling, as evident from reduced Akt phosphorylation and decreased cellular glucose transporter (Glut4) levels. Glucose intolerance and insulin resistance were also associated with changes in expression of genes regulating fat, glucose, and energy metabolism in adipose tissue and liver. Taken together, these data demonstrate that (a) AHNAK is involved in glucose homeostasis and weight balance (b) under normal feeding KO mice are insulin sensitive yet insulin deficient; and (c) AHNAK deletion protects against HFD-induced obesity, but not against HFD-induced insulin resistance and glucose intolerance in vivo.</AbstractText>
                <CopyrightInformation>?? Georg Thieme Verlag KG Stuttgart ?? New York.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ramdas</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Institute of Endocrinology, Diabetes and Metabolism, Rambam Medical Center, and Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Harel</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Institute of Endocrinology, Diabetes and Metabolism, Rambam Medical Center, and Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Armoni</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Institute of Endocrinology, Diabetes and Metabolism, Rambam Medical Center, and Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Karnieli</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Institute of Endocrinology, Diabetes and Metabolism, Rambam Medical Center, and Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <VernacularTitle/>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Horm Metab Res</MedlineTA>
            <NlmUniqueID>0177722</NlmUniqueID>
            <ISSNLinking>0018-5043</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0034-1387736</ArticleId>
            <ArticleId IdType="pubmed">25153686</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153680</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Development of ??-Lactoglobulin-Specific Chimeric Human IgE?? Monoclonal Antibodies for In Vitro Safety Assessment of Whey Hydrolysates.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e106025</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0106025</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cow's milk-derived whey hydrolysates are nutritional substitutes for allergic infants. Safety or residual allergenicity assessment of these whey hydrolysates is crucial. Currently, rat basophilic leukemia RBL-2H3 cells expressing the human IgE receptor ??-chain (huFc??RI??-RBL-2H3), sensitized with serum IgE from cow's milk allergic children, are being employed to assess in vitro residual allergenicity of these whey hydrolysates. However, limited availability and inter-lot variation of these allergic sera impede standardization of whey hydrolysate safety testing in degranulation assays.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">An oligoclonal pool of chimeric human (chu)IgE antibodies against bovine ??-lactoglobulin (a major allergen in whey) was generated to increase sensitivity, specificity, and reproducibility of existing degranulation assays.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Mice were immunized with bovine ??-lactoglobulin, and subsequently the variable domains of dissimilar anti-??-lactoglobulin mouse IgG antibodies were cloned and sequenced. Six chimeric antibodies were generated comprising mouse variable domains and human constant IgE/?? domains.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">After sensitization with this pool of anti-??-lactoglobulin chuIgEs, huFc??RI??-expressing RBL-2H3 cells demonstrated degranulation upon cross-linking with whey, native 18 kDa ??-lactoglobulin, and 5-10 kDa whey hydrolysates, whereas a 3 kDa whey hydrolysate and cow's milk powder (mainly casein) showed no degranulation. In parallel, allergic serum IgEs were less sensitive. In addition, our pool anti-??-lactoglobulin chuIgEs recognized multiple allergenic immunodominant regions on ??-lactoglobulin, which were also recognized by serum IgEs from cow's milk allergic children.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Usage of our 'unlimited' source and well-defined pool of ??-lactoglobulin-specific recombinant chuIgEs to sensitize huFc??RI?? on RBL-2H3 cells showed to be a relevant and sensitive alternative for serum IgEs from cow's milk allergic patients to assess safety of whey-based non-allergic hydrolyzed formula.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Knipping</LastName>
                    <ForeName>Karen</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Nutricia Research B.V., Utrecht, The Netherlands; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Simons</LastName>
                    <ForeName>Peter J</ForeName>
                    <Initials>PJ</Initials>
                    <Affiliation>Bioceros Holding B.V., Utrecht, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Buelens-Sleumer</LastName>
                    <ForeName>Laura S</ForeName>
                    <Initials>LS</Initials>
                    <Affiliation>Nutricia Research B.V., Utrecht, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cox</LastName>
                    <ForeName>Linda</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Bioceros Holding B.V., Utrecht, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>den Hartog</LastName>
                    <ForeName>Marcel</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Bioceros Holding B.V., Utrecht, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>de Jong</LastName>
                    <ForeName>Niels</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Bioceros Holding B.V., Utrecht, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Teshima</LastName>
                    <ForeName>Reiko</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Division of Foods, National Institute of Health Sciences, Tokyo, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Garssen</LastName>
                    <ForeName>Johan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Nutricia Research B.V., Utrecht, The Netherlands; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Boon</LastName>
                    <ForeName>Louis</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Bioceros Holding B.V., Utrecht, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Knippels</LastName>
                    <ForeName>L??on M J</ForeName>
                    <Initials>LM</Initials>
                    <Affiliation>Nutricia Research B.V., Utrecht, The Netherlands; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0106025</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-13141</ArticleId>
            <ArticleId IdType="pubmed">25153680</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153636</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1422-0067</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>15</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of molecular sciences</Title>
                <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Multi-Step Pathogenesis and Induction of Local Immune Response by Systemic Candida Albicans Infection in an Intravenous Challenge Mouse Model.</ArticleTitle>
            <Pagination>
                <MedlinePgn>14848-14867</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Different murine species differ in their susceptibility to systemic infection with Candida albicans, giving rise to varied host immune responses, and this is compounded by variations in virulence of the different yeast strains used. Hence, this study was aimed at elucidating the pathogenesis of a clinical C. albicans isolate (HVS6360) in a murine intravenous challenge model by examining the different parameters which included the counts of red blood cells and associated components as well as the organ-specific expression profiles of cytokines and chemokines. Kidneys and brains of infected mice have higher fungal recovery rates as compared to other organs and there were extensive yeast infiltration with moderate to severe inflammation seen in kidney and brain tissues. Red blood cells (RBCs) and haemoglobin (Hb) counts were reduced throughout the infection period. Pattern recognition receptors (PRRs), chemokines and cytokine transcription profiles were varied among the different organs (kidney, spleen and brain) over 72 h post infections. Transcription of most of the PRRs, cytokines and chemokines were suppressed at 72 h post infection in spleen while continuous expression of PRRs, cytokines and chemokines genes were seen in brain and kidney. Reduction in red blood cells and haemoglobin counts might be associated with the action of extracellular haemolysin enzyme and haeme oxygenase of C. albicans in conjunction with iron scavenging for the fungal growth. Renal cells responsible for erythropoietin production may be injured by the infection and hence the combined effect of haemolysis plus lack of erythropoietin-induced RBC replenishment leads to aggravated reduction in RBC numbers. The varied local host immune profiles among target organs during systemic C. albicans infection could be of importance for future work in designing targeted immunotherapy through immunomodulatory approaches.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chin</LastName>
                    <ForeName>Voon-Kin</ForeName>
                    <Initials>VK</Initials>
                    <Affiliation>Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor 43400, Malaysia. cvk717@gmail.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Foong</LastName>
                    <ForeName>Kuan-Jeang</ForeName>
                    <Initials>KJ</Initials>
                    <Affiliation>Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor 43400, Malaysia. darkangel_wuu@hotmail.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Maha</LastName>
                    <ForeName>Abdullah</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor 43400, Malaysia. maha@upm.edu.my.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rusliza</LastName>
                    <ForeName>Basir</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Human Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor 43400, Malaysia. rusliza@upm.edu.my.</Affiliation>
                </Author>
                <Author>
                    <LastName>Norhafizah</LastName>
                    <ForeName>Mohtarrudin</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor 43400, Malaysia. norhafizahm@upm.edu.my.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chong</LastName>
                    <ForeName>Pei Pei</ForeName>
                    <Initials>PP</Initials>
                    <Affiliation>Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor 43400, Malaysia. cpp@upm.edu.my.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Int J Mol Sci</MedlineTA>
            <NlmUniqueID>101092791</NlmUniqueID>
            <ISSNLinking>1422-0067</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ijms150814848</ArticleId>
            <ArticleId IdType="doi">10.3390/ijms150814848</ArticleId>
            <ArticleId IdType="pubmed">25153636</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153525</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nuclear Glycolytic Enzyme Enolase of Toxoplasma gondii Functions as a Transcriptional Regulator.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105820</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0105820</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Apicomplexan parasites including Toxoplasma gondii have complex life cycles within different hosts and their infectivity relies on their capacity to regulate gene expression. However, little is known about the nuclear factors that regulate gene expression in these pathogens. Here, we report that T. gondii enolase TgENO2 is targeted to the nucleus of actively replicating parasites, where it specifically binds to nuclear chromatin in vivo. Using a ChIP-Seq technique, we provide evidence for TgENO2 enrichment at the 5' untranslated gene regions containing the putative promoters of 241 nuclear genes. Ectopic expression of HA-tagged TgENO1 or TgENO2 led to changes in transcript levels of numerous gene targets. Targeted disruption of TgENO1 gene results in a decrease in brain cyst burden of chronically infected mice and in changes in transcript levels of several nuclear genes. Complementation of this knockout mutant with ectopic TgENO1-HA fully restored normal transcript levels. Our findings reveal that enolase functions extend beyond glycolytic activity and include a direct role in coordinating gene regulation in T. gondii.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Mouveaux</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Center for Infection and Immunity of Lille, CNRS UMR 8204, INSERM U 1019, Institut Pasteur de Lille, Universit?? Lille Nord de France, Lille, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Oria</LastName>
                    <ForeName>Gabrielle</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Center for Infection and Immunity of Lille, CNRS UMR 8204, INSERM U 1019, Institut Pasteur de Lille, Universit?? Lille Nord de France, Lille, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Werkmeister</LastName>
                    <ForeName>Elisabeth</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Center for Infection and Immunity of Lille, CNRS UMR 8204, INSERM U 1019, Institut Pasteur de Lille, Universit?? Lille Nord de France, Lille, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Slomianny</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Laboratory of Cell Physiology, INSERM U 1003, Universit?? Lille Nord de France, Villeneuve d'Ascq, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fox</LastName>
                    <ForeName>Barbara A</ForeName>
                    <Initials>BA</Initials>
                    <Affiliation>Department of Microbiology and Immunology, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bzik</LastName>
                    <ForeName>David J</ForeName>
                    <Initials>DJ</Initials>
                    <Affiliation>Department of Microbiology and Immunology, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tomavo</LastName>
                    <ForeName>Stanislas</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Center for Infection and Immunity of Lille, CNRS UMR 8204, INSERM U 1019, Institut Pasteur de Lille, Universit?? Lille Nord de France, Lille, France.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105820</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-19643</ArticleId>
            <ArticleId IdType="pubmed">25153525</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153515</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7972</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neuroscience letters</Title>
                <ISOAbbreviation>Neurosci. Lett.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Age-dependent redistribution and hypersialylation of the central myelin paranodal loop membrane protein Opalin in the mouse brain.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0304-3940(14)00667-3</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.neulet.2014.08.017</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Opalin/Tmem10 is a myelin-associated sialylglycoprotein that is specific to only the mammalian central nervous system. However, little is known about the properties or function of this protein. Here, we analyzed the expression and glycosylation patterns of Opalin in the postnatal mouse brain. Immunolocalization patterns of Opalin were similar to those of myelin basic protein in juvenile and adolescent mice. On the other hand, in the adult mouse brain, decreasing immunoreactivity for Opalin was observed in the hindbrain region especially in the cerebellar white matter compared with the corpus callosum in the forebrain. In addition, Opalin showed increasing molecular size with mouse aging. This age-dependent increase in Opalin molecular weight was mainly owing to hypersialylation of O-glycans. These results indicate that the regional redistribution and the degree of sialylation of Opalin protein are age-dependently regulated in mouse brains.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ireland Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sato</LastName>
                    <ForeName>Yumi</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Laboratory for Molecular Neurogenesis, RIKEN Brain Science Institute, Saitama 351-0198, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yoshikawa</LastName>
                    <ForeName>Fumio</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Laboratory for Molecular Neurogenesis, RIKEN Brain Science Institute, Saitama 351-0198, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sadakata</LastName>
                    <ForeName>Tetsushi</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Laboratory for Molecular Neurogenesis, RIKEN Brain Science Institute, Saitama 351-0198, Japan; Advanced Scientific Research Leaders Development Unit, Gunma University, Gunma 371-8511, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shinoda</LastName>
                    <ForeName>Yo</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Laboratory for Molecular Neurogenesis, RIKEN Brain Science Institute, Saitama 351-0198, Japan; Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Chiba 278-8510, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Koebis</LastName>
                    <ForeName>Michinori</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Chiba 278-8510, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Furuichi</LastName>
                    <ForeName>Teiichi</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Laboratory for Molecular Neurogenesis, RIKEN Brain Science Institute, Saitama 351-0198, Japan; Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Chiba 278-8510, Japan. Electronic address: tfuruichi@rs.tus.ac.jp.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neurosci Lett</MedlineTA>
            <NlmUniqueID>7600130</NlmUniqueID>
            <ISSNLinking>0304-3940</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Myelin</Keyword>
            <Keyword MajorTopicYN="N">Oligodendrocyte</Keyword>
            <Keyword MajorTopicYN="N">Opalin</Keyword>
            <Keyword MajorTopicYN="N">Paranodal loops</Keyword>
            <Keyword MajorTopicYN="N">Sialylated glycoprotein</Keyword>
            <Keyword MajorTopicYN="N">Tmem10</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0304-3940(14)00667-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neulet.2014.08.017</ArticleId>
            <ArticleId IdType="pubmed">25153515</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153513</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-4995</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemistry</Title>
                <ISOAbbreviation>Biochemistry</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Biological activity differences between TGF-??1 and TGF-??3 correlate with differences in the rigidity and arrangement of their component monomers.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">TGF-??1, -??2, and ??3 are small, secreted signaling proteins. They share 71-80% sequence identity and signal through the same receptors, yet the isoform-specific null mice have distinctive phenotypes and are inviable. The replacement of the coding sequence of TGF-??1 with TGF-??3 and TGF-??3 with TGF-??1 led to only partial rescue of the mutant phenotypes, suggesting that intrinsic differences between them contribute to the requirement of each in vivo. Here, we investigated whether the previously reported differences in the flexibility of the interfacial helix and arrangement of monomers was responsible for the differences in activity by generating two chimeric proteins in which residues 54-75 in the homodimer interface were swapped. Structural analysis of these using NMR and functional analysis using a dermal fibroblast migration assay showed that swapping the interfacial region swapped both the conformational preferences and activity. Conformational and activity differences were also observed between TGF-??3 and a variant with four helix-stabilizing residues from TGF-??1, suggesting that the observed changes were due to increased helical stability and the altered conformation, as proposed. SPR analysis showed that TGF-??1, TGF-??3, and variants bound the type II signaling receptor, T??RII, nearly identically, but had small differences in the dissociation rate constant for recruitment of the type I signaling receptor, T??RI. However, the latter did not correlate with conformational preference or activity. Hence, the difference in activity arises from differences in their conformations, not their manner of receptor binding, suggesting that a matrix protein that differentially binds them might determine their distinct activities.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Tao</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Schor</LastName>
                    <ForeName>Seth L</ForeName>
                    <Initials>SL</Initials>
                </Author>
                <Author>
                    <LastName>Hinck</LastName>
                    <ForeName>Andrew Peterson</ForeName>
                    <Initials>AP</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biochemistry</MedlineTA>
            <NlmUniqueID>0370623</NlmUniqueID>
            <ISSNLinking>0006-2960</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi500647d</ArticleId>
            <ArticleId IdType="pubmed">25153513</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153506</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1536-4844</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Inflammatory bowel diseases</Title>
                <ISOAbbreviation>Inflamm. Bowel Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Emerging Significance of NLRs in Inflammatory Bowel Disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">: Pattern recognition receptors are essential mediators of host defense and inflammation in the gastrointestinal system. Recent data have revealed that toll-like receptors and nucleotide-binding domain and leucine-rich repeat-containing proteins (NLRs) function to maintain homeostasis between the host microbiome and mucosal immunity. The NLR proteins are a diverse class of cytoplasmic pattern recognition receptors. In humans, only about half of the identified NLRs have been adequately characterized. The majority of well-characterized NLRs participate in the formation of a multiprotein complex, termed the inflammasome, which is responsible for the maturation of interleukin-1?? and interleukin-18. However, recent observations have also uncovered the presence of a novel subgroup of NLRs that function as positive or negative regulators of inflammation through modulating critical signaling pathways, including NF-??B. Dysregulation of specific NLRs from both proinflammatory and inhibitory subgroups have been associated with the development of inflammatory bowel disease (IBD) in genetically susceptible human populations. Our own preliminary retrospective data mining efforts have identified a diverse range of NLRs that are significantly altered at the messenger RNA level in colons from patients with IBD. Likewise, studies using genetically modified mouse strains have revealed that multiple NLR family members have the potential to dramatically modulate the immune response during IBD. Targeting NLR signaling represents a promising and novel therapeutic strategy. However, significant effort is necessary to translate the current understanding of NLR biology into effective therapies.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Davis</LastName>
                    <ForeName>Beckley K</ForeName>
                    <Initials>BK</Initials>
                    <Affiliation>*Department of Biology, Franklin and Marshall College, Lancaster, Pennsylvania; ???Nutritional Immunology and Molecular Medicine Laboratory, Center for Modeling Immunity to Enteric Pathogens, Virginia Bioinformatics Institute, Virginia Tech, Blacksburg, Virginia; and ???Department of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Philipson</LastName>
                    <ForeName>Casandra</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Hontecillas</LastName>
                    <ForeName>Raquel</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Eden</LastName>
                    <ForeName>Kristin</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Bassaganya-Riera</LastName>
                    <ForeName>Josep</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Allen</LastName>
                    <ForeName>Irving C</ForeName>
                    <Initials>IC</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Inflamm Bowel Dis</MedlineTA>
            <NlmUniqueID>9508162</NlmUniqueID>
            <ISSNLinking>1078-0998</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MIB.0000000000000151</ArticleId>
            <ArticleId IdType="pubmed">25153506</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153456</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1532-2378</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>26</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Jan</Month>
                        <Day>2</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Animal biotechnology</Title>
                <ISOAbbreviation>Anim. Biotechnol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Liver Lobe and Strain Difference in Gene Expression After Hydrodynamics-Based Gene Delivery in Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>51-57</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Hydrodynamics-based gene delivery (HGD) is a widely recognized technique for delivering exogenous DNA with high efficiency to murine hepatocytes. In this study, we investigated stimulation of exogenous DNA uptake and expression using a commercially available reagent for HGD. We also examined which mouse strain and mouse liver lobe would achieve the best gene delivery performance. Mice were injected with a solution containing reporter plasmid DNA or DNA and a gene delivery reagent. One day after the HGD procedure, liver samples were isolated and subjected to biochemical and histochemical analyses. The reporter plasmid DNA showed the strongest signal when the DNA was dissolved in TransIT-EE Hydrodynamic Delivery Solution (Takara Bio Inc., Shiga, Japan). Evaluation of transgene expression in each hepatic lobe in ICR, C57BL/6N, Balb/cA, and B6C3F1 mice showed that ICR mice exhibited the best gene transfer and that the right median lobe had the highest level of transgene expression. These findings suggest the importance of choice in mouse strains and liver lobes when performing gene-based manipulations of the liver.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Nakamura</LastName>
                    <ForeName>Shingo</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>a Department of Surgery II , National Defense Medical College , Saitama , Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Maehara</LastName>
                    <ForeName>Tadaaki</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Watanabe</LastName>
                    <ForeName>Satoshi</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Ishihara</LastName>
                    <ForeName>Masayuki</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Sato</LastName>
                    <ForeName>Masahiro</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Anim Biotechnol</MedlineTA>
            <NlmUniqueID>9011409</NlmUniqueID>
            <ISSNLinking>1049-5398</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CAG, cytomegalovirus enhancer??+??chicken ??-actin promoter</Keyword>
            <Keyword MajorTopicYN="N">EGFP, enhanced green fluorescent protein</Keyword>
            <Keyword MajorTopicYN="N">HGD, hydrodynamics-based gene delivery</Keyword>
            <Keyword MajorTopicYN="N">Hydrodynamics-based gene delivery (HGD)</Keyword>
            <Keyword MajorTopicYN="N">IRES, internal ribosomal entry site</Keyword>
            <Keyword MajorTopicYN="N">In vivo gene transfer</Keyword>
            <Keyword MajorTopicYN="N">Liver lobe</Keyword>
            <Keyword MajorTopicYN="N">Nonviral vector</Keyword>
            <Keyword MajorTopicYN="N">PEI, polyethylenimine</Keyword>
            <Keyword MajorTopicYN="N">RLU, relative light units</Keyword>
            <Keyword MajorTopicYN="N">SVp, SV40 early promoter</Keyword>
            <Keyword MajorTopicYN="N">Strain difference</Keyword>
            <Keyword MajorTopicYN="N">luc, luciferase</Keyword>
            <Keyword MajorTopicYN="N">pA, poly(A) sites</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10495398.2014.886583</ArticleId>
            <ArticleId IdType="pubmed">25153456</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153388</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1437-4315</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>395</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biological chemistry</Title>
                <ISOAbbreviation>Biol. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Kallikrein-related peptidase 7 (KLK7) is a proliferative factor that is aberrantly expressed in human colon cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1075-1086</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1515/hsz-2014-0142</ELocationID>
            <ELocationID EIdType="pii">/j/bchm.2014.395.issue-9/hsz-2014-0142/hsz-2014-0142.xml</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Abstract Emerging evidence indicates that serine proteases of the tissue kallikrein-related peptidases family (KLK) are implicated in tumorigenesis. We recently reported the ectopic expression of KLK4 and KLK14 in colonic cancers and their signaling to control cell proliferation. Human tissue kallikrein-related peptidase 7 (KLK7) is often dysregulated in many cancers; however, its role in colon tumorigenesis has not yet been established. In the present study, we analyzed expression of KLK7 in 15 colon cancer cell lines and in 38 human colonic tumors. In many human colon cancer cells, KLK7 mRNA was observed, which leads to KLK7 protein expression and secretion. Furthermore, KLK7 was detected in human colon adenocarcinomas, but it was absent in normal epithelia. KLK7 overexpression in HT29 colon cancer cells upon stable transfection with a KLK7 expression plasmid resulted in increased cell proliferation. Moreover, subcutaneous inoculation of transfected cells into nude mice led to increased tumor growth that was associated with increased tumor cell proliferation as reflected by a positive Ki-67 staining. Our results demonstrate the aberrant expression of KLK7 in colon cancer cells and tissues and its involvement in cell proliferation in vitro and in vivo. Thus, KLK7 may represent a potential therapeutic target for human colon tumorigenesis.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Walker</LastName>
                    <ForeName>Francine</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>Nicole</LastName>
                    <ForeName>Pascal</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author>
                    <LastName>Jallane</LastName>
                    <ForeName>Abdelhak</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Soosaipillai</LastName>
                    <ForeName>Antoninus</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Mosbach</LastName>
                    <ForeName>Valentine</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author>
                    <LastName>Oikonomopoulou</LastName>
                    <ForeName>Katerina</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Diamandis</LastName>
                    <ForeName>Eleftherios P</ForeName>
                    <Initials>EP</Initials>
                </Author>
                <Author>
                    <LastName>Magdolen</LastName>
                    <ForeName>Viktor</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author>
                    <LastName>Darmoul</LastName>
                    <ForeName>Dalila</ForeName>
                    <Initials>D</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biol Chem</MedlineTA>
            <NlmUniqueID>9700112</NlmUniqueID>
            <ISSNLinking>1431-6730</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1515/hsz-2014-0142</ArticleId>
            <ArticleId IdType="pii">/j/bchm.2014.395.issue-9/hsz-2014-0142/hsz-2014-0142.xml</ArticleId>
            <ArticleId IdType="pubmed">25153388</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153387</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1437-4315</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>395</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biological chemistry</Title>
                <ISOAbbreviation>Biol. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1063-1073</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1515/hsz-2014-0141</ELocationID>
            <ELocationID EIdType="pii">/j/bchm.2014.395.issue-9/hsz-2014-0141/hsz-2014-0141.xml</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Abstract Recent studies provide a functional link between kallikrein 6 (Klk6) and the development and progression of disease in patients with multiple sclerosis (MS) and in its murine models. To evaluate the involvement of additional kallikrein family members, we compared Klk6 expression with four other kallikreins (Klk1, Klk7, Klk8, and Klk10) in the brain and spinal cord of mice infected with Theiler's murine encephalomyelitis virus, an experimental model of progressive MS. The robust upregulation of Klk6 and Klk8 in the brain during the acute phase of viral encephalitis and in the spinal cord during disease development and progression points to their participation in inflammation, demyelination, and progressive axon degeneration. More limited changes in Klk1, Klk7, and Klk10 were also observed. In addition, Klk1, Klk6, and Klk10 were dynamically regulated in T cells in vitro as a recall response to viral antigen and in activated monocytes, pointing to their activities in the development of adaptive and innate immune function. Together, these results point to overlapping and unique roles for multiple kallikreins in the development and progression of virus-mediated central nervous system inflammatory demyelinating disease, including activities in the development of the adaptive and innate immune response, in demyelination, and in progressive axon degeneration.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Panos</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Christophi</LastName>
                    <ForeName>George P</ForeName>
                    <Initials>GP</Initials>
                </Author>
                <Author>
                    <LastName>Rodriguez</LastName>
                    <ForeName>Moses</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Scarisbrick</LastName>
                    <ForeName>Isobel A</ForeName>
                    <Initials>IA</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biol Chem</MedlineTA>
            <NlmUniqueID>9700112</NlmUniqueID>
            <ISSNLinking>1431-6730</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1515/hsz-2014-0141</ArticleId>
            <ArticleId IdType="pii">/j/bchm.2014.395.issue-9/hsz-2014-0141/hsz-2014-0141.xml</ArticleId>
            <ArticleId IdType="pubmed">25153387</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153385</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1437-4315</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>395</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biological chemistry</Title>
                <ISOAbbreviation>Biol. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CrataBL, a lectin and Factor Xa inhibitor, plays a role in blood coagulation and impairs thrombus formation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1027-1035</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1515/hsz-2014-0127</ELocationID>
            <ELocationID EIdType="pii">/j/bchm.2014.395.issue-9/hsz-2014-0127/hsz-2014-0127.xml</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Abstract Arterial thrombosis is an important complication of diabetes and cancer, being an important target for therapeutic intervention. Crataeva tapia bark lectin (CrataBL) has been previously shown to have hypoglycemiant effect and also to induce cancer cell apoptosis. It also showed inhibitory activity against Factor Xa (Kiapp=8.6 ??m). In the present study, we evaluated the anti-thrombotic properties of CrataBL in arterial thrombosis model. CrataBL prolongs the activated partial thromboplastin time on human and mouse plasma, and it impairs the heparin-induced potentiation of antithrombin III and heparin-induced platelet activation in the presence of low-dose ADP. It is likely that the dense track of positive charge on CrataBL surface competes with the heparin ability to bind to antithrombin III and to stimulate platelets. In the photochemically induced thrombosis model in mice, in the groups treated with 1.25, 5.0, or 10 mg/kg CrataBL, prior to the thrombus induction, the time of total artery occlusion was prolonged by 33.38%, 65%, and 66.11%, respectively, relative to the time of the control group. In contrast to heparin, the bleeding time in CrataBL-treated mice was no longer than in the control. In conclusion, CrataBL was effective in blocking coagulation and arterial thrombus formation, without increasing bleeding time.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Salu</LastName>
                    <ForeName>Bruno R</ForeName>
                    <Initials>BR</Initials>
                </Author>
                <Author>
                    <LastName>Ferreira</LastName>
                    <ForeName>Rodrigo S</ForeName>
                    <Initials>RS</Initials>
                </Author>
                <Author>
                    <LastName>Brito</LastName>
                    <ForeName>Marlon V</ForeName>
                    <Initials>MV</Initials>
                </Author>
                <Author>
                    <LastName>Ottaiano</LastName>
                    <ForeName>Tatiana F</ForeName>
                    <Initials>TF</Initials>
                </Author>
                <Author>
                    <LastName>Cruz</LastName>
                    <ForeName>Jos?? Walber M C</ForeName>
                    <Initials>JW</Initials>
                </Author>
                <Author>
                    <LastName>Silva</LastName>
                    <ForeName>Mariana Cristina C</ForeName>
                    <Initials>MC</Initials>
                </Author>
                <Author>
                    <LastName>Correia</LastName>
                    <ForeName>Maria Tereza S</ForeName>
                    <Initials>MT</Initials>
                </Author>
                <Author>
                    <LastName>Paiva</LastName>
                    <ForeName>Patr??cia M G</ForeName>
                    <Initials>PM</Initials>
                </Author>
                <Author>
                    <LastName>Maffei</LastName>
                    <ForeName>Francisco Humberto A</ForeName>
                    <Initials>FH</Initials>
                </Author>
                <Author>
                    <LastName>Oliva</LastName>
                    <ForeName>Maria Luiza Vilela</ForeName>
                    <Initials>ML</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biol Chem</MedlineTA>
            <NlmUniqueID>9700112</NlmUniqueID>
            <ISSNLinking>1431-6730</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1515/hsz-2014-0127</ArticleId>
            <ArticleId IdType="pii">/j/bchm.2014.395.issue-9/hsz-2014-0127/hsz-2014-0127.xml</ArticleId>
            <ArticleId IdType="pubmed">25153385</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153384</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1437-4315</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>395</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biological chemistry</Title>
                <ISOAbbreviation>Biol. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Evolution of Klk4 and enamel maturation in eutherians.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1003-1013</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1515/hsz-2014-0122</ELocationID>
            <ELocationID EIdType="pii">/j/bchm.2014.395.issue-9/hsz-2014-0122/hsz-2014-0122.xml</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Abstract Kallikrein-related peptidase 4 (KLK4) is a secreted serine protease that degrades residual enamel proteins to facilitate their removal by ameloblasts, which increases mineralization and hardens the enamel. Mutations in human KLK4 cause hypomaturation amelogenesis imperfecta. Enamel formed by Klk4 null mice is normal in thickness and prism structure, but the enamel layer retains proteins, is hypomineralized, and undergoes rapid attrition following tooth eruption. We searched multiple databases, retrieved Klk4 and Klk5 from various mammalian genomes, and identified Klk4 in 46 boreoeutherian genomes. In non-Boreoeutheria, Klk4 was detected in only one afrotherian genome (as a pseudogene), and not in the other six afrotherian, two xenarthran, or three marsupial genomes. In contrast, Klk5 was detected in both marsupial and eutherian mammals. Our phylogenetic and mutation rate analyses support the hypothesis that Klk4 arose from Klk5 by gene duplication near the divergence of Afrotheria, Xenarthra and Boreoeutheria, and that functionally-differentiated Klk4 survived only in Boreoeutheria. Afrotherian mammals share the feature of delayed dental eruption relative to boreoeutherian mammals. KLK4 shortens the time required for enamel maturation and could have alleviated negative selection following mutations that resulted in thicker enamel or earlier tooth eruption, without reducing enamel hardness or causing dental attrition.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kawasaki</LastName>
                    <ForeName>Kazuhiko</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Jan C-C</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author>
                    <LastName>Simmer</LastName>
                    <ForeName>James P</ForeName>
                    <Initials>JP</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biol Chem</MedlineTA>
            <NlmUniqueID>9700112</NlmUniqueID>
            <ISSNLinking>1431-6730</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1515/hsz-2014-0122</ArticleId>
            <ArticleId IdType="pii">/j/bchm.2014.395.issue-9/hsz-2014-0122/hsz-2014-0122.xml</ArticleId>
            <ArticleId IdType="pubmed">25153384</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153381</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1437-4315</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>395</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biological chemistry</Title>
                <ISOAbbreviation>Biol. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>945-958</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1515/hsz-2014-0137</ELocationID>
            <ELocationID EIdType="pii">/j/bchm.2014.395.issue-9/hsz-2014-0137/hsz-2014-0137.xml</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Abstract Netherton syndrome (NS) is an orphan genetic skin disease with a profound skin barrier defect and severe allergic manifestations. NS is caused by loss of function mutations in SPINK5 encoding lympho-epithelial Kazal-type inhibitor (LEKTI), a secreted multi-domain serine protease inhibitor expressed in stratified epithelia. Studies in mouse models and in NS patients have established that unopposed kallikrein 5 activity triggers stratum corneum detachment and activates PAR-2 signaling, leading to the autonomous production of pro-allergic and pro-inflammatory mediators. This emerging knowledge on NS pathogenesis has highlighted a central role for protease regulation in skin homeostasis but also in the complexity of the disease, and holds the promise of new specific treatments.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Furio</LastName>
                    <ForeName>Laetitia</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Hovnanian</LastName>
                    <ForeName>Alain</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biol Chem</MedlineTA>
            <NlmUniqueID>9700112</NlmUniqueID>
            <ISSNLinking>1431-6730</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1515/hsz-2014-0137</ArticleId>
            <ArticleId IdType="pii">/j/bchm.2014.395.issue-9/hsz-2014-0137/hsz-2014-0137.xml</ArticleId>
            <ArticleId IdType="pubmed">25153381</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153375</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2191-0286</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>7</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of basic and clinical physiology and pharmacology</Title>
                <ISOAbbreviation>J Basic Clin Physiol Pharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Role for monoaminergic systems in the antidepressant and anxiolytic properties of the hydroethanolic leaf extract from Adenia cissampeloides.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1515/jbcpp-2014-0015</ELocationID>
            <ELocationID EIdType="pii">/j/jbcpp.ahead-of-print/jbcpp-2014-0015/jbcpp-2014-0015.xml</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Abstract Background: Adenia cissampeloides (Planch ex. Hook) Harms (Passifloraceae) leaf infusion is used in traditional African medicine as a stimulant to treat depression and insanity. Thus, this study investigates antidepressant and anxiolytic activities of the hydroethanol leaf extract of Adenia cissampeloides (ACE) in mice. Methods: ACE (50-200 mg/kg, p.o.) was administered to mice 1 h before behavioral studies; the forced swimming test (FST), tail suspension test (TST), elevated-plus maze test (EPM) hole-board test (HBT) and open field test (OFT). In addition, the probable mechanisms of antidepressant- and anxiolytic-like actions of ACE were also investigated. Results: ACE (100 and 200 mg/kg) produced significant (p&lt;0.01) reduction in immobility, along with a significant increase in swimming activity (75.20%) and climbing (190.00%), respectively, similar to anti-immobility effect of imipramine in the FST. Also, in TST, ACE (100 and 200 mg/kg) treatment significantly (p&lt;0.01) reduced the immobility time by 35.60%, and 35.27%, respectively, which was similar to anti-immobility effect of fluoxetine (32.50%). However, the antidepressant-like effect produced by ACE was prevented (p&lt;0.01) by yohimbine (??2-adrenoceptor antagonist), or sulpiride (dopamine D2 receptor antagonist) pretreatment. ACE (50 and 100 mg/kg) treatment (p&lt;0.01) increased number (41.67%) and duration of head-dips (52.27%) in HBT. Similarly, ACE (50-200 mg/kg) increased duration of open arm entries (p&lt;0.001) in EPM. However, this effect was reversed (p&lt;0.001) by pretreatment of mice with cyproheptadine (5-HT2 receptor antagonist) (60.87%). Conclusions: Findings from these studies revealed antidepressant-like effect of ACE mediated through interaction with dopamine D2- receptor or ??2-adrenoceptor. Also an anxiolytic-like effect through interaction with 5-HT2 receptors.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ishola</LastName>
                    <ForeName>Ismail O</ForeName>
                    <Initials>IO</Initials>
                </Author>
                <Author>
                    <LastName>Olayemi</LastName>
                    <ForeName>Sunday O</ForeName>
                    <Initials>SO</Initials>
                </Author>
                <Author>
                    <LastName>Yemitan</LastName>
                    <ForeName>Omoniyi K</ForeName>
                    <Initials>OK</Initials>
                </Author>
                <Author>
                    <LastName>Akinseye</LastName>
                    <ForeName>Kolawole</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Basic Clin Physiol Pharmacol</MedlineTA>
            <NlmUniqueID>9101750</NlmUniqueID>
            <ISSNLinking>0792-6855</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1515/jbcpp-2014-0015</ArticleId>
            <ArticleId IdType="pii">/j/jbcpp.ahead-of-print/jbcpp-2014-0015/jbcpp-2014-0015.xml</ArticleId>
            <ArticleId IdType="pubmed">25153375</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153355</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-3650</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Seminars in cancer biology</Title>
                <ISOAbbreviation>Semin. Cancer Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and epithelial-mesenchymal transition.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1044-579X(14)00100-X</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.semcancer.2014.08.003</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Cripto-1 (CR-1)/Teratocarcinoma-derived growth factor1 (TDGF-1) is a cell surface glycosylphosphatidylinositol (GPI)-linked glycoprotein that can function either in cis (autocrine) or in trans (paracrine). The cell membrane cis form is found in lipid rafts and endosomes while the trans acting form lacking the GPI anchor is soluble. As a member of the epidermal growth factor (EGF)/Cripto-1-FRL-1-Cryptic (CFC) family, CR-1 functions as an obligatory co-receptor for the transforming growth factor-?? (TGF-??) family members, Nodal and growth and differentiation factors 1 and 3 (GDF1/3) by activating Alk4/Alk7 signaling pathways that involve Smads 2, 3 and 4. In addition, CR-1 can activate non-Smad-dependent signaling elements such as PI3K, Akt and MAPK. Both of these pathways depend upon the 78kDa glucose regulated protein (GRP78). Finally, CR-1 can facilitate signaling through the canonical Wnt/??-catenin and Notch/Cbf-1 pathways by functioning as a chaperone protein for LRP5/6 and Notch, respectively. CR-1 is essential for early embryonic development and maintains embryonic stem cell pluripotentiality. CR-1 performs an essential role in the etiology and progression of several types of human tumors where it is expressed in a population of cancer stem cells (CSCs) and facilitates epithelial-mesenchymal transition (EMT). In this context, CR-1 can significantly enhance tumor cell migration, invasion and angiogenesis. Collectively, these facts suggest that CR-1 may be an attractive target in the diagnosis, prognosis and therapy of several types of human cancer.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Klauzinska</LastName>
                    <ForeName>Malgorzata</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Mouse Cancer Genetics Program, Center for Cancer Research, Frederick, MD 21702, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Castro</LastName>
                    <ForeName>Nadia P</ForeName>
                    <Initials>NP</Initials>
                    <Affiliation>Mouse Cancer Genetics Program, Center for Cancer Research, Frederick, MD 21702, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rangel</LastName>
                    <ForeName>Maria Cristina</ForeName>
                    <Initials>MC</Initials>
                    <Affiliation>Mouse Cancer Genetics Program, Center for Cancer Research, Frederick, MD 21702, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Spike</LastName>
                    <ForeName>Benjamin T</ForeName>
                    <Initials>BT</Initials>
                    <Affiliation>Gene Expression Laboratory.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gray</LastName>
                    <ForeName>Peter C</ForeName>
                    <Initials>PC</Initials>
                    <Affiliation>Clayton Foundation Laboratories for Peptide Biology,Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bertolette</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Mouse Cancer Genetics Program, Center for Cancer Research, Frederick, MD 21702, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cuttitta</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Mouse Cancer Genetics Program, Center for Cancer Research, Frederick, MD 21702, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Salomon</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Mouse Cancer Genetics Program, Center for Cancer Research, Frederick, MD 21702, USA. Electronic address: salomond@mail.nih.gov.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>REVIEW</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Semin Cancer Biol</MedlineTA>
            <NlmUniqueID>9010218</NlmUniqueID>
            <ISSNLinking>1044-579X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cancer Stem cells Epithelial-mesenchymal transition GRP78 Cripto-1</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1044-579X(14)00100-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.semcancer.2014.08.003</ArticleId>
            <ArticleId IdType="pubmed">25153355</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153354</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-3650</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Seminars in cancer biology</Title>
                <ISOAbbreviation>Semin. Cancer Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Implications Of Stemness-Related Signaling Pathways In Breast Cancer Response To Therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1044-579X(14)00101-1</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.semcancer.2014.08.004</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">There is accumulating evidence that breast cancer may arise from a small subpopulation of transformed mammary stem/progenitor cells, termed breast cancer-initiating cells (BCICs), responsible for initiation and maintenance of cancer. BCICs have been identified in clinical specimens based on CD44(+)/CD24(-/low) membrane expression and/or enzymatic activity of aldehyde dehydrogenase 1 (ALDH1+), or isolated and in vitro propagated as non adherent spheres. This cell population has been demonstrated to be able to recreate, when injected in mice even at very low concentrations, the same histopathological features of the tumor they were derived from and to escape from current therapeutic strategies. Alterations in genes involved in stemness-related pathways, such as Wnt, Notch, and Sonic Hedgehog, have been proven to play a role in breast cancer progression. Targeting these key elements represents an attractive option, with a solid rationale, although possible concerns may derive from the poor knowledge of tolerance and efficacy of inhibiting these mechanisms without inducing severe side effects. In addition, efforts to develop alternative BCIC-targeted therapies against stemness markers (CD44 and ALDH1) and molecules involved in regulating EMT- and HER2-related pathways, or able to reverse the multi-drug resistance phenotype, or to induce differentiation and to control cell survival pathways are currently ongoing and encouraging results from pre-clinical studies have already been obtained using in vitro and in vivo models.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Angeloni</LastName>
                    <ForeName>Valentina</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Biomarkers Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G.A. Amadeo, 42, 20133 Milan, Italy. Electronic address: valentina.angeloni@istitutotumori.mi.it.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tiberio</LastName>
                    <ForeName>Paola</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Biomarkers Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G.A. Amadeo, 42, 20133 Milan, Italy. Electronic address: paola.tiberio@istitutotumori.mi.it.</Affiliation>
                </Author>
                <Author>
                    <LastName>Appierto</LastName>
                    <ForeName>Valentina</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Biomarkers Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G.A. Amadeo, 42, 20133 Milan, Italy. Electronic address: valentina.appierto@istitutotumori.mi.it.</Affiliation>
                </Author>
                <Author>
                    <LastName>Daidone</LastName>
                    <ForeName>Maria Grazia</ForeName>
                    <Initials>MG</Initials>
                    <Affiliation>Biomarkers Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G.A. Amadeo, 42, 20133 Milan, Italy. Electronic address: mariagrazia.daidone@istitutotumori.mi.it.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>REVIEW</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Semin Cancer Biol</MedlineTA>
            <NlmUniqueID>9010218</NlmUniqueID>
            <ISSNLinking>1044-579X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">breast cancer-initiating cell</Keyword>
            <Keyword MajorTopicYN="N">stemness marker</Keyword>
            <Keyword MajorTopicYN="N">stemness pathway</Keyword>
            <Keyword MajorTopicYN="N">targeted therapy</Keyword>
            <Keyword MajorTopicYN="N">treatment response</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1044-579X(14)00101-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.semcancer.2014.08.004</ArticleId>
            <ArticleId IdType="pubmed">25153354</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153352</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-6882</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Analytical chemistry</Title>
                <ISOAbbreviation>Anal. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Automated Anatomical Interpretation of Ion Distributions in Tissue: Linking Imaging Mass Spectrometry to Curated Atlases.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Imaging mass spectrometry (IMS) has become a prime tool for studying the distribution of biomolecules in tissue. Although IMS data sets can become very large, computational methods have made it practically feasible to search these experiments for relevant findings. However, these methods lack access to an important source of information that many human interpretations rely upon: anatomical insight. In this work, we address this need by (1) integrating a curated anatomical data source with an empirically acquired IMS data source, establishing an algorithm-accessible link between them and (2) demonstrating the potential of such an IMS-anatomical atlas link by applying it toward automated anatomical interpretation of ion distributions in tissue. The concept is demonstrated in mouse brain tissue, using the Allen Mouse Brain Atlas as the curated anatomical data source that is linked to MALDI-based IMS experiments. We first develop a method to spatially map the anatomical atlas to the IMS data sets using nonrigid registration techniques. Once a mapping is established, a second computational method, called correlation-based querying, gives an elementary demonstration of the link by delivering basic insight into relationships between ion images and anatomical structures. Finally, a third algorithm moves further beyond both registration and correlation by providing automated anatomical interpretation of ion images. This task is approached as an optimization problem that deconstructs ion distributions as combinations of known anatomical structures. We demonstrate that establishing a link between an IMS experiment and an anatomical atlas enables automated anatomical annotation, which can serve as an important accelerator both for human and machine-guided exploration of IMS experiments.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Verbeeck</LastName>
                    <ForeName>Nico</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Electrical Engineering (ESAT), STADIUS Center for Dynamical Systems, Signal Processing, and Data Analytics, KU Leuven , Kasteelpark Arenberg 10, Box 2446, 3001 Leuven, Belgium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Junhai</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>De Moor</LastName>
                    <ForeName>Bart</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author>
                    <LastName>Caprioli</LastName>
                    <ForeName>Richard M</ForeName>
                    <Initials>RM</Initials>
                </Author>
                <Author>
                    <LastName>Waelkens</LastName>
                    <ForeName>Etienne</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author>
                    <LastName>Van de Plas</LastName>
                    <ForeName>Raf</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Anal Chem</MedlineTA>
            <NlmUniqueID>0370536</NlmUniqueID>
            <ISSNLinking>0003-2700</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ac502838t</ArticleId>
            <ArticleId IdType="pubmed">25153352</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153350</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7980</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer letters</Title>
                <ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>AAV-sBTLA Facilitates HSP70 vaccine-triggered prophylactic antitumor immunity against a murine melanoma pulmonary metastasis model in vivo.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0304-3835(14)00434-0</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.canlet.2014.08.006</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Activation of the BTLA-HVEM co-inhibitory signaling pathway impairs antitumor immunity. Our previous study demonstrated that the extracellular domain of murine BTLA (the soluble form of BTLA) can facilitate HSP70 vaccine-triggered antitumor immunity by blocking BTLA-HVEM interactions in a murine TC-1 non-metastatic tumor model. However, it is unknown whether this strategy has beneficial effects on highly malignant metastatic tumors, such as melanoma. To address this question, we expressed the soluble form of BTLA (sBTLA) in combination with HSP70 vaccine and examined the resulting antitumor activity in a melanoma pulmonary metastasis model. A recombinant adeno-associated virus (AAV) vector was used for the sBTLA gene delivery because of its high transfection efficiency and low toxicity. In vitro expression of AAV-sBTLA enhanced lymphocyte activation and induced specific cytotoxicity against B16F1 murine melanoma cells, while in vivo administration of AAV-sBTLA plus HSP70 vaccine by tail vein injection exerted a limited, late-stage antitumor effect against the existing B16F1 cells. However, the combination treatment generated a potent prophylactic antitumor response in the melanoma lung metastasis model in B6 mice. In this case, most of the metastatic foci were inhibited, and mouse survival was prolonged. Furthermore, the Th1 cytokines IL-2 and IFN-?? were up-regulated, while the negative regulatory molecules IL-10 and TGF-?? were down-regulated. The number of regulatory T cells also decreased in the tumor environment. Therefore, AAV-sBTLA plus HSP70 vaccine may have therapeutic potential for the prevention of metastatic melanoma.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Han</LastName>
                    <ForeName>Lingfei</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine,Shanghai. Electronic address: lingfeihan@hotmail.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University, Guangzhou, P.R.China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lu</LastName>
                    <ForeName>Jiahong</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Neurological and Oncological Sciences, Mount Sinai School of Medicine, New York City, NY 10029, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kong</LastName>
                    <ForeName>Fanfei</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine,Shanghai.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ma</LastName>
                    <ForeName>Ge</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Neurological and Oncological Sciences, Mount Sinai School of Medicine, New York City, NY 10029, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhu</LastName>
                    <ForeName>Yiping</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine,Shanghai.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhao</LastName>
                    <ForeName>Dong</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine,Shanghai.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhu</LastName>
                    <ForeName>Jianlong</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine,Shanghai.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shuai</LastName>
                    <ForeName>Wen</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine,Shanghai.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Qian</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine,Shanghai.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Ping</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine,Shanghai.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ye</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine,Shanghai.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tao</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine,Shanghai.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ahmad</LastName>
                    <ForeName>Sarfraz</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Florida Hospital Gynecologic Oncology, Florida Hospital Cancer Institute and the Global Robotics Institute, Orlando, FL 32804, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Fang</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine,Shanghai. Electronic address: 09lifang@tongji.edu.cn.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sun</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine,Shanghai. Electronic address: sunjing61867@yahoo.com.cn.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cancer Lett</MedlineTA>
            <NlmUniqueID>7600053</NlmUniqueID>
            <ISSNLinking>0304-3835</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">AAV</Keyword>
            <Keyword MajorTopicYN="N">BTLA</Keyword>
            <Keyword MajorTopicYN="N">HSP70 vaccine</Keyword>
            <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
            <Keyword MajorTopicYN="N">Metastatic melanoma</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0304-3835(14)00434-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.canlet.2014.08.006</ArticleId>
            <ArticleId IdType="pubmed">25153350</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153345</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1999-4915</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>6</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Viruses</Title>
                <ISOAbbreviation>Viruses</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Divergence of Primary Cognate B- and T-Cell Proliferative Responses to Subcutaneous and Intravenous Immunization with Virus-Like Particles.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3334-3347</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">A major advantage of virus-like particle (VLP) vaccines against HIV is their structural identity to wild-type viruses, ensuring that antigen-specific B-cells encounter the envelope protein in its natural conformation. For the induction of affinity-matured antibodies, the B-cells must also obtain help from T-cells that are restricted by linear epitopes. Using B- and T-cell transgenic mouse models, we compared the efficacy of modified HIV-VLPs delivered by subcutaneous and intravenous immunization to stimulate primary B- and T-cell proliferative responses in different lymphoid organs. VLPs containing an influenza virus hemagglutinin epitope within the HIV-Gag protein induced comparable primary cognate T-cell proliferative responses in the draining lymph node and the spleen, irrespective of the delivery route. In contrast, after subcutaneous immunization with HIV-Gag VLPs containing hen egg lysozyme (HEL) on their surface, the proliferative response of transgenic HEL-specific B-cells was restricted to the draining lymph nodes, while intravenous VLP immunization primarily induced a B-cell proliferative response in the spleen. In vitro co-culture experiments further revealed that the presentation of VLP-associated surface antigens by dendritic cells to cognate B-cells is inefficient. This is consistent with a direct triggering of the B-cell proliferative response by the VLPs and suggests that HIV VLPs may indeed be suitable to directly promote the expansion of B-cells specific for conformational epitopes that are unique to functionally-active Env spikes on the virion. Further investigations are warranted to explore potential differences in the quality and protective potency of HIV-specific antibody responses induced by the two routes.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Temchura</LastName>
                    <ForeName>Vladimir</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Department of Molecular and Medical Virology, Ruhr-University Bochum, Bochum, D-44780, Germany. temchura@yandex.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kalinin</LastName>
                    <ForeName>Svetlana</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Molecular and Medical Virology, Ruhr-University Bochum, Bochum, D-44780, Germany. svetlana.kalinin@ruhr-uni-bochum.de.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nabi</LastName>
                    <ForeName>Ghulam</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Molecular and Medical Virology, Ruhr-University Bochum, Bochum, D-44780, Germany. ghulam.nabi@ruhr-uni-bochum.de.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tippler</LastName>
                    <ForeName>Bettina</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Molecular and Medical Virology, Ruhr-University Bochum, Bochum, D-44780, Germany. bettina.g.tippler@rub.de.</Affiliation>
                </Author>
                <Author>
                    <LastName>Niezold</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Molecular and Medical Virology, Ruhr-University Bochum, Bochum, D-44780, Germany. thomas.niezold@gmx.de.</Affiliation>
                </Author>
                <Author>
                    <LastName>Uberla</LastName>
                    <ForeName>Klaus</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Molecular and Medical Virology, Ruhr-University Bochum, Bochum, D-44780, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Viruses</MedlineTA>
            <NlmUniqueID>101509722</NlmUniqueID>
            <ISSNLinking>1999-4915</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">v6083334</ArticleId>
            <ArticleId IdType="doi">10.3390/v6083334</ArticleId>
            <ArticleId IdType="pubmed">25153345</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153343</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-5126</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of the American Chemical Society</Title>
                <ISOAbbreviation>J. Am. Chem. Soc.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A Supramolecular Host-Guest Carrier System for Growth Factors Employing VHH Fragments.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">A supramolecular strategy is presented for the assembly of growth factors employing His6-tagged single-domain antibodies (VHH). A combination of orthogonal supramolecular interactions of ??-cyclodextrin (??CD)-adamantyl (Ad) host-guest and N-nitrilotriacetic acid (NTA)-histidine (His) interactions was employed to generate reversible and homogeneous layers of growth factors. A single-domain antibody VHH fragment was identified to bind to the human bone morphogenetic protein-6 (hBMP6) growth factor and could be recombinantly expressed in E. coli. The VHH fragment was equipped with a C-terminal hexahistidine (His6) tether to facilitate the assembly on ??CD surfaces using a linker that contains an Ad group to bind to the ??CD receptors and an NTA moiety to interact with the His6-tag upon co-complexation of Ni2+ ions. After exploring the thermodynamic and kinetic stability of the VHH assemblies on ??CD surfaces using a variety of experimental techniques including microcontact printing (??CP), surface plasmon resonance (SPR), microscale thermophoresis (MST) and theoretical models for determining the thermodynamic behavior of the system, hBMP6 was assembled onto the VHH-functionalized surfaces. After analyzing the immobilized hBMP6 using immunostaining, the biological activity of hBMP6 was demonstrated in cell differentiation experiments. Early osteogenic differentiation was analyzed in terms of alkaline phosphatase (ALP) activity of KS483-4C3 mouse progenitor cells and the results indicated that the reversibly immobilized growth factors were functionally delivered to the cells. In conclusion, the supramolecular strategy used here offers the necessary affinity, reversibility and temporal control to promote biological function of the growth factors that were delivered by this strategy.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Cabanas-Dan??s</LastName>
                    <ForeName>Jordi</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Rodrigues</LastName>
                    <ForeName>Emilie</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author>
                    <LastName>Landman</LastName>
                    <ForeName>Ellie</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author>
                    <LastName>Weerd</LastName>
                    <ForeName>Jasper van</ForeName>
                    <Initials>JV</Initials>
                </Author>
                <Author>
                    <LastName>van Blitterswijk</LastName>
                    <ForeName>Clemens A</ForeName>
                    <Initials>CA</Initials>
                </Author>
                <Author>
                    <LastName>Verrips</LastName>
                    <ForeName>Theo</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Huskens</LastName>
                    <ForeName>Jurriaan</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Karperien</LastName>
                    <ForeName>Marcel</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Jonkheijm</LastName>
                    <ForeName>Pascal</ForeName>
                    <Initials>P</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Am Chem Soc</MedlineTA>
            <NlmUniqueID>7503056</NlmUniqueID>
            <ISSNLinking>0002-7863</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ja505695w</ArticleId>
            <ArticleId IdType="pubmed">25153343</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153316</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genome Sequence Analysis of In Vitro and In Vivo Phenotypes of Bunyamwera and Ngari Virus Isolates from Northern Kenya.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105446</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0105446</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Biological phenotypes of tri-segmented arboviruses display characteristics that map to mutation/s in the S, M or L segments of the genome. Plaque variants have been characterized for other viruses displaying varied phenotypes including attenuation in growth and/or pathogenesis. In order to characterize variants of Bunyamwera and Ngari viruses, we isolated individual plaque size variants; small plaque (SP) and large plaque (LP) and determined in vitro growth properties and in vivo pathogenesis in suckling mice. We performed gene sequencing to identify mutations that may be responsible for the observed phenotype. The LP generally replicated faster than the SP and the difference in growth rate was more pronounced in Bunyamwera virus isolates. Ngari virus isolates were more conserved with few point mutations compared to Bunyamwera virus isolates which displayed mutations in all three genome segments but majority were silent mutations. Contrary to expectation, the SP of Bunyamwera virus killed suckling mice significantly earlier than the LP. The LP attenuation may probably be due to a non-synonymous substitution (T858I) that mapped within the active site of the L protein. In this study, we identify natural mutations whose exact role in growth and pathogenesis need to be determined through site directed mutagenesis studies.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Odhiambo</LastName>
                    <ForeName>Collins</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Human Health Division, International Centre of Insect Physiology and Ecology, Nairobi, Kenya; Zoonoses Research Unit, Department Medical Virology, University of Pretoria, Pretoria, South Africa; Centre for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya.</Affiliation>
                </Author>
                <Author>
                    <LastName>Venter</LastName>
                    <ForeName>Marietjie</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Zoonoses Research Unit, Department Medical Virology, University of Pretoria, Pretoria, South Africa.</Affiliation>
                </Author>
                <Author>
                    <LastName>Limbaso</LastName>
                    <ForeName>Konongoi</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Centre for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya.</Affiliation>
                </Author>
                <Author>
                    <LastName>Swanepoel</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Zoonoses Research Unit, Department Medical Virology, University of Pretoria, Pretoria, South Africa.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sang</LastName>
                    <ForeName>Rosemary</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Human Health Division, International Centre of Insect Physiology and Ecology, Nairobi, Kenya; Centre for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya; Division of Emerging Infectious Disease, United States Army Medical Research Unit, Nairobi, Kenya.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105446</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-11390</ArticleId>
            <ArticleId IdType="pubmed">25153316</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153315</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Meloxicam and Buprenorphine Treatment after Ovarian Transplantation Does Not Affect Estrous Cyclicity and Follicular Integrity in Aged CBA/J Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e106013</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0106013</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Angiogenesis, the formation of new blood vessels, is important for the survival of ovarian transplants and the restoration of ovarian functions. Without angiogenesis, transplanted ovarian tissue becomes more susceptible to tissue damage and necrosis. Administration of analgesics for pain management has been shown to decrease angiogenesis, which can influence transplant success especially in aged animals. Aging and the effects of hypoxia after transplantation decrease reproductive viability of the ovarian transplant; therefore, it is important to understand the additional effects of analgesics on aged animal models. The present study investigated the effects of two analgesics, buprenorphine, an opiate, and meloxicam, a non-steroidal anti-inflammatory drug (NSAID), on the reproductive indicators related to estrous cyclicity and follicular integrity after ovarian transplantation of young ovaries into aged CBA/J mice. These aged females did not show any different reproductive responses when treated with either buprenorphine or meloxicam. No significant differences were observed in estrous cycle length, the onset of estrous cycling, the regularity of estrous cycles, and the proportion of viable follicles and total number of follicles per ovarian sample across treatment groups.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Le</LastName>
                    <ForeName>Anna H</ForeName>
                    <Initials>AH</Initials>
                    <Affiliation>Department of Biological Sciences, San Jos?? State University, San Jos??, California, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bonachea</LastName>
                    <ForeName>Luis A</ForeName>
                    <Initials>LA</Initials>
                    <Affiliation>Department of Biological Sciences, San Jos?? State University, San Jos??, California, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cargill</LastName>
                    <ForeName>Shelley L</ForeName>
                    <Initials>SL</Initials>
                    <Affiliation>Department of Biological Sciences, San Jos?? State University, San Jos??, California, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0106013</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-24781</ArticleId>
            <ArticleId IdType="pubmed">25153315</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153248</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1569-1802</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Matrix biology : journal of the International Society for Matrix Biology</Title>
                <ISOAbbreviation>Matrix Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Binding of MAGP2 to microfibrils is regulated by proprotein convertase cleavage.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0945-053X(14)00129-2</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.matbio.2014.08.003</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">MAGP2 is a small extracellular protein with both tumor angiogenesis and cell signaling activity. MAGP2 was originally isolated biochemically from microfibril-rich connective tissue. The localization of MAGP2 to microfibrils has been confirmed by both immunohistochemistry and immunogold electron microscopy. Whether MAGP2 binding to microfibrils is regulated post-translationally is still unclear, however, and a better understanding of this process would be instructive to understanding the angiogenesis and signaling functions ascribed to MAGP2. Here we show via immunofluorescence studies that the T3 cell line, derived from ovarian mouse tumor cells, produces abundant fibrillin-2 microfibrils to which MAGP2 can bind. Co-localization of MAGP2 and fibrillin-2 can be detected either when MAGP2 is overexpressed in, or exogenously introduced to, the cells. As expected, matrix association of MAGP2 required its conserved Matrix Binding Domain. Matrix association was positively regulated by proprotein convertase (PC) cleavage of MAGP2; mutation of the MAGP2 PC consensus site reduced the amount of matrix-associated MAGP2. Deletion analysis of the C-terminal 20-amino acid domain that is defined by the PC cleavage site suggests this domain also positively modulates matrix localization of MAGP2, in a manner that requires the amino-terminal half of the protein. Together, our data indicate that matrix localization of MAGP2 by its Matrix Binding Domain is promoted by PC cleavage and the presence of its C-terminal 20 amino acids.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Miyamoto</LastName>
                    <ForeName>Alison</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Biological Science, California State University Fullerton, Fullerton, CA 92831; Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA 92831. Electronic address: almiyamoto@fullerton.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Donovan</LastName>
                    <ForeName>Lauren J</ForeName>
                    <Initials>LJ</Initials>
                    <Affiliation>Department of Biological Science, California State University Fullerton, Fullerton, CA 92831; Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA 92831.</Affiliation>
                </Author>
                <Author>
                    <LastName>Perez</LastName>
                    <ForeName>Edgar</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Biological Science, California State University Fullerton, Fullerton, CA 92831; Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA 92831.</Affiliation>
                </Author>
                <Author>
                    <LastName>Connett</LastName>
                    <ForeName>Breanna</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Biological Science, California State University Fullerton, Fullerton, CA 92831; Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA 92831.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cervantes</LastName>
                    <ForeName>Richard</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Biological Science, California State University Fullerton, Fullerton, CA 92831; Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA 92831.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lai</LastName>
                    <ForeName>Khang</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Biological Science, California State University Fullerton, Fullerton, CA 92831; Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA 92831.</Affiliation>
                </Author>
                <Author>
                    <LastName>Withers</LastName>
                    <ForeName>Gordon</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Biological Science, California State University Fullerton, Fullerton, CA 92831; Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA 92831.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hogrebe</LastName>
                    <ForeName>Gregory</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Biological Science, California State University Fullerton, Fullerton, CA 92831; Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA 92831.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Matrix Biol</MedlineTA>
            <NlmUniqueID>9432592</NlmUniqueID>
            <ISSNLinking>0945-053X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Fibrillin</Keyword>
            <Keyword MajorTopicYN="N">MAGP2</Keyword>
            <Keyword MajorTopicYN="N">MFAP5</Keyword>
            <Keyword MajorTopicYN="N">Microfibril</Keyword>
            <Keyword MajorTopicYN="N">Proprotein convertase</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0945-053X(14)00129-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.matbio.2014.08.003</ArticleId>
            <ArticleId IdType="pubmed">25153248</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153170</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Polycomb Group Protein Ezh2 Regulates Hepatic Progenitor Cell Proliferation and Differentiation in Murine Embryonic Liver.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e104776</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0104776</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">In embryonic liver, hepatic progenitor cells are actively proliferating and generate a fundamental cellular pool for establishing parenchymal components. However, the molecular basis for the expansion of the progenitors maintaining their immature state remains elusive. Polycomb group proteins regulate gene expression throughout the genome by modulating of chromatin structure and play crucial roles in development. Enhancer of zeste homolog 2 (Ezh2), a key component of polycomb group proteins, catalyzes tri-methylation of lysine 27 of histone H3 (H3K27me3), which trigger the gene suppression. In the present study, we investigated a role of Ezh2 in the regulation of the expanding hepatic progenitor population in vivo. We found that Ezh2 is highly expressed in the actively proliferating cells at the early developmental stage. Using a conditional knockout mouse model, we show that the deletion of the SET domain of Ezh2, which is responsible for catalytic induction of H3K27me3, results in significant reduction of the total liver size, absolute number of liver parenchymal cells, and hepatic progenitor cell population in size. A clonal colony assay in the hepatic progenitor cells directly isolated from in vivo fetal livers revealed that the bi-potent clonogenicity was significantly attenuated by the Ezh2 loss of function. Moreover, a marker expression based analysis and a global gene expression analysis showed that the knockout of Ezh2 inhibited differentiation to hepatocyte with reduced expression of a number of liver-function related genes. Taken together, our results indicate that Ezh2 is required for the hepatic progenitor expansion in vivo, which is essential for the functional maturation of embryonic liver, through its activity for catalyzing H3K27me3.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Koike</LastName>
                    <ForeName>Hiroyuki</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Kanagawa, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ouchi</LastName>
                    <ForeName>Rie</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Kanagawa, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ueno</LastName>
                    <ForeName>Yasuharu</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Kanagawa, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nakata</LastName>
                    <ForeName>Susumu</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Division of Oncological Pathology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Obana</LastName>
                    <ForeName>Yuta</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Kanagawa, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sekine</LastName>
                    <ForeName>Keisuke</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Kanagawa, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zheng</LastName>
                    <ForeName>Yun-Wen</ForeName>
                    <Initials>YW</Initials>
                    <Affiliation>Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Kanagawa, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Takebe</LastName>
                    <ForeName>Takanori</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Kanagawa, Japan; Project Leader of Advanced Medical Research Center, Yokohama City University, Kanazawa-ku, Yokohama, Kanagawa, Japan; PRESTO, Japan Science and Technology Agency, Saitama, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Isono</LastName>
                    <ForeName>Kyoichi</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Laboratory for Developmental Genetics, RIKEN Research Center for Allergy and Immunology, Tsurumi-ku, Yokohama, Kanagawa, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Koseki</LastName>
                    <ForeName>Haruhiko</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Laboratory for Developmental Genetics, RIKEN Research Center for Allergy and Immunology, Tsurumi-ku, Yokohama, Kanagawa, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Taniguchi</LastName>
                    <ForeName>Hideki</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Kanagawa, Japan; Project Leader of Advanced Medical Research Center, Yokohama City University, Kanazawa-ku, Yokohama, Kanagawa, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0104776</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-08536</ArticleId>
            <ArticleId IdType="pubmed">25153170</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153169</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1543-8392</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular pharmaceutics</Title>
                <ISOAbbreviation>Mol. Pharm.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Evaluation of Prognostic Integrin ??2??1 PET Tracer and Concurrent Targeting Delivery Using Focused Ultrasound for Brain Glioma Detection.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The ability to early detect and assess the treatment response of recurrent and/or disseminated metastatic glioblastoma is critical for the effective management of this group of patients. Accumulating experimental evidence indicates that integrin ??2??1 might be a prognostic biomarker for advanced phenotype of cancers. In this study, a novel (68)Ga-labeled integrin ??2??1-targeted PET tracer (68)Ga-NOTA-PEG4-cyclo (GDGEAyK) ((68)Ga-A2B1) was designed and evaluated for the potential prognostic imaging of glioblastoma tumor in preclinical model. To prospectively verify the prognostic value of integrin ??2??1, the in vitro Western blot and flow cytometry studies were performed to validate the integrin expression level of human glioblastoma (U87MG) cells. Extremely high expression level of integrin ??2??1 justifies its role as a potential targeting marker. Thus, (68)Ga-A2B1 positron emission tomography was performed in subcutaneous U87MG tumor bearing athymic mice at 15 min postinjection after injection of 7-8MBq tracers. The receptor targeting specificity was confirmed in a competition blocking experiment. The tumor uptake of (68)Ga-A2B1 in the control and blockage groups was 1.57 ?? 0.13 %ID/g (n = 3) and 0.96 ?? 0.23 %ID/g** (n = 3), respectively. However, because of the quick renal washout rate and labile nature of peptide tracers in circulation conditions, the focus ultrasound (FUS) mediated delivery method was adopted to enhance tumor uptake and retention of tracers. To test the FUS delivery efficacy in vivo, three experimental arms were designed as follows: tumor bearing mice were administrated with (68)Ga-A2B1 only or microbubbles (MBs) with FUS treatment ((68)Ga-A2B1 + FUS + MBs) or embedded (68)Ga-A2B1-microbubbles ((68)Ga-A2B1-MBs + FUS) followed with FUS sonication. The average radioactivity accumulation within a tumor was quantified from the multiple region of interest volumes using the %ID/g value and was analyzed in accordance with the ex vivo autoradiographic and pathologic data. The significant tumor uptake in (68)Ga-A2B1 + FUS +MBs group (n = 6) and (68)Ga-A2B1-MBs + FUS group (n = 4) following FUS treatment were calculated as 2.25 ?? 0.50 %ID/g* and 2.6 ?? 0.49 %ID/g**, comparing with (68)Ga-A2B1 only group 1.48 ?? 0.42 %ID/g (n = 10). These results suggest that there is significant difference in (68)Ga-A2B1 tumor uptake by FUS treatment either with or without tracer integration with microbubbles, which demonstrate a promising delivery strategy and critical multimodal setting for phenotyping imaging of aggressive glioma tumor. In conclusion, (68)Ga labeled (68)Ga-A2B1 allows noninvasive imaging of tumor-associated ??2??1 expression and can be embedded in MB lipid shell for enhanced delivery and controlled release by sonoporation.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chung</LastName>
                    <ForeName>Yi-Hsiu</ForeName>
                    <Initials>YH</Initials>
                    <Affiliation>Center for Advanced Molecular Imaging and Translation (CAMIT), Chang Gung Memorial Hospital , Taoyuan 333, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hsu</LastName>
                    <ForeName>Po-Hung</ForeName>
                    <Initials>PH</Initials>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Chiun-Wei</ForeName>
                    <Initials>CW</Initials>
                </Author>
                <Author>
                    <LastName>Hsieh</LastName>
                    <ForeName>Wen-Chuan</ForeName>
                    <Initials>WC</Initials>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Feng-Ting</ForeName>
                    <Initials>FT</Initials>
                </Author>
                <Author>
                    <LastName>Chang</LastName>
                    <ForeName>Wen-Chi</ForeName>
                    <Initials>WC</Initials>
                </Author>
                <Author>
                    <LastName>Chiu</LastName>
                    <ForeName>Han</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Hsu</LastName>
                    <ForeName>Shih-Ting</ForeName>
                    <Initials>ST</Initials>
                </Author>
                <Author>
                    <LastName>Yen</LastName>
                    <ForeName>Tzu-Chen</ForeName>
                    <Initials>TC</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mol Pharm</MedlineTA>
            <NlmUniqueID>101197791</NlmUniqueID>
            <ISSNLinking>1543-8384</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/mp500296n</ArticleId>
            <ArticleId IdType="pubmed">25153169</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153150</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Identification and Characterization of Germ Cell Genes Expressed in the F9 Testicular Teratoma Stem Cell Line.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e103837</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0103837</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The F9 cell line, which was derived from a mouse testicular teratoma that originated from pluripotent germ cells, has been used as a model for differentiation. However, it is largely unknown whether F9 cells possess the characteristics of male germ cells. In the present study, we investigated spermatogenic stage- and cell type-specific gene expression in F9 cells. Analysis of previous microarray data showed that a large number of stage-regulated germ cell genes are expressed in F9 cells. Specifically, genes that are prominently expressed in spermatogonia and have transcriptional regulatory functions appear to be enriched in F9 cells. Our in silico and in vitro analyses identified several germ cell-specific or -predominant genes that are expressed in F9 cells. Among them, strong promoter activities were observed in the regions upstream of the spermatogonial genes, Dmrt1 (doublesex and mab-3 related transcription factor 1), Stra8 (stimulated by retinoic acid gene 8) and Tex13 (testis expressed gene 13), in F9 cells. A detailed analysis of the Tex13 promoter allowed us to identify an enhancer and a region that is implicated in germ cell-specificity. We also found that Tex13 expression is regulated by DNA methylation. Finally, analysis of GFP (green fluorescent protein) TEX13 localization revealed that the protein distributes heterogeneously in the cytoplasm and nucleus, suggesting that TEX13 shuttles between these two compartments. Taken together, our results demonstrate that F9 cells express numerous spermatogonial genes and could be used for transcriptional studies focusing on such genes. As an example of this, we use F9 cells to provide comprehensive expressional information about Tex13, and report that this gene appears to encode a germ cell-specific protein that functions in the nucleus during early spermatogenesis.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kwon</LastName>
                    <ForeName>Jun Tae</ForeName>
                    <Initials>JT</Initials>
                    <Affiliation>School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jin</LastName>
                    <ForeName>Sora</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Choi</LastName>
                    <ForeName>Heejin</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Jihye</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jeong</LastName>
                    <ForeName>Juri</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Jaehwan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Youil</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cho</LastName>
                    <ForeName>Byung-Nam</ForeName>
                    <Initials>BN</Initials>
                    <Affiliation>Department of Biology, The Catholic University of Korea, Bucheon, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cho</LastName>
                    <ForeName>Chunghee</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Korea.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0103837</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-19130</ArticleId>
            <ArticleId IdType="pubmed">25153150</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153123</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Interacting Chemokine Signals Regulate Dendritic Cells in Acute Brain Injury.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e104754</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0104754</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Brain trauma is known to activate inflammatory cells via various chemokine signals although their interactions remain to be characterized. Mice deficient in Ccl3, Ccr2 or Cxcl10 were compared with wildtype mice after controlled cortical impact injury. Expression of Ccl3 in wildtypes was rapidly upregulated in resident, regularly spaced reactive microglia. Ccl3-deficiency enhanced endothelial expression of platelet selectin and invasion of peripheral inflammatory cells. Appearance of Ccr2 transcripts, encoding the Ccl2 receptor, reflected invasion of lysozyme 2-expressing phagocytes and classical antigen-presenting dendritic cells expressing major histocompatibility complex class II. Ccr2 also directed clustered plasmacytoid dendritic cells positive for the T-cell attracting chemokine Cxcl10. A reduction in Ccr2 and dendritic cells was found in injured wildtype cortex after cyclophosphamide treatment resembling effects of Ccr2-deficiency. The findings demonstrate the feasibility to control inflammation in the injured brain by regulating chemokine-dependent pathways.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Israelsson</LastName>
                    <ForeName>Charlotte</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Neuroscience, Developmental Neuroscience, Biomedical Center, Uppsala University, Uppsala, Sweden.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kylberg</LastName>
                    <ForeName>Annika</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Neuroscience, Developmental Neuroscience, Biomedical Center, Uppsala University, Uppsala, Sweden.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bengtsson</LastName>
                    <ForeName>Henrik</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Neuroscience, Developmental Neuroscience, Biomedical Center, Uppsala University, Uppsala, Sweden.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hillered</LastName>
                    <ForeName>Lars</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Neuroscience, Neurosurgery, Uppsala University, Uppsala, Sweden.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ebendal</LastName>
                    <ForeName>Ted</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Neuroscience, Developmental Neuroscience, Biomedical Center, Uppsala University, Uppsala, Sweden.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0104754</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-16258</ArticleId>
            <ArticleId IdType="pubmed">25153123</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153088</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Unexpected Phenotype of Mice Lacking Shcbp1, a Protein Induced during T Cell Proliferation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105576</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0105576</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">T cell development and activation are highly regulated processes, and their proper execution is important for a competent immune system. Shc SH2-domain binding protein-1 (Shcbp1) is an evolutionarily conserved protein that binds to the adaptor protein ShcA. Studies in Drosophila and in cell lines have strongly linked Shcbp1 to cell proliferation, embryonic development, growth factor signaling, and tumorigenesis. Here we show that Shcbp1 expression is strikingly upregulated during the ??-selection checkpoint in thymocytes, and that its expression tightly correlates with proliferative stages of T cell development. To evaluate the role for Shcbp1 during thymic selection and T cell function in vivo, we generated mice with global and conditional deletion of Shcbp1. Surprisingly, the loss of Shcbp1 expression did not have an obvious effect during T cell development. However, in a mouse model of experimental autoimmune encephalomyelitis (EAE), which depends on CD4+ T cell function and mimics multiple features of the human disease multiple sclerosis, Shcbp1 deficient mice had reduced disease severity and improved survival, and this effect was T cell intrinsic. These data suggest that despite the striking upregulation of Shcbp1 during T cell proliferation, loss of Shcbp1 does not directly affect T cell development, but regulates CD4+ T cell effector function in vivo.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Buckley</LastName>
                    <ForeName>Monica W</ForeName>
                    <Initials>MW</Initials>
                    <Affiliation>Department of Microbiology, Immunology, Cancer biology, University of Virginia, Charlottesville, Virginia, United States of America; Carter Immunology Center, University of Virginia, Charlottesville, Virginia, United States of America; Center for Cell Clearance, University of Virginia, Charlottesville, Virginia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Arandjelovic</LastName>
                    <ForeName>Sanja</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Microbiology, Immunology, Cancer biology, University of Virginia, Charlottesville, Virginia, United States of America; Carter Immunology Center, University of Virginia, Charlottesville, Virginia, United States of America; Center for Cell Clearance, University of Virginia, Charlottesville, Virginia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Trampont</LastName>
                    <ForeName>Paul C</ForeName>
                    <Initials>PC</Initials>
                    <Affiliation>Department of Microbiology, Immunology, Cancer biology, University of Virginia, Charlottesville, Virginia, United States of America; Carter Immunology Center, University of Virginia, Charlottesville, Virginia, United States of America; Center for Cell Clearance, University of Virginia, Charlottesville, Virginia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Taeg S</ForeName>
                    <Initials>TS</Initials>
                    <Affiliation>Center for Cell Clearance, University of Virginia, Charlottesville, Virginia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Braciale</LastName>
                    <ForeName>Thomas J</ForeName>
                    <Initials>TJ</Initials>
                    <Affiliation>Center for Cell Clearance, University of Virginia, Charlottesville, Virginia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ravichandran</LastName>
                    <ForeName>Kodi S</ForeName>
                    <Initials>KS</Initials>
                    <Affiliation>Department of Microbiology, Immunology, Cancer biology, University of Virginia, Charlottesville, Virginia, United States of America; Carter Immunology Center, University of Virginia, Charlottesville, Virginia, United States of America; Center for Cell Clearance, University of Virginia, Charlottesville, Virginia, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105576</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-26328</ArticleId>
            <ArticleId IdType="pubmed">25153088</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153086</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Visual Sensorial Impairments in Neurodevelopmental Disorders: Evidence for a Retinal Phenotype in Fragile X Syndrome.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105996</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0105996</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Visual sensory impairments are common in Mental Deficiency (MD) and Autism Spectrum Disorder (ASD). These defects are linked to cerebral dysfunction in the visual cortical area characterized by the deregulation of axon growth/guidance and dendrite spine immaturity of neurons. However, visual perception had not been addressed, although the retina is part of the central nervous system with a common embryonic origin. Therefore, we investigated retinal perception, the first event of vision, in a murine model of MD with autistic features. We document that retinal function is altered in Fmr1 KO mice, a model of human Fragile X Syndrome. Indeed, In Fmr1 KO mice had a lower retinal function characterized by a decreased photoreceptors neuron response, due to a 40% decrease in Rhodopsin content and to Rod Outer Segment destabilization. In addition, we observed an alteration of the visual signal transmission between photoreceptors and the inner retina which could be attributed to deregulations of pre- and post- synaptic proteins resulting in retinal neurons synaptic destabilization and to retinal neurons immaturity. Thus, for the first time, we demonstrated that retinal perception is altered in a murine model of MD with autistic features and that there are strong similarities between cerebral and retinal cellular and molecular defects. Our results suggest that both visual perception and integration must be taken into account in assessing visual sensory impairments in MD and ASD.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Rossignol</LastName>
                    <ForeName>Rafa??lle</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>UMR7355, CNRS, Orl??ans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orl??ans, Orl??ans, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ranchon-Cole</LastName>
                    <ForeName>Isabelle</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Laboratory of Sensorial Biophysical, University of Clermont 1, Clermont-Ferrand, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>P??ris</LastName>
                    <ForeName>Arnaud</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>UMR7355, CNRS, Orl??ans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orl??ans, Orl??ans, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Herzine</LastName>
                    <ForeName>Ameziane</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>UMR7355, CNRS, Orl??ans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orl??ans, Orl??ans, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Perche</LastName>
                    <ForeName>Astrid</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Genetic Department, Regional Hospital, Orl??ans, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Laurenceau</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Genetic Department, Regional Hospital, Orl??ans, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bertrand</LastName>
                    <ForeName>Pauline</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Laboratory of Sensorial Biophysical, University of Clermont 1, Clermont-Ferrand, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cercy</LastName>
                    <ForeName>Christine</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Laboratory of Sensorial Biophysical, University of Clermont 1, Clermont-Ferrand, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pichon</LastName>
                    <ForeName>Jacques</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>UMR7355, CNRS, Orl??ans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orl??ans, Orl??ans, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mortaud</LastName>
                    <ForeName>St??phane</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>UMR7355, CNRS, Orl??ans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orl??ans, Orl??ans, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Briault</LastName>
                    <ForeName>Sylvain</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>UMR7355, CNRS, Orl??ans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orl??ans, Orl??ans, France; Genetic Department, Regional Hospital, Orl??ans, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Menuet</LastName>
                    <ForeName>Arnaud</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>UMR7355, CNRS, Orl??ans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orl??ans, Orl??ans, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Perche</LastName>
                    <ForeName>Olivier</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>UMR7355, CNRS, Orl??ans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orl??ans, Orl??ans, France; Genetic Department, Regional Hospital, Orl??ans, France.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105996</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-22403</ArticleId>
            <ArticleId IdType="pubmed">25153086</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153081</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Anti-Inflammatory Activity of Odina wodier Roxb, an Indian Folk Remedy, through Inhibition of Toll-Like Receptor 4 Signaling Pathway.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e104939</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0104939</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Inflammation is part of self-limiting non-specific immune response, which occurs during bodily injury. In some disorders the inflammatory process becomes continuous, leading to the development of chronic inflammatory diseases including cardiovascular diseases, diabetes, cancer etc. Several Indian tribes used the bark of Odina wodier (OWB) for treating inflammatory disorders. Thus, we have evaluated the immunotherapeutic potential of OWB methanol extract and its major constituent chlorogenic acid (CA), using three popular in vivo antiinflammatory models: Carrageenan- and Dextran-induced paw edema, Cotton pellet granuloma, and Acetic acid-induced vascular permeability. To elucidate the possible anti-inflammatory mechanism of action we determine the level of major inflammatory mediators (NO, iNOS, COX-2-dependent prostaglandin E2 or PGE2), and pro-inflammatory cytokines (TNF-??, IL-1??, IL-6, and IL-12). Further, we determine the toll-like receptor 4 (TLR4), Myeloid differentiation primary response gene 88 (MyD88), c-Jun N-terminal kinases (JNK), nuclear factor kappa-B cells (NF-??B), and NF-kB inhibitor alpha (IK-B??) by protein and mRNA expression, and Western blot analysis in drug treated LPS-induced murine macrophage model. Moreover, we determined the acute and sub-acute toxicity of OWB extract in BALB/c mice. Our study demonstrated a significant anti-inflammatory activity of OWB extract and CA along with the inhibition of TNF-??, IL-1??, IL-6 and IL-12 expressions. Further, the expression of TLR4, NF-??Bp65, MyD88, iNOS and COX-2 molecules were reduced in drug-treated groups, but not in the LPS-stimulated untreated or control groups, Thus, our results collectively indicated that the OWB extract and CA can efficiently inhibit inflammation through the down regulation of TLR4/MyD88/NF-kB signaling pathway.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ojha</LastName>
                    <ForeName>Durbadal</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>ICMR Virus Unit, I.D. &amp; B.G. Hospital, Beliaghata, Kolkata, India; Division of Microbiology, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mukherjee</LastName>
                    <ForeName>Hemanta</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>ICMR Virus Unit, I.D. &amp; B.G. Hospital, Beliaghata, Kolkata, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mondal</LastName>
                    <ForeName>Supriya</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>ICMR Virus Unit, I.D. &amp; B.G. Hospital, Beliaghata, Kolkata, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jena</LastName>
                    <ForeName>Aditya</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>ICMR Virus Unit, I.D. &amp; B.G. Hospital, Beliaghata, Kolkata, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dwivedi</LastName>
                    <ForeName>Ved Prakash</ForeName>
                    <Initials>VP</Initials>
                    <Affiliation>ICMR Virus Unit, I.D. &amp; B.G. Hospital, Beliaghata, Kolkata, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mondal</LastName>
                    <ForeName>Keshab C</ForeName>
                    <Initials>KC</Initials>
                    <Affiliation>Department of Microbiology, Vidyasagar University, Midnapur, West Bengal, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Malhotra</LastName>
                    <ForeName>Bharti</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Microbiology, SMS Medical College &amp; Hospital, Jaipur, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Samanta</LastName>
                    <ForeName>Amalesh</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Division of Microbiology, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chattopadhyay</LastName>
                    <ForeName>Debprasad</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>ICMR Virus Unit, I.D. &amp; B.G. Hospital, Beliaghata, Kolkata, India.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0104939</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-09334</ArticleId>
            <ArticleId IdType="pubmed">25153081</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153079</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Central and Systemic Responses to Methionine-Induced Hyperhomocysteinemia in Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105704</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0105704</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Hyperhomocysteinemia has been considered a risk factor for neuropsychiatric disorders, but the mechanisms involved in this process have not been completely elucidated. The aim of this study was to analyze the influence of hyperhomocysteinemia induction by methionine supplementation considering different levels and periods of exposure in mice. For this purpose, methionine supplementation at concentrations of 0.5 and 1% were administered in water to increase homocysteinemia in male C57BL/6 mice, and was maintained for 3 time periods (2, 4 and 6 months of treatment). The results from one-carbon metabolism parameters, brain-derived neurotrophic factor (BDNF) concentrations and behavioral evaluation were compared. The 0.5% supplementation was efficient in increasing plasma homocysteine levels after 2 and 6 months. The 1% supplementation, increased plasma homocysteine after 2, 4 and 6 months. Little influence was observed in cysteine and glutathione concentrations. Frontal cortex BDNF levels showed a lack of treatment influence in all periods; only the expected decrease due to increasing age was observed. Moreover, the only behavioral alteration observed using a novel object recognition task was that which was expected with increasing age. We found that responses to hyperhomocysteinemia varied based on how it was reached, and the length of toxicity. Moreover, hyperhomocysteinemia can affect the normal pattern of one carbon metabolism during age increase in mice. These findings allow the establishment of a reliable animal model for studies in this field.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Rezende</LastName>
                    <ForeName>Marina Mastelaro de</ForeName>
                    <Initials>MM</Initials>
                    <Affiliation>Department of Psychobiology, Universidade Federal de S??o Paulo, S??o Paulo, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>D'Almeida</LastName>
                    <ForeName>V??nia</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Department of Psychobiology, Universidade Federal de S??o Paulo, S??o Paulo, Brazil.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105704</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-18892</ArticleId>
            <ArticleId IdType="pubmed">25153079</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153040</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">1424-8247</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>7</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmaceuticals (Basel, Switzerland)</Title>
                <ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mitochondrial Targeted Endonuclease III DNA Repair Enzyme Protects against Ventilator Induced Lung Injury in Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>894-912</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The mitochondrial targeted DNA repair enzyme, 8-oxoguanine DNA glycosylase 1, was previously reported to protect against mitochondrial DNA (mtDNA) damage and ventilator induced lung injury (VILI). In the present study we determined whether mitochondrial targeted endonuclease III (EndoIII) which cleaves oxidized pyrimidines rather than purines from damaged DNA would also protect the lung. Minimal injury from 1 h ventilation at 40 cmH2O peak inflation pressure (PIP) was reversed by EndoIII pretreatment. Moderate lung injury due to ventilation for 2 h at 40 cmH2O PIP produced a 25-fold increase in total extravascular albumin space, a 60% increase in W/D weight ratio, and marked increases in MIP-2 and IL-6. Oxidative mtDNA damage and decreases in the total tissue glutathione (GSH) and the GSH/GSSH ratio also occurred. All of these indices of injury were attenuated by mitochondrial targeted EndoIII. Massive lung injury caused by 2 h ventilation at 50 cmH2O PIP was not attenuated by EndoIII pretreatment, but all untreated mice died prior to completing the two hour ventilation protocol, whereas all EndoIII-treated mice lived for the duration of ventilation. Thus, mitochondrial targeted DNA repair enzymes were protective against mild and moderate lung damage and they enhanced survival in the most severely injured group.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hashizume</LastName>
                    <ForeName>Masahiro</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Physiology, University of South Alabama, Mobile, AL 36688, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mouner</LastName>
                    <ForeName>Marc</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Physiology, University of South Alabama, Mobile, AL 36688, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chouteau</LastName>
                    <ForeName>Joshua M</ForeName>
                    <Initials>JM</Initials>
                    <Affiliation>Center for Lung Biology, University of South Alabama, Mobile, AL 36688, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gorodnya</LastName>
                    <ForeName>Olena M</ForeName>
                    <Initials>OM</Initials>
                    <Affiliation>Department of Pharmacology, University of South Alabama, Mobile, AL 36688, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ruchko</LastName>
                    <ForeName>Mykhaylo V</ForeName>
                    <Initials>MV</Initials>
                    <Affiliation>Center for Lung Biology, University of South Alabama, Mobile, AL 36688, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wilson</LastName>
                    <ForeName>Glenn L</ForeName>
                    <Initials>GL</Initials>
                    <Affiliation>Department of Cell Biology and Neuroscience, University of South Alabama, Mobile, AL 36688, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gillespie</LastName>
                    <ForeName>Mark N</ForeName>
                    <Initials>MN</Initials>
                    <Affiliation>Center for Lung Biology, University of South Alabama, Mobile, AL 36688, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Parker</LastName>
                    <ForeName>James C</ForeName>
                    <Initials>JC</Initials>
                    <Affiliation>Department of Physiology, University of South Alabama, Mobile, AL 36688, USA. jparker@southalabama.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Pharmaceuticals (Basel)</MedlineTA>
            <NlmUniqueID>101238453</NlmUniqueID>
            <ISSNLinking>1424-8247</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ph7080894</ArticleId>
            <ArticleId IdType="doi">10.3390/ph7080894</ArticleId>
            <ArticleId IdType="pubmed">25153040</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153034</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1089-8611</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society</Title>
                <ISOAbbreviation>Nitric Oxide</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Gene expression profiles of NO- and HNO-donor treated breast cancer cells: insights into tumor response and resistance pathways.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1089-8603(14)00277-8</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.niox.2014.08.003</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Nitric oxide (NO) synthase 2 (NOS2), a major inflammatory protein, modulates disease progression via NO in a number of pathologies, including cancer. The role of NOS2-derived NO is not only flux-dependent, which is higher in mouse vs. human cells, but also varies based on spatial and temporal distribution both within tumor cells and in the tumor microenvironment. NO donors have been utilized to mimic NO flux conditions and to investigate the effects of varied NO concentrations. As a wide range of effects mediated by NO and other nitrogen oxides such as nitroxyl (HNO) have been elucidated, multiple NO- and HNO-releasing compounds have been developed as potential therapeutics, including as tumor modulators. One of the challenges is to determine differences in biomarker expression from extracellular vs. intracellular generation of NO or HNO. Taking advantage of new NO and HNO releasing agents, we have characterized the gene expression profile of estrogen receptor-negative human breast cancer (MDA-MB-231) cells following exposure to aspirin, the NO donor DEA/NO, the HNO donor IPA/NO and their intracellularly-activated prodrug conjugates DEA/NO-aspirin and IPA/NO-aspirin. Comparison of the gene expression profiles demonstrated that several genes were uniquely expressed with respect to NO or HNO, such as miR-21, HSP70, cystathionine ??-lyase and IL24. These findings provide insight into targets and pathways that could be therapeutically exploited by the redox related species NO and HNO.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Cheng</LastName>
                    <ForeName>Robert Ys</ForeName>
                    <Initials>RY</Initials>
                    <Affiliation>Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892. Electronic address: robert.cheng2@nih.gov.</Affiliation>
                </Author>
                <Author>
                    <LastName>Basudhar</LastName>
                    <ForeName>Debashree</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892; Department of Chemistry, University of Arizona, Tucson AZ 85721.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ridnour</LastName>
                    <ForeName>Lisa A</ForeName>
                    <Initials>LA</Initials>
                    <Affiliation>Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892.</Affiliation>
                </Author>
                <Author>
                    <LastName>Heinecke</LastName>
                    <ForeName>Julie L</ForeName>
                    <Initials>JL</Initials>
                    <Affiliation>Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kesarwala</LastName>
                    <ForeName>Aparna H</ForeName>
                    <Initials>AH</Initials>
                    <Affiliation>Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892.</Affiliation>
                </Author>
                <Author>
                    <LastName>Glynn</LastName>
                    <ForeName>Sharon</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Prostate Cancer Institute, NUI Galway, Ireland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Switzer</LastName>
                    <ForeName>Christopher H</ForeName>
                    <Initials>CH</Initials>
                    <Affiliation>Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ambs</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892.</Affiliation>
                </Author>
                <Author>
                    <LastName>Miranda</LastName>
                    <ForeName>Katrina M</ForeName>
                    <Initials>KM</Initials>
                    <Affiliation>Department of Chemistry, University of Arizona, Tucson AZ 85721.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wink</LastName>
                    <ForeName>David A</ForeName>
                    <Initials>DA</Initials>
                    <Affiliation>Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Nitric Oxide</MedlineTA>
            <NlmUniqueID>9709307</NlmUniqueID>
            <ISSNLinking>1089-8603</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">cancer biology</Keyword>
            <Keyword MajorTopicYN="N">cell signaling</Keyword>
            <Keyword MajorTopicYN="N">nitric oxide</Keyword>
            <Keyword MajorTopicYN="N">nitric oxide synthase</Keyword>
            <Keyword MajorTopicYN="N">nitroxyl</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1089-8603(14)00277-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.niox.2014.08.003</ArticleId>
            <ArticleId IdType="pubmed">25153034</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153023</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7573</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of ethnopharmacology</Title>
                <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The gardenia jasminoides extract and its constituent, geniposide, elicit anti-allergic effects on atopic dermatitis by inhibiting histamine in vitro and in vivo.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0378-8741(14)00579-0</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jep.2014.07.060</ELocationID>
            <Abstract>
                <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Gardenia jasminoides Ellis has been used in traditional medicine for treatment of inflammation, edema, and dermaitis. The aim of this study was to investigate the mechanism by which Gardenia jasminoides extract (GJE) elicits anti-allergic effects in mast cells and in mice with atopic dermatitis (AD).</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We investigated the effects of GJE and its fractions on compound 48/80-induced histamine release from MC/9 cells and Dermatophagoides farinae-exposed NC/Nga mice. The effects of its constituents on histamine release from MC/9 cells were also investigated.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">GJE and its ethyl acetate fraction (GJE-EA) inhibited compound 48/80-induced histamine release from MC/9 mast cells. The topical application of GJE or GJE-EA to Dermatophagoides farinae-exposed NC/Nga mice reduced the symptoms of AD, inhibited the infiltration of inflammatory cells, and lowered the serum levels of immunoglobulin E and histamine. Both GJE and GJE-EA reduced the expression of cytokines (interleukin [IL]-4, IL-6, and tumor necrosis factor-alpha) and adhesion molecules (intercellular adhesion molecule-1 and vascular cell adhesion molecule-1) in ear lesions. In addition, the quantitative analysis of GJE and GJE-EA by high-performance liquid chromatography revealed the presence of crocin and geniposide. Geniposide, but not crocin, inhibited the release of histamine from mast cells, which may contribute to the anti-allergic effect of GJE and GJE-EA.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results suggest that GJE and GJE-EA can suppress mast cell degranulation-induced histamine release, and geniposide may be potential therapeutic candidates for AD.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sung</LastName>
                    <ForeName>Yoon-Young</ForeName>
                    <Initials>YY</Initials>
                    <Affiliation>Herbal Medicine Resources Group, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon 305-811, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>A Yeong</ForeName>
                    <Initials>AY</Initials>
                    <Affiliation>Herbal Medicine Resources Group, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon 305-811, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Ho Kyoung</ForeName>
                    <Initials>HK</Initials>
                    <Affiliation>Herbal Medicine Resources Group, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon 305-811, Republic of Korea. Electronic address: hkkim@kiom.re.kr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Ethnopharmacol</MedlineTA>
            <NlmUniqueID>7903310</NlmUniqueID>
            <ISSNLinking>0378-8741</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Anti-allergic</Keyword>
            <Keyword MajorTopicYN="N">Anti-inflammatory</Keyword>
            <Keyword MajorTopicYN="N">Gardenia jasminoides</Keyword>
            <Keyword MajorTopicYN="N">Geniposide</Keyword>
            <Keyword MajorTopicYN="N">Histamine</Keyword>
            <Keyword MajorTopicYN="N">Mast cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0378-8741(14)00579-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jep.2014.07.060</ArticleId>
            <ArticleId IdType="pubmed">25153023</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153022</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7573</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of ethnopharmacology</Title>
                <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cathinone, an active principle of Catha edulis, accelerates oxidative stress in the limbic area of swiss albino mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0378-8741(14)00596-0</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jep.2014.08.004</ELocationID>
            <Abstract>
                <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Cathinone hydrochloride is an active principle of the khat plant (Catha edulis) that produces pleasurable and stimulating effects in khat chewers. To the best of our knowledge no data of cathinone on oxidative stress in limbic areas of mice is available. This is the first study of cathinone on oxidative stress in limbic areas of the brain in Swiss albino male mice.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The animals were divided into four groups. Group- I was the control group and received vehicle, while groups-II to IV received (-)-cathinone hydrochloride 0.125, 0.25 and 0.5mg/kg body wt., i.p.) once daily for 15 days.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The level of lipid per oxidation (LPO) was elevated dose-dependently and was significant (p&lt;0.05, p&lt;0.01) with doses of 0.25 and 0.5mg/kg body wt. of cathinone as compared to control group. In contrast, the content of reduced glutathione (GSH) was decreased significantly (p&lt;0.01, p&lt;0.001) with doses of 0.25 and 0.5mg/kg body wt. of cathinone as compared to control group. The activity of antioxidant enzyme (GPx, GR, GST, CAT, and SOD) was also decreased dose-dependently: the decreased activity of GPx, GR, catalase and SOD was significant with doses of 0.25 and 0.5mg of cathinone as compared to control group, while the activity of GST was decreased dose-dependently and was significant with 0.5mg of cathinone as compared to control group.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results indicate that the cathinone generated oxidative stress hampered antioxidant enzymes, glutathione and lipid peroxidation.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ireland Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Safhi</LastName>
                    <ForeName>Mohammed M</ForeName>
                    <Initials>MM</Initials>
                    <Affiliation>Neuroscience and Toxicology Unit, College of Pharmacy, Jazan University, Ministry of Higher Education, Jazan, Kingdom of Saudi Arabia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Alam</LastName>
                    <ForeName>Mohammad Firoz</ForeName>
                    <Initials>MF</Initials>
                    <Affiliation>Neuroscience and Toxicology Unit, College of Pharmacy, Jazan University, Ministry of Higher Education, Jazan, Kingdom of Saudi Arabia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hussain</LastName>
                    <ForeName>Sohail</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Neuroscience and Toxicology Unit, College of Pharmacy, Jazan University, Ministry of Higher Education, Jazan, Kingdom of Saudi Arabia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hakeem Siddiqui</LastName>
                    <ForeName>Mohammed Abdul</ForeName>
                    <Initials>MA</Initials>
                    <Affiliation>Neuroscience and Toxicology Unit, College of Pharmacy, Jazan University, Ministry of Higher Education, Jazan, Kingdom of Saudi Arabia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Khuwaja</LastName>
                    <ForeName>Gulrana</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Neuroscience and Toxicology Unit, College of Pharmacy, Jazan University, Ministry of Higher Education, Jazan, Kingdom of Saudi Arabia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jubran Khardali</LastName>
                    <ForeName>Ibrahim Abdu</ForeName>
                    <Initials>IA</Initials>
                    <Affiliation>Poison Control &amp; Medical Forensic Chemistry Center, Ministry of Health, Jazan, Kingdom of Saudi Arabia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Al-Sanosi</LastName>
                    <ForeName>Rashad Mohammed</ForeName>
                    <Initials>RM</Initials>
                    <Affiliation>Substance Abuse Research Center, Jazan University, Ministry of Higher Education, Jazan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Islam</LastName>
                    <ForeName>Fakhrul</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Neuroscience and Toxicology Unit, College of Pharmacy, Jazan University, Ministry of Higher Education, Jazan, Kingdom of Saudi Arabia. Electronic address: drfislam@gmail.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Ethnopharmacol</MedlineTA>
            <NlmUniqueID>7903310</NlmUniqueID>
            <ISSNLinking>0378-8741</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Antioxidant enzymes</Keyword>
            <Keyword MajorTopicYN="N">Cathinone</Keyword>
            <Keyword MajorTopicYN="N">Glutathione</Keyword>
            <Keyword MajorTopicYN="N">Limbic areas</Keyword>
            <Keyword MajorTopicYN="N">Lipid peroxidation</Keyword>
            <Keyword MajorTopicYN="N">Swiss albino mice</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0378-8741(14)00596-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jep.2014.08.004</ArticleId>
            <ArticleId IdType="pubmed">25153022</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25153020</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7573</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of ethnopharmacology</Title>
                <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mechanisms involved in the gastroprotective activity of Celtis iguanaea (Jacq.) Sargent on gastric lesions in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0378-8741(14)00598-4</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jep.2014.08.006</ELocationID>
            <Abstract>
                <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Celtis iguanaea (Canabaceae) is popularly known as espor??o-de-galo, stands out among the medicinal plants used for treatment of gastric ulcers. In Brazil, the leaves they are used traditionally in infusion forms as an analgesic, antiasthmatic, digestive and diuretic.</AbstractText>
                <AbstractText Label="AIM OF THE STUDY" NlmCategory="OBJECTIVE">The present study was aimed to investigate the antiulcer mechanisms of hexane extract Celtis iguanaea leaves (HE) in several induced-gastric ulcer and characterize its chemical composition.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The HE was obtained by exhaustive extraction in Soxhlet apparatus. The chemical characterization of HE was perfomed Electrospray Fourier transform ion cyclotron mass spectrometry (ESI FT-ICR MS) analysis. Mice were used for the evaluation of the gastroprotective activity. HE was analyzed in the HCl/ethanol, hypothermic restraint stress ulcer and acetic acid. In the investigation of the gastroprotective mechanisms of HE, were performed the amount of adhered gastric mucus, participation of the ??2-adrenoceptor, nitric oxide (NO) and prostaglandins (PGs) using the HCl/ethanol -induced gastric mucosa lesion model.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">ESI FT-ICR MS analysis of HE suggest the presence of compounds as lipids, sterol lipids, steroids glycosides and polyphenol glycosides. The oral administration of HE at doses of 100mg/kg or 200mg/kg was able to protect the gastric mucosa against HCl/ethanol (10mL/kg p.o.), and HE at dose of 100mg/kg protected against hypothermic-restraint stress and acetic -induced gastric lesions. The pretreatment with Yoimbine (2mg/kg, s.c.), an antagonist ??2-adrenergic, L-NAME (20mg/kg, s.c.), an inhibitor of nitric oxide synthesis or indomethacin (10mg/kg, s.c.), an inhibitor of prostaglandin production, reversed the gastroprotective activity of HE (100mg/kg, p.o.).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results suggestive that the Celtis iguanaea HE exhibits gastroprotective activity in different gastric ulcer models. The mechanism of gastroprotective effect of Celtis iguanaea HE suggests the participation of mucus as well as the involvement of ??2-adrenergic receptors, NO and prostaglandins. The hydroxyl-linolenic acid, linoleic acids and conjugated oxo-linoleic acids are among the phytoconstituents that were identified in the Celtis iguanaea HE.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ireland Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Martins</LastName>
                    <ForeName>Jos?? Lu??s Rodrigues</ForeName>
                    <Initials>JL</Initials>
                    <Affiliation>Institute of Biological Sciences, Department of Physiological Sciences, Federal University of Goi??s, Campus Samambaia, Goi??nia-GO, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rodrigues</LastName>
                    <ForeName>Oscar Romero Lopes</ForeName>
                    <Initials>OR</Initials>
                    <Affiliation>Institute of Biological Sciences, Department of Physiological Sciences, Federal University of Goi??s, Campus Samambaia, Goi??nia-GO, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>da Silva</LastName>
                    <ForeName>Dayane Moreira</ForeName>
                    <Initials>DM</Initials>
                    <Affiliation>Institute of Biological Sciences, Department of Physiological Sciences, Federal University of Goi??s, Campus Samambaia, Goi??nia-GO, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Galdino</LastName>
                    <ForeName>Pablinny Moreira</ForeName>
                    <Initials>PM</Initials>
                    <Affiliation>Institute of Biological Sciences, Department of Physiological Sciences, Federal University of Goi??s, Campus Samambaia, Goi??nia-GO, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>de Paula</LastName>
                    <ForeName>Jos?? Realino</ForeName>
                    <Initials>JR</Initials>
                    <Affiliation>Faculty of Pharmacy, Federal University of Goi??s, Setor Universit??rio, Goi??nia-GO, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rom??o</LastName>
                    <ForeName>Wanderson</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Laboratory of Petrole??mica and Chemistry Forense, Department of Chemistry, Federal University of Esp??rito Santo, Goiabeiras, Vit??ria-ES, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>da Costa</LastName>
                    <ForeName>Helber Barcellos</ForeName>
                    <Initials>HB</Initials>
                    <Affiliation>Laboratory of Petrole??mica and Chemistry Forense, Department of Chemistry, Federal University of Esp??rito Santo, Goiabeiras, Vit??ria-ES, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Vaz</LastName>
                    <ForeName>Boniek Gontijo</ForeName>
                    <Initials>BG</Initials>
                    <Affiliation>Institute of Chemistry, Federal University of Goi??s, Campus Samambaia, Goi??nia-GO, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ghedini</LastName>
                    <ForeName>Paulo C??sar</ForeName>
                    <Initials>PC</Initials>
                    <Affiliation>Institute of Biological Sciences, Department of Physiological Sciences, Federal University of Goi??s, Campus Samambaia, Goi??nia-GO, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Costa</LastName>
                    <ForeName>Elson Alves</ForeName>
                    <Initials>EA</Initials>
                    <Affiliation>Institute of Biological Sciences, Department of Physiological Sciences, Federal University of Goi??s, Campus Samambaia, Goi??nia-GO, Brazil. Electronic address: xico@ufg.br.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Ethnopharmacol</MedlineTA>
            <NlmUniqueID>7903310</NlmUniqueID>
            <ISSNLinking>0378-8741</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Celtis iguanaea</Keyword>
            <Keyword MajorTopicYN="N">Gastroprotective mechanisms</Keyword>
            <Keyword MajorTopicYN="N">Hydroxyl-linolenic</Keyword>
            <Keyword MajorTopicYN="N">Linoleic acids</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0378-8741(14)00598-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jep.2014.08.006</ArticleId>
            <ArticleId IdType="pubmed">25153020</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25152895</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2314-7156</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of immunology research</Title>
                <ISOAbbreviation>J Immunol Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dose of Incorporated Immunodominant Antigen in Recombinant BCG Impacts Modestly on Th1 Immune Response and Protective Efficiency against Mycobacterium tuberculosis in Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>196124</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/196124</ELocationID>
            <Abstract>
                <AbstractText>One approach for improving BCG efficacy is to utilize BCG as vehicle to develop recombinant BCG (rBCG) strains overexpressing Mycobacterium tuberculosis (M. tb) antigens. Also expression level of a candidate antigen should impact the final T cell responses conferred by rBCG. In this study, based on our previously constructed differential expression system, we developed two rBCG strains overexpressing M. tb chimeric antigen Ag856A2 (coding a recombinant ag85a with 2 copies of esat-6 inserted at Acc I site of ag85a) at differential levels under the control of the subtly modified furA promoters. These two rBCG strains were used to vaccinate C57BL/6 mice and exploit dose of incorporated antigen in rBCG to optimize immune response and protective efficiency against M. tb challenge in mouse model. The results showed that rBCG strains overexpressing Ag856A2 at differential levels induced different antigen-specific IFN-?? production and comparable number of M. tb-specific CD4 T cells expressing IL-2. M. tb challenge experiment showed that rBCG strains afforded enhanced but comparable immune protection characterized by reduced bacillary load, lung pathology, and inflammation. These results suggested that the dose of antigens incorporated in rBCG can impact T cell immune responses but imposed no significantly differential protective efficacies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Hui</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Kang</ForeName>
                    <Initials>K</Initials>
                    <Identifier Source="ORCID">0000-0002-9024-795X</Identifier>
                    <Affiliation>Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Fang</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Hua</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kang</LastName>
                    <ForeName>Han</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China ; Key Laboratory of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, Shanghai 200032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Ning-Ning</ForeName>
                    <Initials>NN</Initials>
                    <Affiliation>Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yuan</LastName>
                    <ForeName>Qin</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Wen-Jiang</ForeName>
                    <Initials>WJ</Initials>
                    <Affiliation>Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fan</LastName>
                    <ForeName>Xiao-Yong</ForeName>
                    <Initials>XY</Initials>
                    <Identifier Source="ORCID">0000-0001-6654-3559</Identifier>
                    <Affiliation>Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China ; Key Laboratory of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, Shanghai 200032, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Immunol Res</MedlineTA>
            <NlmUniqueID>101627166</NlmUniqueID>
            <ISSNLinking>2314-7156</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/196124</ArticleId>
            <ArticleId IdType="pubmed">25152895</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25152762</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1741-427X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Evidence-based complementary and alternative medicine : eCAM</Title>
                <ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Elemene injection induced autophagy protects human hepatoma cancer cells from starvation and undergoing apoptosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>637528</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/637528</ELocationID>
            <Abstract>
                <AbstractText>Elemene, a compound found in an herb used in traditional Chinese medicine, has shown promising anticancer effects against a broad spectrum of tumors. In an in vivo experiment, we found that apatinib, a tyrosine kinase inhibitor that selectively inhibits VEGFR2, combined with elemene injection (Ele) for the treatment of H22 solid tumor in mice resulted in worse effectiveness than apatinib alone. Moreover, Ele could protect HepG2 cells from death induced by serum-free starvation. Further data on the mechanism study revealed that Ele induced protective autophagy and prevented human hepatoma cancer cells from undergoing apoptosis. Proapoptosis effect of Ele was enhanced when proautophagy effect was inhibited by hydroxychloroquine. Above all, Ele has the effect of protecting cancer cells from death either in apatinib induced nutrient deficient environment or in serum-free induced starvation. A combination of elemene injection with autophagy inhibitor might thus be a useful therapeutic option for hepatocellular carcinoma.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Institute of First Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210046, China ; Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210021, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Keming</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210021, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Chunping</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Laboratory of Cellular and Molecular Biology, Jiangsu Province Institute of Traditional Chinese Medicine, 100 Shizi Street, Hongshan Road, Nanjing, Jiangsu 210028, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Lin</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Laboratory of Cellular and Molecular Biology, Jiangsu Province Institute of Traditional Chinese Medicine, 100 Shizi Street, Hongshan Road, Nanjing, Jiangsu 210028, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qin</LastName>
                    <ForeName>Shukui</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Oncology Center of Chinese, 81 Hospital of PLA, Nanjing, Jiangsu 210002, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cai</LastName>
                    <ForeName>Xueting</ForeName>
                    <Initials>X</Initials>
                    <Identifier Source="ORCID">0000-0002-1390-4629</Identifier>
                    <Affiliation>Laboratory of Cellular and Molecular Biology, Jiangsu Province Institute of Traditional Chinese Medicine, 100 Shizi Street, Hongshan Road, Nanjing, Jiangsu 210028, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
            <NlmUniqueID>101215021</NlmUniqueID>
            <ISSNLinking>1741-427X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/637528</ArticleId>
            <ArticleId IdType="pubmed">25152762</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25152753</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1687-4757</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PPAR research</Title>
                <ISOAbbreviation>PPAR Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>TRPV1 Activation Attenuates High-Salt Diet-Induced Cardiac Hypertrophy and Fibrosis through PPAR-?? Upregulation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>491963</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/491963</ELocationID>
            <Abstract>
                <AbstractText>High-salt diet-induced cardiac hypertrophy and fibrosis are associated with increased reactive oxygen species production. Transient receptor potential vanilloid type 1 (TRPV1), a specific receptor for capsaicin, exerts a protective role in cardiac remodeling that resulted from myocardial infarction, and peroxisome proliferation-activated receptors ?? (PPAR-??) play an important role in metabolic myocardium remodeling. However, it remains unknown whether activation of TRPV1 could alleviate cardiac hypertrophy and fibrosis and the effect of cross-talk between TRPV1 and PPAR-?? on suppressing high-salt diet-generated oxidative stress. In this study, high-salt diet-induced cardiac hypertrophy and fibrosis are characterized by significant enhancement of HW/BW%, LVEDD, and LVESD, decreased FS and EF, and increased collagen deposition. These alterations were associated with downregulation of PPAR-??, UCP2 expression, upregulation of iNOS production, and increased oxidative/nitrotyrosine stress. These adverse effects of long-term high-salt diet were attenuated by chronic treatment with capsaicin. However, this effect of capsaicin was absent in TRPV1(-/-) mice on a high-salt diet. Our finding suggests that chronic dietary capsaicin consumption attenuates long-term high-salt diet-induced cardiac hypertrophy and fibrosis. This benefit effect is likely to be caused by TRPV1 mediated upregulation of PPAR-?? expression.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Feng</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Chongqing Institute of Hypertension, Daping Hospital, Third Military Medical University, Chongqing 400042, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>Yi</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Chongqing Institute of Hypertension, Daping Hospital, Third Military Medical University, Chongqing 400042, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Xiang</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Ultrasound, Daping Hospital, Third Military Medical University, Chongqing 400042, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Zongshi</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Chongqing Institute of Hypertension, Daping Hospital, Third Military Medical University, Chongqing 400042, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Chongqing Institute of Hypertension, Daping Hospital, Third Military Medical University, Chongqing 400042, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Shanjun</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Cardiovascular Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Daoyan</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Chongqing Institute of Hypertension, Daping Hospital, Third Military Medical University, Chongqing 400042, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yan</LastName>
                    <ForeName>Zhencheng</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Chongqing Institute of Hypertension, Daping Hospital, Third Military Medical University, Chongqing 400042, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Zhiming</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Chongqing Institute of Hypertension, Daping Hospital, Third Military Medical University, Chongqing 400042, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PPAR Res</MedlineTA>
            <NlmUniqueID>101269101</NlmUniqueID>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/491963</ArticleId>
            <ArticleId IdType="pubmed">25152753</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25152736</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1664-042X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>5</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in physiology</Title>
                <ISOAbbreviation>Front Physiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Adventitial inflammation and its interaction with intimal atherosclerotic lesions.</ArticleTitle>
            <Pagination>
                <MedlinePgn>296</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fphys.2014.00296</ELocationID>
            <Abstract>
                <AbstractText>The presence of adventitial inflammation in correlation with atherosclerotic lesions has been recognized for decades. In the last years, several studies have investigated the relevance and impact of adventitial inflammation on atherogenesis. In the abdominal aorta of elderly Apoe(-/-) mice, adventitial inflammatory structures were characterized as organized ectopic lymphoid tissue, and therefore termed adventitial tertiary lymphoid organs (ATLOs). These ATLOs possess similarities in development, structure and function to secondary lymphoid organs. A crosstalk between intimal atherosclerotic lesions and ATLOs has been suggested, and several studies could demonstrate a potential role for medial vascular smooth muscle cells in this process. We here review the development, phenotypic characteristics, and function of ATLOs in atherosclerosis. Furthermore, we discuss the possible role of medial vascular smooth muscle cells and their interaction between plaque and ATLOs.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Akhavanpoor</LastName>
                    <ForeName>Mohammadreza</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Cardiology, University of Heidelberg Heidelberg, Germany ; DZHK (German Centre for Cardiovascular Research) Partner Site Heidelberg/Mannheim, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wangler</LastName>
                    <ForeName>Susanne</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Cardiology, University of Heidelberg Heidelberg, Germany ; DZHK (German Centre for Cardiovascular Research) Partner Site Heidelberg/Mannheim, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gleissner</LastName>
                    <ForeName>Christian A</ForeName>
                    <Initials>CA</Initials>
                    <Affiliation>Department of Cardiology, University of Heidelberg Heidelberg, Germany ; DZHK (German Centre for Cardiovascular Research) Partner Site Heidelberg/Mannheim, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Korosoglou</LastName>
                    <ForeName>Grigorios</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Cardiology, University of Heidelberg Heidelberg, Germany ; DZHK (German Centre for Cardiovascular Research) Partner Site Heidelberg/Mannheim, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Katus</LastName>
                    <ForeName>Hugo A</ForeName>
                    <Initials>HA</Initials>
                    <Affiliation>Department of Cardiology, University of Heidelberg Heidelberg, Germany ; DZHK (German Centre for Cardiovascular Research) Partner Site Heidelberg/Mannheim, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Erbel</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Cardiology, University of Heidelberg Heidelberg, Germany ; DZHK (German Centre for Cardiovascular Research) Partner Site Heidelberg/Mannheim, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Physiol</MedlineTA>
            <NlmUniqueID>101549006</NlmUniqueID>
            <ISSNLinking>1664-042X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">adventitial inflammation</Keyword>
            <Keyword MajorTopicYN="N">adventitial tertiary lymphoid organs</Keyword>
            <Keyword MajorTopicYN="N">atherosclerosis</Keyword>
            <Keyword MajorTopicYN="N">autoimmunity</Keyword>
            <Keyword MajorTopicYN="N">macrophages</Keyword>
            <Keyword MajorTopicYN="N">vascular smooth muscle cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphys.2014.00296</ArticleId>
            <ArticleId IdType="pubmed">25152736</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25152733</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1663-9812</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>5</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in pharmacology</Title>
                <ISOAbbreviation>Front Pharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Embelin, a small molecule quinone with a co-clinical power for castrate-resistant prostate cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>184</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2014.00184</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Poojari</LastName>
                    <ForeName>Radhika J</ForeName>
                    <Initials>RJ</Initials>
                    <Affiliation>Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay Mumbai, India.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Pharmacol</MedlineTA>
            <NlmUniqueID>101548923</NlmUniqueID>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">castrate resistant prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">co-clinical</Keyword>
            <Keyword MajorTopicYN="N">embelin</Keyword>
            <Keyword MajorTopicYN="N">gene therapy</Keyword>
            <Keyword MajorTopicYN="N">integrated human-mouse cross-species</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2014.00184</ArticleId>
            <ArticleId IdType="pubmed">25152733</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25152719</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1662-5153</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in behavioral neuroscience</Title>
                <ISOAbbreviation>Front Behav Neurosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Distinct behavioral phenotypes in ethanol-induced place preference are associated with different extinction and reinstatement but not behavioral sensitization responses.</ArticleTitle>
            <Pagination>
                <MedlinePgn>267</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fnbeh.2014.00267</ELocationID>
            <Abstract>
                <AbstractText>Conditioned place preference (CPP) is a model to study the role of drug conditioning properties. In outbred strains, individual variability may affect some behavioral measures. However, there are few studies focusing on understanding how different phenotypes of ethanol conditioned behavior may influence its extinction, reinstatement, and behavioral adaptation measures. We used male Swiss Webster mice to study different phenotypes related to ethanol conditioning strength, reinstatement and behavioral sensitization. Mice went through a CPP procedure with ethanol (2.2 g/kg, i.p.). After that, one group of mice was submitted to repeated extinction sessions, while another group remained in their home cages without any drug treatment. Mice went through environmental and ethanol priming (1.0 g/kg, i.p.) reinstatement tests. Ethanol priming test reinstated the conditioned behavior only in the animals kept in the home-cage during the abstinence period. Besides, the ethanol conditioned behavior strength was positively correlated with the time required to be extinguished. In the second set of experiments, some mice went through a CPP protocol followed by behavioral sensitization (five i.p. administrations of ethanol 2.2 g/kg or saline per week, for 3 weeks) and another group of mice went through sensitization followed by CPP. No positive correlation was observed between ethanol CPP strength and the intensity of behavioral sensitization. Considering that different phenotypes observed in CPP strength predicted the variability in other CPP measures, we developed a statistics-based method to classify mice according to CPP strength to be used in the evaluation of ethanol conditioning properties.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pildervasser</LastName>
                    <ForeName>Jo??o V N</ForeName>
                    <Initials>JV</Initials>
                    <Affiliation>Unidade de Depend??ncia de Drogas, Departament of Psicobiologia, Universidade Federal de Sao Paulo Sao Paulo, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abrahao</LastName>
                    <ForeName>Karina P</ForeName>
                    <Initials>KP</Initials>
                    <Affiliation>Laboratory of Integrative Neuroscience, National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health Rockville, MD, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Souza-Formigoni</LastName>
                    <ForeName>Maria L O</ForeName>
                    <Initials>ML</Initials>
                    <Affiliation>Unidade de Depend??ncia de Drogas, Departament of Psicobiologia, Universidade Federal de Sao Paulo Sao Paulo, Brazil.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Behav Neurosci</MedlineTA>
            <NlmUniqueID>101477952</NlmUniqueID>
            <ISSNLinking>1662-5153</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CPP</Keyword>
            <Keyword MajorTopicYN="N">behavioral sensitization</Keyword>
            <Keyword MajorTopicYN="N">different phenotypes</Keyword>
            <Keyword MajorTopicYN="N">ethanol</Keyword>
            <Keyword MajorTopicYN="N">extinction</Keyword>
            <Keyword MajorTopicYN="N">individual variability</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnbeh.2014.00267</ArticleId>
            <ArticleId IdType="pubmed">25152719</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25152714</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1662-5102</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in cellular neuroscience</Title>
                <ISOAbbreviation>Front Cell Neurosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Modulating neurotoxicity through CX3CL1/CX3CR1 signaling.</ArticleTitle>
            <Pagination>
                <MedlinePgn>229</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fncel.2014.00229</ELocationID>
            <Abstract>
                <AbstractText>Since the initial cloning of fractalkine/CX3CL1, it was proposed that the only known member of the CX3C or ?? subfamily of chemotactic cytokines could play some significant role in the nervous system, due to its high expression on neurons. The pivotal description of the localization of the unique CX3CL1 receptor, CX3CR1, on microglial cells, firmed up by the generation of cx3cr1(GFP/GFP) mice, opened the road to the hypothesis of some specific key interactions between microglia and neurons mediated by this pair. This expectation has been indeed supported by recent exciting evidence indicating that CX3CL1-mediated microglia-neuron interaction modulates basic physiological activities during development, adulthood and aging, including: synaptic pruning; promoting survival of neurons and neural precursors; modulating synaptic transmission and plasticity; enhancing synapse and network maturation; and facilitating the establishment of neuropathic pain circuits. Beyond playing such fascinating roles in physiological conditions, CX3CL1 signaling has been implicated in different neuropathologies. Early papers demonstrated that the levels of CX3CL1 may be modulated by various toxic stimuli in vitro and that CX3CL1 signaling is positively or negatively regulated in EAE and MS, in HIV infection and LPS challenge, in epilepsy, in brain tumors, and in other neuropathologies. In this review we focus on the experimental evidence of CX3CL1 involvement in neuroprotection and survey the common molecular and cellular mechanisms described in different brain diseases.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Limatola</LastName>
                    <ForeName>Cristina</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Physiology and Pharmacology, Istituto Pasteur Fondazione Cenci Bolognetti, Sapienza University of Rome Rome, Italy ; Istituto di Ricovero e Cura a Carattere Scientifico Neuromed, Istituto Neurologico Mediterraneo Pozzilli, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ransohoff</LastName>
                    <ForeName>Richard M</ForeName>
                    <Initials>RM</Initials>
                    <Affiliation>Neuroinflammation Research Center, Lerner Research Institute and Cleveland Clinic Lerner College of Medicine Case Western Reserve University Cleveland, OH, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Cell Neurosci</MedlineTA>
            <NlmUniqueID>101477935</NlmUniqueID>
            <ISSNLinking>1662-5102</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CX3CL1</Keyword>
            <Keyword MajorTopicYN="N">CX3CR1</Keyword>
            <Keyword MajorTopicYN="N">microglia</Keyword>
            <Keyword MajorTopicYN="N">neurotoxicity</Keyword>
            <Keyword MajorTopicYN="N">signaling</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fncel.2014.00229</ArticleId>
            <ArticleId IdType="pubmed">25152714</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25152713</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1662-5102</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in cellular neuroscience</Title>
                <ISOAbbreviation>Front Cell Neurosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>High-Fat-Diet-Induced Weight Gain Ameliorates Bone Loss without Exacerbating A??PP Processing and Cognition in Female APP/PS1 Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>225</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fncel.2014.00225</ELocationID>
            <Abstract>
                <AbstractText>Osteoporosis is negatively correlated with body mass, whereas both osteoporosis and weight loss occur at higher incidence during the progression of Alzheimer's disease (AD) than the age-matched non-dementia individuals. Given that there is no evidence that being overweight is associated with AD-type cognitive dysfunction, we hypothesized that moderate weight gain might have a protective effect on the bone loss in AD without exacerbating cognitive dysfunction. In this study, feeding a high-fat diet (HFD, 45% calorie from fat) to female APP/PS1 transgenic mice, an AD animal model, induced weight gain. The bone mineral density, microarchitecture, and biomechanical properties of the femurs were then evaluated. The results showed that the middle-aged female APP/PS1 transgenic mice were susceptible to osteoporosis of the femoral bones and that weight gain significantly enhanced bone mass and mechanical properties. Notably, HFD was not detrimental to brain insulin signaling and A??PP processing, as well as to exploration ability and working, learning, and memory performance of the transgenic mice measured by T maze and Morris water maze, compared with the mice fed a normal-fat diet (10% calorie from fat). In addition, the circulating levels of leptin but not estradiol were remarkably elevated in HFD-treated mice. These results suggest that a body weight gain induced by the HFD feeding regimen significantly improved bone mass in female APP/PS1 mice with no detriments to exploration ability and spatial memory, most likely via the action of elevated circulating leptin.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Yunhua</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology and Frontier Institute of Science and Technology, Xi'an Jiaotong University , Xi'an , China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology and Frontier Institute of Science and Technology, Xi'an Jiaotong University , Xi'an , China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology and Frontier Institute of Science and Technology, Xi'an Jiaotong University , Xi'an , China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Jianshu</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Shaanxi Translational Center for Functional Foods , Xi'an , China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Tingting</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Shaanxi Translational Center for Functional Foods , Xi'an , China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Shujun</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology and Frontier Institute of Science and Technology, Xi'an Jiaotong University , Xi'an , China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Hua</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology and Frontier Institute of Science and Technology, Xi'an Jiaotong University , Xi'an , China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hou</LastName>
                    <ForeName>Chen</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology and Frontier Institute of Science and Technology, Xi'an Jiaotong University , Xi'an , China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Jiankang</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology and Frontier Institute of Science and Technology, Xi'an Jiaotong University , Xi'an , China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Long</LastName>
                    <ForeName>Jiangang</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology and Frontier Institute of Science and Technology, Xi'an Jiaotong University , Xi'an , China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Cell Neurosci</MedlineTA>
            <NlmUniqueID>101477935</NlmUniqueID>
            <ISSNLinking>1662-5102</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alzheimer???s disease</Keyword>
            <Keyword MajorTopicYN="N">bone mineral density</Keyword>
            <Keyword MajorTopicYN="N">leptin</Keyword>
            <Keyword MajorTopicYN="N">osteoporosis</Keyword>
            <Keyword MajorTopicYN="N">weight gain</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fncel.2014.00225</ArticleId>
            <ArticleId IdType="pubmed">25152713</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25152712</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1662-5102</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in cellular neuroscience</Title>
                <ISOAbbreviation>Front Cell Neurosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inward rectifier potassium (Kir) current in dopaminergic periglomerular neurons of the mouse olfactory bulb.</ArticleTitle>
            <Pagination>
                <MedlinePgn>223</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fncel.2014.00223</ELocationID>
            <Abstract>
                <AbstractText>Dopaminergic (DA) periglomerular (PG) neurons are critically placed at the entry of the bulbar circuitry, directly in contact with both the terminals of olfactory sensory neurons and the apical dendrites of projection neurons; they are autorhythmic and are the target of numerous terminals releasing a variety of neurotransmitters. Despite the centrality of their position, suggesting a critical role in the sensory processing, their properties -and consequently their function- remain elusive. The current mediated by inward rectifier potassium (Kir) channels in DA-PG cells was recorded by adopting the perforated-patch configuration in thin slices; IKir could be distinguished from the hyperpolarization-activated current (I h ) by showing full activation in &lt;10 ms, no inactivation, suppression by Ba(2+) in a typical voltage-dependent manner (IC50 208 ??M) and reversal potential nearly coincident with EK. Ba(2+) (2 mM) induces a large depolarization of DA-PG cells, paralleled by an increase of the input resistance, leading to a block of the spontaneous activity, but the Kir current is not an essential component of the pacemaker machinery. The Kir current is negatively modulated by intracellular cAMP, as shown by a decrease of its amplitude induced by forskolin or 8Br-cAMP. We have also tested the neuromodulatory effects of the activation of several metabotropic receptors known to be present on these cells, showing that the current can be modulated by a multiplicity of pathways, whose activation in some case increases the amplitude of the current, as can be observed with agonists of D2, muscarinic, and GABAA receptors, whereas in other cases has the opposite effect, as it can be observed with agonists of ??1 noradrenergic, 5-HT and histamine receptors. These characteristics of the Kir currents provide the basis for an unexpected plasticity of DA-PG cell function, making them potentially capable to reconfigure the bulbar network to allow a better flexibility.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Borin</LastName>
                    <ForeName>Mirta</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Life Sciences and Biotechnology, University of Ferrara Ferrara, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fogli Iseppe</LastName>
                    <ForeName>Alex</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Life Sciences and Biotechnology, University of Ferrara Ferrara, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pignatelli</LastName>
                    <ForeName>Angela</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Life Sciences and Biotechnology, University of Ferrara Ferrara, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Belluzzi</LastName>
                    <ForeName>Ottorino</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Department of Life Sciences and Biotechnology, University of Ferrara Ferrara, Italy.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Cell Neurosci</MedlineTA>
            <NlmUniqueID>101477935</NlmUniqueID>
            <ISSNLinking>1662-5102</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Kir channels</Keyword>
            <Keyword MajorTopicYN="N">dopaminergic neurons</Keyword>
            <Keyword MajorTopicYN="N">olfactory bulb</Keyword>
            <Keyword MajorTopicYN="N">patch-clamp techniques</Keyword>
            <Keyword MajorTopicYN="N">periglomerular cell</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fncel.2014.00223</ArticleId>
            <ArticleId IdType="pubmed">25152712</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152705</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1574-3624</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Current signal transduction therapy</Title>
                <ISOAbbreviation>Curr Signal Transduct Ther</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Metastasis-Initiating Cells in Renal Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>240-246</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Metastasis is a complex process that propagates cells from the primary or initial site of the cancer occurrence to distant parts of the body. Cancer cells break from the cancer site and circulate through the bloodstream or lymph vessels, allowing them to reach nearly all parts of the body. These circulating tumour cells (CTCs) contain specialized metastasis-initiating cells (MICs) that reside in the biological heterogeneous primary tumour. Researchers have hypothesized that metastasis of renal cell carcinoma is initiated by circulation of MICs in patients' blood and bone marrow. Based on the cancer stem/progenitor cell concept of carcinogenesis, understanding the molecular phenotypes of metastasis-initiating cells (MICs) in renal cancer could play a vital role in developing strategies for therapeutic interventions in renal cancer. Existence of MICs among CTCs in renal carcinoma has not been proven in large scale. However, some studies have reported that specialized markers are found on the surface of circulating cells from the primary tumour. In mice, MICs have been isolated from CTCs using such markers, which have then been transplanted into xenograft model to show whether they give rise to metastasis in different organs. Considering these findings, in this review we have attempted to summarize the studies connected with MICs and their gene expression profiles that are responsible for metastasis in renal cancer.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Khan</LastName>
                    <ForeName>Mohammed I</ForeName>
                    <Initials>MI</Initials>
                    <Affiliation>Molecular Oncology Laboratory, Clinic of Oncology, Military Institute of Medicine, ul. Szaser??w 128, 04-141 Warsaw, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Czarnecka</LastName>
                    <ForeName>Anna M</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>Molecular Oncology Laboratory, Clinic of Oncology, Military Institute of Medicine, ul. Szaser??w 128, 04-141 Warsaw, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Duchnowska</LastName>
                    <ForeName>Renata</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Molecular Oncology Laboratory, Clinic of Oncology, Military Institute of Medicine, ul. Szaser??w 128, 04-141 Warsaw, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kukwa</LastName>
                    <ForeName>Wojciech</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Department of Otolaryngology, Czerniakowski Hospital, Medical University of Warsaw, ul. Stepinska 19/25, Warsaw, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Szczylik</LastName>
                    <ForeName>Cezary</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Molecular Oncology Laboratory, Clinic of Oncology, Military Institute of Medicine, ul. Szaser??w 128, 04-141 Warsaw, Poland.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Curr Signal Transduct Ther</MedlineTA>
            <NlmUniqueID>101273157</NlmUniqueID>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Circulating tumour cells</Keyword>
            <Keyword MajorTopicYN="N">metastasis-initiating cells</Keyword>
            <Keyword MajorTopicYN="N">renal cell carcinoma</Keyword>
            <Keyword MajorTopicYN="N">tumour-initiating cells.</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1574362409666140206222431</ArticleId>
            <ArticleId IdType="pii">CSTT-8-240</ArticleId>
            <ArticleId IdType="pubmed">25152705</ArticleId>
        </ArticleIdList>
        <?pmcsd?>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25152619</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1178-2013</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of nanomedicine</Title>
                <ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Size-dependent accumulation of particles in lysosomes modulates dendritic cell function through impaired antigen degradation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3885-902</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S64353</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Nanosized particles may enable therapeutic modulation of immune responses by targeting dendritic cell (DC) networks in accessible organs such as the lung. To date, however, the effects of nanoparticles on DC function and downstream immune responses remain poorly understood.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Bone marrow-derived DCs (BMDCs) were exposed in vitro to 20 or 1,000 nm polystyrene (PS) particles. Particle uptake kinetics, cell surface marker expression, soluble protein antigen uptake and degradation, as well as in vitro CD4(+) T-cell proliferation and cytokine production were analyzed by flow cytometry. In addition, co-localization of particles within the lysosomal compartment, lysosomal permeability, and endoplasmic reticulum stress were analyzed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The frequency of PS particle-positive CD11c(+)/CD11b(+) BMDCs reached an early plateau after 20 minutes and was significantly higher for 20 nm than for 1,000 nm PS particles at all time-points analyzed. PS particles did not alter cell viability or modify expression of the surface markers CD11b, CD11c, MHC class II, CD40, and CD86. Although particle exposure did not modulate antigen uptake, 20 nm PS particles decreased the capacity of BMDCs to degrade soluble antigen, without affecting their ability to induce antigen-specific CD4(+) T-cell proliferation. Co-localization studies between PS particles and lysosomes using laser scanning confocal microscopy detected a significantly higher frequency of co-localized 20 nm particles as compared with their 1,000 nm counterparts. Neither size of PS particle caused lysosomal leakage, expression of endoplasmic reticulum stress gene markers, or changes in cytokines profiles.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data indicate that although supposedly inert PS nanoparticles did not induce DC activation or alteration in CD4(+) T-cell stimulating capacity, 20 nm (but not 1,000 nm) PS particles may reduce antigen degradation through interference in the lysosomal compartment. These findings emphasize the importance of performing in-depth analysis of DC function when developing novel approaches for immune modulation with nanoparticles.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Seydoux</LastName>
                    <ForeName>Emilie</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Respiratory Medicine, Inselspital, Bern University Hospital, Department of Clinical Research, University of Bern, Switzerland ; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rothen-Rutishauser</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Respiratory Medicine, Inselspital, Bern University Hospital, Department of Clinical Research, University of Bern, Switzerland ; Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nita</LastName>
                    <ForeName>Izabela M</ForeName>
                    <Initials>IM</Initials>
                    <Affiliation>Department of Respiratory Medicine, Inselspital, Bern University Hospital, Department of Clinical Research, University of Bern, Switzerland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Balog</LastName>
                    <ForeName>Sandor</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gazdhar</LastName>
                    <ForeName>Amiq</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Respiratory Medicine, Inselspital, Bern University Hospital, Department of Clinical Research, University of Bern, Switzerland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stumbles</LastName>
                    <ForeName>Philip A</ForeName>
                    <Initials>PA</Initials>
                    <Affiliation>School of Veterinary and Life Sciences, Molecular and Biomedical Sciences, Murdoch University, Perth, WA, Australia ; Telethon Kids Institute, Perth, WA, Australia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Petri-Fink</LastName>
                    <ForeName>Alke</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland ; Department of Chemistry, University of Fribourg, Fribourg, Switzerland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blank</LastName>
                    <ForeName>Fabian</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Respiratory Medicine, Inselspital, Bern University Hospital, Department of Clinical Research, University of Bern, Switzerland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>von Garnier</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Respiratory Medicine, Inselspital, Bern University Hospital, Department of Clinical Research, University of Bern, Switzerland.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Int J Nanomedicine</MedlineTA>
            <NlmUniqueID>101263847</NlmUniqueID>
            <ISSNLinking>1176-9114</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CD4+ T-cells</Keyword>
            <Keyword MajorTopicYN="N">immune modulation</Keyword>
            <Keyword MajorTopicYN="N">mouse dendritic cells</Keyword>
            <Keyword MajorTopicYN="N">nanoparticles</Keyword>
            <Keyword MajorTopicYN="N">polystyrene particles</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S64353</ArticleId>
            <ArticleId IdType="pii">ijn-9-3885</ArticleId>
            <ArticleId IdType="pubmed">25152619</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152529</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0984</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of virological methods</Title>
                <ISOAbbreviation>J. Virol. Methods</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Development of single-chain Fv against the nucleoprotein of type A influenza virus and its use in ELISA.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0166-0934(14)00326-7</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jviromet.2014.08.009</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Single chain fragment variable (ScFv) antibodies specific to the nucleoprotein (NP) of avian influenza virus (AIV) were developed using a phage display system. The variable heavy (VH) and the variable light (VL) chain gene fragments were derived from spleen cells of Balb/c mouse immunized with a recombinant NP (rNP) antigen (???63kDa) of H5N1 influenza virus. The VH and the VL DNA fragments were assembled through a flexible linker DNA to generate ScFv DNA that was cloned subsequently in a phagemid to express ScFv protein in E. coli cells. The specific reactivity of the ScFv with the rNP antigen and viral antigen (H5N1) was confirmed by Western blot and ELISA. A competitive inhibition ELISA (CI-ELISA) was developed using the rNP and the anti-NP ScFv for detection of type-specific antibodies to AIV in chicken sera. The ScFv based CI-ELISA was compared with hemagglutination inhibition (HI) test and Agar Gel Immuno-Diffusion (AGID) test over 850 sera. Sensitivity of the CI-ELISA was 100% with HI and AGID and specificity was 98.7% with HI and 100% with AGID.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sengupta</LastName>
                    <ForeName>Devyani</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>High Security Animal Disease Laboratory, Indian Veterinary Research Institute, Anand Nagar, Bhopal, Madhya Pradesh, 462021, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shaikh</LastName>
                    <ForeName>Asma</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>High Security Animal Disease Laboratory, Indian Veterinary Research Institute, Anand Nagar, Bhopal, Madhya Pradesh, 462021, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bhatia</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>High Security Animal Disease Laboratory, Indian Veterinary Research Institute, Anand Nagar, Bhopal, Madhya Pradesh, 462021, India. Electronic address: sandeep.bhatia@hsadl.in.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pateriya</LastName>
                    <ForeName>A K</ForeName>
                    <Initials>AK</Initials>
                    <Affiliation>High Security Animal Disease Laboratory, Indian Veterinary Research Institute, Anand Nagar, Bhopal, Madhya Pradesh, 462021, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Khandia</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>High Security Animal Disease Laboratory, Indian Veterinary Research Institute, Anand Nagar, Bhopal, Madhya Pradesh, 462021, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sood</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>High Security Animal Disease Laboratory, Indian Veterinary Research Institute, Anand Nagar, Bhopal, Madhya Pradesh, 462021, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Prakash</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Biotechnology and Bioinformatics, Barkatullah University, Bhopal, Madhya Pradesh, 462021, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pattnaik</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>High Security Animal Disease Laboratory, Indian Veterinary Research Institute, Anand Nagar, Bhopal, Madhya Pradesh, 462021, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pradhan</LastName>
                    <ForeName>H K</ForeName>
                    <Initials>HK</Initials>
                    <Affiliation>High Security Animal Disease Laboratory, Indian Veterinary Research Institute, Anand Nagar, Bhopal, Madhya Pradesh, 462021, India.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Virol Methods</MedlineTA>
            <NlmUniqueID>8005839</NlmUniqueID>
            <ISSNLinking>0166-0934</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">AIV</Keyword>
            <Keyword MajorTopicYN="N">ELISA</Keyword>
            <Keyword MajorTopicYN="N">Nucleoprotein</Keyword>
            <Keyword MajorTopicYN="N">Recombinant antibody</Keyword>
            <Keyword MajorTopicYN="N">ScFv</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0166-0934(14)00326-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jviromet.2014.08.009</ArticleId>
            <ArticleId IdType="pubmed">25152529</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25152523</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1642-431X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>14</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Reproductive biology</Title>
                <ISOAbbreviation>Reprod Biol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Long-term adverse effects of cyclophosphamide on follicular growth and angiogenesis in mouse ovaries.</ArticleTitle>
            <Pagination>
                <MedlinePgn>238-42</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.repbio.2014.04.007</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1642-431X(14)00048-5</ELocationID>
            <Abstract>
                <AbstractText>The adverse effects of the anti-cancer agent cyclophosphamide (CTX) on follicular growth and ovarian angiogenesis were investigated in mice. CTX treatment irreversibly induced a loss of follicles through apoptosis and decreased microvascularization of the corpora lutea and follicles in a dose-dependent manner. Our findings demonstrated that CTX adversely affected the ovaries indicating the need to support an awareness of fertility preservation before chemotherapy is initiated.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Society for Biology of Reproduction &amp; the Institute of Animal Reproduction and Food Research of Polish Academy of Sciences in Olsztyn. Published by Elsevier Urban &amp; Partner Sp. z o.o. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ezoe</LastName>
                    <ForeName>Kenji</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Kato Ladies Clinic, 7-20-3 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murata</LastName>
                    <ForeName>Nana</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Kato Ladies Clinic, 7-20-3 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yabuuchi</LastName>
                    <ForeName>Akiko</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Kato Ladies Clinic, 7-20-3 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan. Electronic address: a-yabuuchi@towako-kato.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Okuno</LastName>
                    <ForeName>Takashi</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Kato Ladies Clinic, 7-20-3 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kobayashi</LastName>
                    <ForeName>Tamotsu</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Kato Ladies Clinic, 7-20-3 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kato</LastName>
                    <ForeName>Osamu</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Kato Ladies Clinic, 7-20-3 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kato</LastName>
                    <ForeName>Keiichi</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Kato Ladies Clinic, 7-20-3 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan. Electronic address: k-kato@towako.net.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>05</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Poland</Country>
            <MedlineTA>Reprod Biol</MedlineTA>
            <NlmUniqueID>101160559</NlmUniqueID>
            <ISSNLinking>1642-431X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Angiogenesis</Keyword>
            <Keyword MajorTopicYN="N">Corpus luteum</Keyword>
            <Keyword MajorTopicYN="N">Cyclophosphamide</Keyword>
            <Keyword MajorTopicYN="N">Follicular growth</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>5</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1642-431X(14)00048-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.repbio.2014.04.007</ArticleId>
            <ArticleId IdType="pubmed">25152523</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152502</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-5169</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Peptides</Title>
                <ISOAbbreviation>Peptides</ISOAbbreviation>
            </Journal>
            <ArticleTitle>YY-39, a tick anti-thrombosis peptide containing RGD domain.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0196-9781(14)00251-4</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.peptides.2014.08.008</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Ticks are obligatory blood feeding ectoparasites, which continuously attach to their hosts for 1-2 weeks. There are many biologically active compounds in tick salivary glands interfering host haemostatic system and to successfully obtain blood meal. Several platelet aggregation inhibitors have been identified from ticks. A family of conserved peptides, which were identified from transcriptome analysis of many tick salivary glands, were found to contain unique primary structure including predicted mature peptides of 39-47 amino acid residues in length and a Pro/Glu(P/E)-Pro/His(P/H)- Lys-Gly-Asp(RGD) domain. Given their unique structure and RGD domain, they are considered a novel family of disintegrins that inhibit platelet aggregation. One of them (YY-39) was tested for its effects on platelets and thrombosis in vivo. YY-39 was found effectively to inhibit platelet aggregation induced by adenosine diphosphate (ADP), thrombin and thromboxane A2 (TXA2). Furthermore, YY-39 blocked platelet adhesion to soluble collagen and bound to purified GPIIb/IIIa in a dose-dependent manner. In in vivo experiments, YY-39 reduced thrombus weight effectively in a rat arteriovenous shunt model and inhibited thrombosis in a carrageenan-induced mouse tail thrombosis model. Combined with their prevalence in ticks and platelet inhibitory functions, this family of peptides might be conserved tick anti-haemostatic molecules.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Tang</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Life Sciences College of Nanjing Agricultural University, 1st Weigang, Nanjing, Jiangsu 210095, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fang</LastName>
                    <ForeName>Yaqun</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Life Sciences College of Nanjing Agricultural University, 1st Weigang, Nanjing, Jiangsu 210095, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Han</LastName>
                    <ForeName>Yajun</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Life Sciences College of Nanjing Agricultural University, 1st Weigang, Nanjing, Jiangsu 210095, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bai</LastName>
                    <ForeName>Xuewei</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Life Sciences College of Nanjing Agricultural University, 1st Weigang, Nanjing, Jiangsu 210095, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yan</LastName>
                    <ForeName>Xiuwen</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Life Sciences College of Nanjing Agricultural University, 1st Weigang, Nanjing, Jiangsu 210095, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Yun</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences &amp; Yunnan Province, Kunming Institute of Zoology, Kunming 650223, Yunnan, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lai</LastName>
                    <ForeName>Ren</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Life Sciences College of Nanjing Agricultural University, 1st Weigang, Nanjing, Jiangsu 210095, China; Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences &amp; Yunnan Province, Kunming Institute of Zoology, Kunming 650223, Yunnan, China. Electronic address: rlai@mail.kiz.ac.cn.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Zhiye</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences &amp; Yunnan Province, Kunming Institute of Zoology, Kunming 650223, Yunnan, China; University of Chinese Academy of Sciences, Beijing 100009, China. Electronic address: zhangzhiye5225@163.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Peptides</MedlineTA>
            <NlmUniqueID>8008690</NlmUniqueID>
            <ISSNLinking>0196-9781</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Anti-thrombosis</Keyword>
            <Keyword MajorTopicYN="N">Glycoprotein IIb/IIIa</Keyword>
            <Keyword MajorTopicYN="N">Platelet inhibitor</Keyword>
            <Keyword MajorTopicYN="N">Salivary gland</Keyword>
            <Keyword MajorTopicYN="N">Tick</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0196-9781(14)00251-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.peptides.2014.08.008</ArticleId>
            <ArticleId IdType="pubmed">25152502</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152468</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-6240</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Brain research</Title>
                <ISOAbbreviation>Brain Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The temporo-spatial localization of polymorphonuclear cells related to the neurovascular unit after transient focal cerebral ischemia.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0006-8993(14)01112-3</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.brainres.2014.08.037</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Inflammatory responses after cerebral ischemia are important for the development of final infarct size but the role of polymorphonuclear cells (PMN) is still a matter of debate, since previously used antibodies were recently declared as non-specific. In the present study, we investigated the temporo-spatial localization of PMN related to the neurovascular unit using specific antibodies, 7/4 and Ly6G, and applying of G-CSF to induce proliferation and mobilization of PMN precursors after transient focal cerebral ischemia in mice. Infarct volumes, sensorimotor function, neurological outcome and immunohistochemical analysis of PMN were performed after G-CSF administration or placebo treatment. G-CSF-treated mice showed reduced infarct size (51.15??15.68mm(2) vs. 39.31??16.13mm(2) at day 1; 50.11??16.68mm(2) vs. 33.16??4.86mm(2) at day 4; p&lt;0.05). They showed improved motor-function recovery and had a significantly better outcome compared to placebo treated animals. Comparison of the two PMN detecting antibodies showed no difference in saturation plots or cell quantification. Studying the basement membrane-associated localization revealed ca. 60% extravascular PMN, independent of G-CSF administration. Extravascular PMN were without any connection to laminin, but all near to the vessels. We conclude that 7/4 is a suitable marker to investigate PMN compared to Ly6G, which confirms results from former studies using the 7/4-antibody. Furthermore we report the observation that PMN were detected outside the laminin barrier but almost exclusively in close vicinity to the neurovascular unit.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ullrich</LastName>
                    <ForeName>Nora</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Dept. of Neurology, University Hospital M??nster.</Affiliation>
                </Author>
                <Author>
                    <LastName>Strecker</LastName>
                    <ForeName>Jan-Kolja</ForeName>
                    <Initials>JK</Initials>
                    <Affiliation>Dept. of Neurology, University Hospital M??nster.</Affiliation>
                </Author>
                <Author>
                    <LastName>Minnerup</LastName>
                    <ForeName>Jens</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Dept. of Neurology, University Hospital M??nster.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schilling</LastName>
                    <ForeName>Matthias</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Dept. of Neurology, University Hospital M??nster. Electronic address: matthias.schilling@ukmuenster.de.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Brain Res</MedlineTA>
            <NlmUniqueID>0045503</NlmUniqueID>
            <ISSNLinking>0006-8993</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Experimental stroke</Keyword>
            <Keyword MajorTopicYN="N">Granulocyte colony stimulating factor</Keyword>
            <Keyword MajorTopicYN="N">Neurovascular unit</Keyword>
            <Keyword MajorTopicYN="N">Polymorphonuclear cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0006-8993(14)01112-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.brainres.2014.08.037</ArticleId>
            <ArticleId IdType="pubmed">25152468</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152467</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-6240</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Brain research</Title>
                <ISOAbbreviation>Brain Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Preferential localization of type I phosphatidylinositol 4-phosphate 5-kinase ?? at the periactive zone of mouse photoreceptor ribbon synapses.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0006-8993(14)01126-3</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.brainres.2014.08.051</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Type I phosphatidylinositol 4-phosphate 5 kinase ?? (PIP5KI??) constitutes a major pathway for the generation of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) that regulates a variety of neuronal functions at both presynaptic and postsynaptic compartments. In this study, we examined the expression and localization of PIP5KI?? in the adult mouse retina. RT-PCR analysis revealed that PIP5KI??_v2 was predominantly expressed in the retina while PIP5KI??_v3 was also expressed faintly. Immunostaining of the adult mouse retina revealed intense PIP5KI??-immunoreactivity in the inner and outer plexiform layers in a punctate manner. In the photoreceptor ribbon synapse, PIP5KI?? was highly concentrated at the periactive zone. These findings suggest that PIP5KI??, especially PIP5KI??_i2, is localized at the periactive zone, a functionally suitable compartment for the endocytosis of synaptic vesicles in photoreceptor ribbon synapses.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sakagami</LastName>
                    <ForeName>Hiroyuki</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Anatomy, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan. Electronic address: sakagami@med.kitasato-u.ac.jp.</Affiliation>
                </Author>
                <Author>
                    <LastName>Katsumata</LastName>
                    <ForeName>Osamu</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Department of Anatomy, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hara</LastName>
                    <ForeName>Yoshinobu</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Anatomy, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tamaki</LastName>
                    <ForeName>Hideaki</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Anatomy, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fukaya</LastName>
                    <ForeName>Masahiro</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Anatomy, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Brain Res</MedlineTA>
            <NlmUniqueID>0045503</NlmUniqueID>
            <ISSNLinking>0006-8993</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Active zone</Keyword>
            <Keyword MajorTopicYN="N">Endocytosis</Keyword>
            <Keyword MajorTopicYN="N">Phosphoinositide</Keyword>
            <Keyword MajorTopicYN="N">Photoreceptor</Keyword>
            <Keyword MajorTopicYN="N">Retina</Keyword>
            <Keyword MajorTopicYN="N">Ribbon synapse</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0006-8993(14)01126-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.brainres.2014.08.051</ArticleId>
            <ArticleId IdType="pubmed">25152467</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152461</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-6240</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Brain research</Title>
                <ISOAbbreviation>Brain Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>MicroRNA-135a and -200b, potential Biomarkers for Alzheimer's disease, regulate ?? secretase and amyloid precursor protein.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0006-8993(14)00543-5</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.brainres.2014.04.026</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Amyloid precursor protein (APP) and ??-site amyloid precursor protein cleaving enzyme (BACE-1) play important roles in the generation of Alzheimer's disease (AD), a progressive neurodegenerative disorder. In the present study, microRNA (miR) microarray was used to analyze the miR expression profiles in the hippocampi from APP/PS1 transgenic and wild type mice. The miRs with significant alteration and putative targets on APP or BACE-1 were retrieved (miR-135a, -200b and -429). The deregulations of these miRs were confirmed in mice and further verified in AD patient samples by qPCR. Primary mouse hippocampal neurons, SH-SY5Y and HEK293 cells were used to study the function of miRs on APP and BACE-1. We found that miR-135a, which was downregulated significantly in hippocampi from APP/PS1 transgenic mice compared with the wild type control, directly interacted with the 3'-UTR of BACE-1 and repressed its expression and activity. On the other hand, miR-200b and -429, which were downregulated significantly in hippocampi from APP/PS1 transgenic mice compared with the wild type control, targeted the 3'-UTR of APP and repressed its expression. Furthermore, A??42 could downregulate miR-200b expression which may generate a vicious cycle resulted in accumulating A??42. The levels of miR-135a and -200b in the serum of DAT group were significantly lower than that of control groups (P&lt;0.05). The serum miR-200b level of MCI group was higher than that of DAT group (P&lt;0.05) and lower than that of control group (P&lt;0.05). We also found decreased miR-135a and -200b levels in the cerebrospinal fluid of DAT group compared with the control group (P&lt;0.05). In conclusion, these findings showed that miR-135a, -200b and -429 may take part in the progress of AD; miR-200b was of great potential as noninvasive and easily detected blood-based biomarkers of MCI and DAT patients.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Chen-Geng</ForeName>
                    <Initials>CG</Initials>
                    <Affiliation>Department of Clinical Laboratory, Xuanwu Hospital, Capital Medical University, , No.45 Changchun Road, Beijing, 100053, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Jin-Ling</ForeName>
                    <Initials>JL</Initials>
                    <Affiliation>Department of Clinical Laboratory, Xuanwu Hospital, Capital Medical University, , No.45 Changchun Road, Beijing, 100053, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Clinical Laboratory, Xuanwu Hospital, Capital Medical University, , No.45 Changchun Road, Beijing, 100053, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xue</LastName>
                    <ForeName>Li-Xiang</ForeName>
                    <Initials>LX</Initials>
                    <Affiliation>Department of Biochemistry and Molecular Biology, Health Science Center, Peking University, Beijing, 100191, People's Republic of China. Electronic address: lixiangxue@hsc.pku.edu.cn.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Yue-Qi</ForeName>
                    <Initials>YQ</Initials>
                    <Affiliation>Department of Clinical Laboratory, Xuanwu Hospital, Capital Medical University, , No.45 Changchun Road, Beijing, 100053, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Pei-Chang</ForeName>
                    <Initials>PC</Initials>
                    <Affiliation>Department of Clinical Laboratory, Xuanwu Hospital, Capital Medical University, , No.45 Changchun Road, Beijing, 100053, People's Republic of China. Electronic address: peichangwang@yahoo.com.cn.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Brain Res</MedlineTA>
            <NlmUniqueID>0045503</NlmUniqueID>
            <ISSNLinking>0006-8993</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alzheimer's disease</Keyword>
            <Keyword MajorTopicYN="N">Amyloid precursor protein</Keyword>
            <Keyword MajorTopicYN="N">microRNA</Keyword>
            <Keyword MajorTopicYN="N">?? secretase</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0006-8993(14)00543-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.brainres.2014.04.026</ArticleId>
            <ArticleId IdType="pubmed">25152461</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152455</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-6605</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of human genetics</Title>
                <ISOAbbreviation>Am. J. Hum. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A Mutation of COX6A1 Causes a Recessive Axonal or Mixed Form of Charcot-Marie-Tooth Disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0002-9297(14)00322-X</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.ajhg.2014.07.013</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Charcot-Marie-Tooth disease (CMT) is the most common inherited neuropathy characterized by clinical and genetic heterogeneity. Although more than 30 loci harboring CMT-causing mutations have been identified, many other genes still remain to be discovered for many affected individuals. For two consanguineous families with CMT (axonal and mixed phenotypes), a parametric linkage analysis using genome-wide SNP chip identified a 4.3 Mb region on 12q24 showing a maximum multipoint LOD score of 4.23. Subsequent whole-genome sequencing study in one of the probands, followed by mutation screening in the two families, revealed a disease-specific 5??bp deletion (c.247-10_247-6delCACTC) in a splicing element (pyrimidine tract) of intron 2 adjacent to the third exon of cytochrome c oxidase subunit VIa polypeptide 1 (COX6A1), which is a component of mitochondrial respiratory complex IV (cytochrome c oxidase [COX]), within the autozygous linkage region. Functional analysis showed that expression of COX6A1 in peripheral white blood cells from the affected individuals and COX activity in their EB-virus-transformed lymphoblastoid cell lines were significantly reduced. In addition, Cox6a1-null mice showed significantly reduced COX activity and neurogenic muscular atrophy leading to a difficulty in walking. Those data indicated that COX6A1 mutation causes the autosomal-recessive axonal or mixed??CMT.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Tamiya</LastName>
                    <ForeName>Gen</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Advanced Molecular Epidemiology Research Institute, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan. Electronic address: gtamiya@genetix-h.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Makino</LastName>
                    <ForeName>Satoshi</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Advanced Molecular Epidemiology Research Institute, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hayashi</LastName>
                    <ForeName>Makiko</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Pediatrics, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Abe</LastName>
                    <ForeName>Akiko</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Pediatrics, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Numakura</LastName>
                    <ForeName>Chikahiko</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pediatrics, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ueki</LastName>
                    <ForeName>Masao</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Advanced Molecular Epidemiology Research Institute, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tanaka</LastName>
                    <ForeName>Atsushi</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Research Institute of Medical Sciences, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ito</LastName>
                    <ForeName>Chizuru</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Reproductive Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Toshimori</LastName>
                    <ForeName>Kiyotaka</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Reproductive Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ogawa</LastName>
                    <ForeName>Nobuhiro</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Medicine, Shiga University of Medical Science, Otsu 520-2192, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Terashima</LastName>
                    <ForeName>Tomoya</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Medicine, Shiga University of Medical Science, Otsu 520-2192, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Maegawa</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Medicine, Shiga University of Medical Science, Otsu 520-2192, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yanagisawa</LastName>
                    <ForeName>Daijiro</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Molecular Neuroscience Research Center, Shiga University of Medical Science, Otsu 520-2192, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tooyama</LastName>
                    <ForeName>Ikuo</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Molecular Neuroscience Research Center, Shiga University of Medical Science, Otsu 520-2192, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tada</LastName>
                    <ForeName>Masayoshi</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Molecular Neuroscience, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Onodera</LastName>
                    <ForeName>Osamu</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Department of Molecular Neuroscience, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hayasaka</LastName>
                    <ForeName>Kiyoshi</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Pediatrics, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan. Electronic address: hayasaka@med.id.yamagata-u.ac.jp.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Hum Genet</MedlineTA>
            <NlmUniqueID>0370475</NlmUniqueID>
            <ISSNLinking>0002-9297</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0002-9297(14)00322-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ajhg.2014.07.013</ArticleId>
            <ArticleId IdType="pubmed">25152455</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152448</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7492</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Virus research</Title>
                <ISOAbbreviation>Virus Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0168-1702(14)00336-0</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.virusres.2014.08.008</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Traditional vaccine strategies that induce antibody responses have failed to protect against HIV infection in clinical trials, and thus cell-mediated immunity is now an additional criterion. Recent clinical trials that aimed to induce strong T cell responses failed to do so. Therefore, to enhance induction of protective T cell responses, it is crucial that the optimum antigen combination is chosen. Limited research has been performed into the number of antigens selected for an HIV vaccine. This study aimed to compare DNA vaccines encoding either a single HIV antigen or a combination of two antigens, using intradermal vaccination of C57BL/6 mice. Immune assays were performed on splenocytes, and in vivo protection was examined by challenge with a chimeric virus, EcoHIV, able to infect mouse but not human leukocytes, at 10 days (short term) and 60 days (long term) post final vaccination. At 60 days there was significantly lower frequency of induced antigen-specific CD8(+) T cells in the spleens of pCMVgag-pol-vaccinated mice compared with mice which received pCMVgag only. Most importantly, short term viral control of EcoHIV was similar for pCMVgag and pCMVgag-pol-vaccinated mice at day 10, but only the pCMVgag-vaccinated significantly controlled EcoHIV at day 60 compared with pCMV-vaccinated mice, showing that control was reduced with the inclusion of the HIV pol gene.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Garrod</LastName>
                    <ForeName>Tamsin J</ForeName>
                    <Initials>TJ</Initials>
                    <Affiliation>Virology Laboratory, Basil Hetzel Institute, Department of Surgery, University of Adelaide, Adelaide, Australia. Electronic address: tamsin.garrod@adelaide.edu.au.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gargett</LastName>
                    <ForeName>Tessa</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Virology Laboratory, Basil Hetzel Institute, Department of Surgery, University of Adelaide, Adelaide, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yu</LastName>
                    <ForeName>Wenbo</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Virology Laboratory, Basil Hetzel Institute, Department of Surgery, University of Adelaide, Adelaide, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Major</LastName>
                    <ForeName>Lee</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Inflammation Biology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Burrell</LastName>
                    <ForeName>Christopher J</ForeName>
                    <Initials>CJ</Initials>
                    <Affiliation>School of Molecular Biosciences, University of Adelaide, Adelaide, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wesselingh</LastName>
                    <ForeName>Steven</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>South Australian Health and Medical Research Institute, Adelaide, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Suhrbier</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Inflammation Biology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Grubor-Bauk</LastName>
                    <ForeName>Branka</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Virology Laboratory, Basil Hetzel Institute, Department of Surgery, University of Adelaide, Adelaide, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gowans</LastName>
                    <ForeName>Eric J</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>Virology Laboratory, Basil Hetzel Institute, Department of Surgery, University of Adelaide, Adelaide, Australia.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Virus Res</MedlineTA>
            <NlmUniqueID>8410979</NlmUniqueID>
            <ISSNLinking>0168-1702</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">DNA vaccine</Keyword>
            <Keyword MajorTopicYN="N">EcoHIV challenge.</Keyword>
            <Keyword MajorTopicYN="N">HIV</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0168-1702(14)00336-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.virusres.2014.08.008</ArticleId>
            <ArticleId IdType="pubmed">25152448</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152440</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2422</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Experimental cell research</Title>
                <ISOAbbreviation>Exp. Cell Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mitf regulates osteoclastogenesis by modulating NFATc1 activity.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0014-4827(14)00346-2</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.yexcr.2014.08.018</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Transcription factors Mitf and NFATc1 share many downstream targets that are critical for osteoclastogenesis. Since RANKL signals induce/activate both NFATc1 and Mitf isoform-E (Mitf-E), a tissue-restricted Mitf isoform in osteoclasts, it is plausible that the two factors work together to promote osteoclastogenesis. Although Mitf was shown to function upstream of NFATc1 previously, this study showed that expression of Mitf had little effects on NFATc1 and NFATc1 was critical for the induction of Mitf-E. In Mitf(mi/mi) mice, the semi-dominant mutation in Mitf gene leads to arrest of osteoclastogenesis in the early stages. However, when stimulated by RANKL, the Mitf(mi/mi) preosteoclasts responded with a significant induction of NFATc1, despite that the cells cannot differentiate into functional osteoclasts. In the absence of RANKL stimulation, very high levels of NFATc1 are required to drive osteoclast development. Our data indicate that Mitf functions downstream of NFATc1 in the RANKL pathway, and it plays an important role in amplifying NFATc1-dependent osteoclastogenic signals, which contributes to the significant synergy between the two factors during osteoclastogenesis. We propose that Mitf-E functions as a tissue-specific modulator for events downstream of NFATc1 activation during osteoclastogenesis.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lu</LastName>
                    <ForeName>Ssu-Yi</ForeName>
                    <Initials>SY</Initials>
                    <Affiliation>Department of Diagnostic and Surgical Sciences, School of Dentistry, University of California, Los Angeles, CA, USA. Electronic address: ssuyilu@yahoo.com.tw.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Mengtao</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Diagnostic and Surgical Sciences, School of Dentistry, University of California, Los Angeles, CA, USA; CHS 23-087, 10833 Le Conte Ave., Los Angeles, CA 90095, USA. Electronic address: mli@dentistry.ucla.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lin</LastName>
                    <ForeName>Yi-Ling</ForeName>
                    <Initials>YL</Initials>
                    <Affiliation>Department of Diagnostic and Surgical Sciences, School of Dentistry, University of California, Los Angeles, CA, USA; Gene regulation program, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA. Electronic address: ylin@dentistry.ucla.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Exp Cell Res</MedlineTA>
            <NlmUniqueID>0373226</NlmUniqueID>
            <ISSNLinking>0014-4827</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Fusion</Keyword>
            <Keyword MajorTopicYN="N">Mitf</Keyword>
            <Keyword MajorTopicYN="N">NFATc1</Keyword>
            <Keyword MajorTopicYN="N">Osteoclasts</Keyword>
            <Keyword MajorTopicYN="N">RANKL</Keyword>
            <Keyword MajorTopicYN="N">Transcription factors</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0014-4827(14)00346-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.yexcr.2014.08.018</ArticleId>
            <ArticleId IdType="pubmed">25152440</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152439</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2422</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Experimental cell research</Title>
                <ISOAbbreviation>Exp. Cell Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pioglitazone inhibits angiotensin II-induced atrial Fibroblasts proliferation via NF-??B/TGF-??1/TRIF/TRAF6 pathway.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0014-4827(14)00359-0</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.yexcr.2014.08.021</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The exact mechanisms underlying inhibitory effects of pioglitazone (Pio) on Angiotensin II (AngII)-induced atrial fibrosis are complex and remain largely unknown. In the present study, we examined the effect of Pio on AngII-induced mice atrial fibrosis in vivo and atrial fibroblasts proliferation in vitro. In vivo study showed that AngII infusion induced atrial fibrosis and increased expressions of Toll/IL-1 receptor domain-containing adaptor inducing IFN-?? (TRIF) and tumor necrosis factor receptor associated factor 6 (TRAF6) in mice models. However, those effects could be attenuated by Pio (P&lt;0.01). As for in vitro experiment, Pio suppressed AngII-induced atrial fibroblasts proliferation via nuclear factor-??B/transforming growth factor-??1/TRIF/TRAF6 signaling pathway in primary cultured mice atrial fibroblasts (P&lt;0.01). In conclusion, suppression of Pio on AngII-induced atrial fibrosis might be related with its inhibitory effects on above signaling pathway.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Xiao-Qing</ForeName>
                    <Initials>XQ</Initials>
                    <Affiliation>Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Xu</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, People's Republic of China. Electronic address: liuxu_xk@163.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Quan-Xing</ForeName>
                    <Initials>QX</Initials>
                    <Affiliation>National Key Laboratory of Medical Immunology, Second Military Medical University, Shanghai, People's Republic of China. Electronic address: wqxejd@126.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Ming-Jian</ForeName>
                    <Initials>MJ</Initials>
                    <Affiliation>National Key Laboratory of Medical Immunology, Second Military Medical University, Shanghai, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Guo</LastName>
                    <ForeName>Meng</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>National Key Laboratory of Medical Immunology, Second Military Medical University, Shanghai, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Fang</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>National Key Laboratory of Medical Immunology, Second Military Medical University, Shanghai, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jiang</LastName>
                    <ForeName>Wei-Feng</ForeName>
                    <Initials>WF</Initials>
                    <Affiliation>Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, People's Republic of China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Exp Cell Res</MedlineTA>
            <NlmUniqueID>0373226</NlmUniqueID>
            <ISSNLinking>0014-4827</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Angiotensin II</Keyword>
            <Keyword MajorTopicYN="N">Atrial fibrosis</Keyword>
            <Keyword MajorTopicYN="N">Pioglitazone</Keyword>
            <Keyword MajorTopicYN="N">Signaling pathway</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0014-4827(14)00359-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.yexcr.2014.08.021</ArticleId>
            <ArticleId IdType="pubmed">25152439</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152402</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2104</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemical and biophysical research communications</Title>
                <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Expression of cGMP-dependent protein kinase type I in mature white adipocytes.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0006-291X(14)01494-6</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbrc.2014.08.071</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The presence of cGMP-dependent protein kinase I (cGKI) in murine adipocytes has been questioned, although cGKI was implicated in the thermogenic program of fat cells (FCs) and to exert anti-hypertrophic/-inflammatory effects in white adipose tissue. Herein, cGKI was detected in adipocytes from control mice, whereas FCs from global cGKI knockouts (cGKI(-/-)) and cGKI?? rescue (??RM) mice remained cGKI-negative. cGKI mutants exhibit decreased adipocyte size, plasma leptin levels and reduced body-weights as compared to litter-matched controls. Low abundance of adiponectin in WAT and plasma of ??RM animals together with previously confirmed high IL-6 levels indicate a low-grade inflammation. However, ??RMs were protected from streptozotocin-induced hyperglycemia. Our results suggest that cGMP/cGKI affects both glucose and FC homeostasis in more complex mode than previously thought.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Leiss</LastName>
                    <ForeName>Veronika</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital Tuebingen, Tuebingen, Germany; FOR 923, Institute of Pharmacology and Toxicology, Technical University Munich, Muenchen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Illison</LastName>
                    <ForeName>Julia</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tuebingen, Tuebingen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Domes</LastName>
                    <ForeName>Katrin</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>FOR 923, Institute of Pharmacology and Toxicology, Technical University Munich, Muenchen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hofmann</LastName>
                    <ForeName>Franz</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>FOR 923, Institute of Pharmacology and Toxicology, Technical University Munich, Muenchen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lukowski</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tuebingen, Tuebingen, Germany. Electronic address: robert.lukowski@uni-tuebingen.de.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
            <NlmUniqueID>0372516</NlmUniqueID>
            <ISSNLinking>0006-291X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Adiponectin</Keyword>
            <Keyword MajorTopicYN="N">Browning</Keyword>
            <Keyword MajorTopicYN="N">Interleukin-6</Keyword>
            <Keyword MajorTopicYN="N">Natriuretic peptides</Keyword>
            <Keyword MajorTopicYN="N">PKG</Keyword>
            <Keyword MajorTopicYN="N">cGMP</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0006-291X(14)01494-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbrc.2014.08.071</ArticleId>
            <ArticleId IdType="pubmed">25152402</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152401</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2104</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemical and biophysical research communications</Title>
                <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Reductive detoxification of acrolein as a potential role for aldehyde reductase (AKR1A) in mammals.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0006-291X(14)01495-8</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbrc.2014.08.072</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Aldehyde reductase (AKR1A), a member of the aldo-keto reductase superfamily, suppresses diabetic complications via a reduction in metabolic intermediates; it also plays a role in ascorbic acid biosynthesis in mice. Because primates cannot synthesize ascorbic acid, a principle role of AKR1A appears to be the reductive detoxification of aldehydes. In this study, we isolated and immortalized mouse embryonic fibroblasts (MEFs) from wild-type (WT) and human Akr1a-transgenic (Tg) mice and used them to investigate the potential roles of AKR1A under culture conditions. Tg MEFs showed higher methylglyoxal- and acrolein-reducing activities than WT MEFs and also were more resistant to cytotoxicity. Enzymatic analyses of purified rat AKR1A showed that the efficiency of the acrolein reduction was about 20% that of glyceraldehyde. Ascorbic acid levels were quite low in the MEFs, and while the administration of ascorbic acid to the cells increased the intracellular levels of ascorbic acid, it had no affect on the resistance to acrolein. Endoplasmic reticulum stress and protein carbonylation induced by acrolein treatment were less evident in Tg MEFs than in WT MEFs. These data collectively indicate that one of the principle roles of AKR1A in primates is the reductive detoxification of aldehydes, notably acrolein, and protection from its detrimental effects.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kurahashi</LastName>
                    <ForeName>Toshihiro</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Biochemistry and Molecular Biology, Yamagata University School of Medicine, Yamagata, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kwon</LastName>
                    <ForeName>Myoungsu</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Biochemistry and Molecular Biology, Yamagata University School of Medicine, Yamagata, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Homma</LastName>
                    <ForeName>Takujiro</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Biochemistry and Molecular Biology, Yamagata University School of Medicine, Yamagata, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Saito</LastName>
                    <ForeName>Yuka</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Biochemistry and Molecular Biology, Yamagata University School of Medicine, Yamagata, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Jaeyong</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Biochemistry and Molecular Biology, Yamagata University School of Medicine, Yamagata, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Takahashi</LastName>
                    <ForeName>Motoko</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yamada</LastName>
                    <ForeName>Ken-Ichi</ForeName>
                    <Initials>KI</Initials>
                    <Affiliation>Department of Bio-functional Science, Faculty of Pharmacological Science, Kyushu University, Fukuoka, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Miyata</LastName>
                    <ForeName>Satoshi</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Internal Medicine, Osaka Hospital, Japan Community Health care Organization, Osaka, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fujii</LastName>
                    <ForeName>Junichi</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Biochemistry and Molecular Biology, Yamagata University School of Medicine, Yamagata, Japan. Electronic address: jfujii@med.id.yamagata-u.ac.jp.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
            <NlmUniqueID>0372516</NlmUniqueID>
            <ISSNLinking>0006-291X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Acrolein</Keyword>
            <Keyword MajorTopicYN="N">Aldehyde reductase</Keyword>
            <Keyword MajorTopicYN="N">Ascorbic acid</Keyword>
            <Keyword MajorTopicYN="N">Detoxification</Keyword>
            <Keyword MajorTopicYN="N">Mouse embryonic fibroblast</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0006-291X(14)01495-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbrc.2014.08.072</ArticleId>
            <ArticleId IdType="pubmed">25152401</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152396</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2104</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemical and biophysical research communications</Title>
                <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>MSC attenuate diabetes-induced functional impairment in adipocytes via secretion of insulin-like growth factor-1.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0006-291X(14)01483-1</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbrc.2014.08.060</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The function of subcutaneous adipocytes in promoting wound healing is significantly suppressed in diabetic wounds. Recent studies have demonstrated the ability of mesenchymal stem cell (MSC) to ameliorate impaired diabetic wound healing. We hypothesized that MSC function may involve subcutaneous adipocytes. The abnormal function of subcutaneous adipocytes from STZ induced diabetic mice including glucose uptake and free fatty acid (FFA) secretion level were assessed. Then these cells were co-cultured with MSC via a transwell system to observe the changes of metabolic index and glucose transporter four (GLUT4) as well as phosphoinositide 3-kinase/ protein kinase (PI3K/AKT) signaling pathway expression. The results of metabolic index suggest that MSC obviously attenuated the diabetes-induced functional impairment. Both mRNA and protein expression analyses showed that PI3K/AKT insulin signaling pathway and GLUT4 expression were up-regulated. These changes were substantially associated with a increased level of insulin-like growth factor-1(IGF-1) secretion from MSC. These findings suggest that MSC could attenuate abnormal function of diabetic adipocytes by IGF-1secretion, which was more or less associated with the beneficial effects of MSC on improving diabetic wound healing.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Gao</LastName>
                    <ForeName>Dongyun</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Key laboratory of wound repair and regeneration of PLA, The First Affiliated Hospital, General Hospital of PLA, Beijing, 100048, P. R China; Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P. R. China; Department of Oncology, Dongtai People's Hospital, Dongtai, 224200, P. R. China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xie</LastName>
                    <ForeName>Jiangfan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P. R. China; Graduate School of Tianjin Medical University, Tianjin, 300052, P.R. China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Junhua</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P. R. China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Feng</LastName>
                    <ForeName>Changjiang</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Key laboratory of wound repair and regeneration of PLA, The First Affiliated Hospital, General Hospital of PLA, Beijing, 100048, P. R China; Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P. R. China; Department of Thoracic and Cardiovascular Surgery, Peking University People's Hospital, Peking University, Beijing, 100044, P. R. China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yao</LastName>
                    <ForeName>Bin</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P. R. China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ma</LastName>
                    <ForeName>Kui</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P. R. China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Jiwei</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Key laboratory of wound repair and regeneration of PLA, The First Affiliated Hospital, General Hospital of PLA, Beijing, 100048, P. R China; Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P. R. China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Xu</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P. R. China. Electronic address: 13926402695@126.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Sha</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Key laboratory of wound repair and regeneration of PLA, The First Affiliated Hospital, General Hospital of PLA, Beijing, 100048, P. R China; Wound Healing and Cell Biology Laboratory, Institute of Basic Medical Sciences, General Hospital of PLA, Beijing, 100853, P. R. China; Hainan Branch of the Chinese PLA General Hospital, Sanya, Hainan Province 572014, P.R. China. Electronic address: stellarahuang@sina.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fu</LastName>
                    <ForeName>Xiaobing</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Key laboratory of wound repair and regeneration of PLA, The First Affiliated Hospital, General Hospital of PLA, Beijing, 100048, P. R China; Wound Healing and Cell Biology Laboratory, Institute of Basic Medical Sciences, General Hospital of PLA, Beijing, 100853, P. R. China. Electronic address: fuxiaobing@vip.sina.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
            <NlmUniqueID>0372516</NlmUniqueID>
            <ISSNLinking>0006-291X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Adipocytes</Keyword>
            <Keyword MajorTopicYN="N">Conditioned medium (CM)</Keyword>
            <Keyword MajorTopicYN="N">IGF-1</Keyword>
            <Keyword MajorTopicYN="N">MSC</Keyword>
            <Keyword MajorTopicYN="N">Wound</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0006-291X(14)01483-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbrc.2014.08.060</ArticleId>
            <ArticleId IdType="pubmed">25152396</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152393</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2104</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemical and biophysical research communications</Title>
                <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Somatodendritic and excitatory postsynaptic distribution of neuron-type dystrophin isoform, Dp40, in hippocampal neurons.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0006-291X(14)01487-9</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbrc.2014.08.064</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The Duchenne muscular dystrophy (DMD) gene produces multiple dystrophin (Dp) products due to the presence of several promoters. We previously reported the existence of a novel short isoform of Dp, Dp40, in adult mouse brain. However, the exact biochemical expression profile and cytological distribution of the Dp40 protein remain unknown. In this study, we generated a polyclonal antibody against the NH2-terminal region of the Dp40 and identified the expression profile of Dp40 in the mouse brain. Through an analysis using embryonic and postnatal mouse cerebrums, we found that Dp40 emerged from the early neonatal stages until adulthood, whereas Dp71, an another Dp short isoform, was highly detected in both prenatal and postnatal cerebrums. Intriguingly, relative expressions of Dp40 and Dp71 were prominent in cultured dissociated neurons and non-neuronal cells derived from mouse hippocampus, respectively. Furthermore, the immunocytological distribution of Dp40 was analyzed in dissociated cultured neurons, revealing that Dp40 is detected in the soma and its dendrites, but not in the axon. It is worthy to note that Dp40 is localized along the subplasmalemmal region of the dendritic shafts, as well as at excitatory postsynaptic sites. Thus, Dp40 was identified as a neuron-type Dp possibly involving dendritic and synaptic functions.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Fujimoto</LastName>
                    <ForeName>Takahiro</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Pathology and Applied Neurobiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Itoh</LastName>
                    <ForeName>Kyoko</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Pathology and Applied Neurobiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. Electronic address: kxi14@koto.kpu-m.ac.jp.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yaoi</LastName>
                    <ForeName>Takeshi</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Pathology and Applied Neurobiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fushiki</LastName>
                    <ForeName>Shinji</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Pathology and Applied Neurobiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
            <NlmUniqueID>0372516</NlmUniqueID>
            <ISSNLinking>0006-291X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Dendrite</Keyword>
            <Keyword MajorTopicYN="N">Dp40</Keyword>
            <Keyword MajorTopicYN="N">Dystrophin</Keyword>
            <Keyword MajorTopicYN="N">Hippocampal neuron</Keyword>
            <Keyword MajorTopicYN="N">Immunocytochemistry</Keyword>
            <Keyword MajorTopicYN="N">Synapse</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0006-291X(14)01487-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbrc.2014.08.064</ArticleId>
            <ArticleId IdType="pubmed">25152393</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152388</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-6815</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Experimental gerontology</Title>
                <ISOAbbreviation>Exp. Gerontol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Growth Hormone Abolishes Beneficial Effects of Calorie Restriction in Long-Lived Ames Dwarf Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0531-5565(14)00246-0</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.exger.2014.08.010</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Disruption of the growth hormone (GH) axis promotes longevity and delays aging. In contrast, GH over-expression may lead to accelerated aging and shorter life. Calorie restriction (CR) improves insulin sensitivity and may extend lifespan. Long-lived Ames dwarf (df/df) mice have additional extension of longevity when subjected to 30% CR. The aim of the study was to assess effects of CR or GH replacement therapy separately and as a combined (CR+GH) treatment in GH-deficient df/df and normal mice, on selected metabolic parameters (e.g., insulin, glucose, cholesterol), insulin signaling components (e.g., insulin receptor [IR] ??-subunit, phosphorylated form of IR [IR pY1158], protein kinase C ??/?? [p-PKC??/??] and mTOR [p-mTOR]), transcription factor p-CREB, and components of the mitogen-activated protein kinases (MAPK) signaling (p-ERK1/2, p-p38), responsible for cell proliferation, differentiation and survival. CR decreased plasma levels of insulin, glucose, cholesterol and leptin, and increased hepatic IR ??-subunit and IR pY1158 levels as well as IR, IRS-1 and GLUT-2 gene expression compared to ad libitum feeding, showing a significant beneficial diet intervention effect. Moreover, hepatic protein levels of p-PKC??/??, p-mTOR and p-p38 decreased, and p-CREB increased in CR mice. On the contrary, GH increased levels of glucose, cholesterol and leptin in plasma, and p-mTOR or p-p38 in livers, and decreased plasma adiponectin and hepatic IR ??-subunit compared to saline treatment. There were no GH effects on adiponectin in N mice. Moreover, GH replacement therapy did not affect IR, IRS-1 and GLUT-2 gene expression. GH treatment abolishes the beneficial effects of CR; it may suggest an important role of GH-IGF1 axis in mediating the CR action. Suppressed somatotrophic signaling seems to predominate over GH replacement therapy in the context of the examined parameters and signaling pathways.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Gesing</LastName>
                    <ForeName>Adam</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Internal Medicine, Geriatrics Research, Southern Illinois University School of Medicine, 801 N Rutledge St., Room 4389, Springfield, IL, 62794, USA; Department of Oncological Endocrinology, Medical University of Lodz, Zeligowski St., No 7/9, 90-752 Lodz, Poland. Electronic address: adges7@wp.pl.</Affiliation>
                </Author>
                <Author>
                    <LastName>Al-Regaiey</LastName>
                    <ForeName>Khalid A</ForeName>
                    <Initials>KA</Initials>
                    <Affiliation>Department of Internal Medicine, Geriatrics Research, Southern Illinois University School of Medicine, 801 N Rutledge St., Room 4389, Springfield, IL, 62794, USA; Department of Physiology, College of Medicine, King Saud University, PO Box 2925, Riyadh 11461, Saudi Arabia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bartke</LastName>
                    <ForeName>Andrzej</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Internal Medicine, Geriatrics Research, Southern Illinois University School of Medicine, 801 N Rutledge St., Room 4389, Springfield, IL, 62794, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Masternak</LastName>
                    <ForeName>Michal M</ForeName>
                    <Initials>MM</Initials>
                    <Affiliation>College of Medicine, Burnett School of Biomedical Sciences, University of Central Florida, 6900 Lake Nona Blvd., Orlando, FL, 32827, USA. Electronic address: michal.masternak@ucf.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Exp Gerontol</MedlineTA>
            <NlmUniqueID>0047061</NlmUniqueID>
            <ISSNLinking>0531-5565</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Ames dwarf mice</Keyword>
            <Keyword MajorTopicYN="N">Growth hormone</Keyword>
            <Keyword MajorTopicYN="N">MAPK signaling</Keyword>
            <Keyword MajorTopicYN="N">calorie restriction</Keyword>
            <Keyword MajorTopicYN="N">metabolism</Keyword>
            <Keyword MajorTopicYN="N">transcription factors</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0531-5565(14)00246-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.exger.2014.08.010</ArticleId>
            <ArticleId IdType="pubmed">25152388</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25152362</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1096-0007</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>126</Volume>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Experimental eye research</Title>
                <ISOAbbreviation>Exp. Eye Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Approaches for detecting lysosomal alkalinization and impaired degradation in fresh and cultured RPE cells: Evidence for a role in retinal degenerations.</ArticleTitle>
            <Pagination>
                <MedlinePgn>68-76</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.exer.2014.05.013</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0014-4835(14)00134-1</ELocationID>
            <Abstract>
                <AbstractText>Lysosomes contribute to a multitude of cellular processes, and the pH of the lysosomal lumen plays a central mechanistic role in many of these functions. In addition to controlling the rate of enzymatic degradation for material delivered through autophagic or phagocytotic pathways, lysosomal pH regulates events such as lysosomal fusion with autophagosomes and the release of lysosomal calcium into the cytoplasm. Disruption of either the steady state lysosomal pH or of the regulated manipulations to lysosomal pH may be pathological. For example, chloroquine elevates the lysosomal pH of retinal pigmented epithelial (RPE) cells and triggers a retinopathy characterized by the accumulation of lipofuscin-like material in both humans and animals. Compensatory responses to restore lysosomal pH are observed; new data illustrate that chronic chloroquine treatment increases mRNA expression of the lysosomal/autophagy master transcription factor TcFEB and of the vesicular proton pump vHATPase in the RPE/choroid of mice. An elevated lysosomal pH with upregulation of TcFEB and vHATPase resembles the pathology in fibroblasts of patients with mutant presenilin 1 (PS1), suggesting a common link between age-related macular degeneration (AMD) and Alzheimer's disease. While the absolute rise in pH is often small in these disorders, elevations of only a few tenths of a pH unit can have a major impact on both lysosomal function and the accumulation of waste over decades. Accurate measurement of lysosomal pH can be complex, and imprecise measurements have clouded the field. Protocols to optimize pH measurement from fresh and cultured cells are discussed, and indirect measurements to confirm changes in lysosomal pH and degradative capacity are addressed. The ability of reacidifying treatments to restore degradative function confirms the central role of lysosomal pH in these disorders and identifies potential approaches to treat diseases of lysosomal accumulation like AMD and Alzheimer's disease. In summary, various approaches to determine lysosomal pH in fresh and cultured cells, as well as the potential to restore pH levels to an optimal range, can help identify and repair pathologies associated with lysosomal defects in RPE cells and perhaps also suggest new approaches to treat lysosomal storage diseases throughout the body.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Guha</LastName>
                    <ForeName>Sonia</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Departments of Anatomy and Cell Biology, University of Pennsylvania, Philadelphia, PA, USA; Department of Ophthalmology, University of California at Los Angeles, Los Angeles, CA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Coffey</LastName>
                    <ForeName>Erin E</ForeName>
                    <Initials>EE</Initials>
                    <Affiliation>Departments of Anatomy and Cell Biology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Wennan</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Departments of Anatomy and Cell Biology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lim</LastName>
                    <ForeName>Jason C</ForeName>
                    <Initials>JC</Initials>
                    <Affiliation>Departments of Anatomy and Cell Biology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beckel</LastName>
                    <ForeName>Jonathan M</ForeName>
                    <Initials>JM</Initials>
                    <Affiliation>Departments of Anatomy and Cell Biology, University of Pennsylvania, Philadelphia, PA, USA; Department of Anesthesiology, University of Pittsburgh, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Laties</LastName>
                    <ForeName>Alan M</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>Departments of Ophthalmology University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boesze-Battaglia</LastName>
                    <ForeName>Kathleen</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Departments of Biochemistry, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mitchell</LastName>
                    <ForeName>Claire H</ForeName>
                    <Initials>CH</Initials>
                    <Affiliation>Departments of Anatomy and Cell Biology, University of Pennsylvania, Philadelphia, PA, USA; Departments of Physiology, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: chm@exchange.upenn.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Exp Eye Res</MedlineTA>
            <NlmUniqueID>0370707</NlmUniqueID>
            <ISSNLinking>0014-4835</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alzheimer's disease</Keyword>
            <Keyword MajorTopicYN="N">aging</Keyword>
            <Keyword MajorTopicYN="N">autophagy</Keyword>
            <Keyword MajorTopicYN="N">cathepsin D</Keyword>
            <Keyword MajorTopicYN="N">lipofuscin</Keyword>
            <Keyword MajorTopicYN="N">lysosome</Keyword>
            <Keyword MajorTopicYN="N">retinal pigmented epithelium</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0014-4835(14)00134-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.exer.2014.05.013</ArticleId>
            <ArticleId IdType="pubmed">25152362</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152336</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1095-564X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Developmental biology</Title>
                <ISOAbbreviation>Dev. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Compartment-dependent activities of Wnt3a/??-catenin signaling during vertebrate axial extension.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0012-1606(14)00403-5</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.ydbio.2014.08.012</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Extension of the vertebrate body results from the concerted activity of many signals in the posterior embryonic end. Among them, Wnt3a has been shown to play relevant roles in the regulation of axial progenitor activity, mesoderm formation and somitogenesis. However, its impact on axial growth remains to be fully understood. Using a transgenic approach in the mouse, we found that the effect of Wnt3a signaling varies depending on the target tissue. High levels of Wnt3a in the epiblast prevented formation of neural tissues, but did not impair axial progenitors from producing different mesodermal lineages. These mesodermal tissues maintained a remarkable degree of organization, even within a severely malformed embryo. However, from the cells that failed to take a neural fate, only those that left the epithelial layer of the epiblast activated a mesodermal program. The remaining tissue accumulated as a folded epithelium that kept some epiblast-like characteristics. Together with previously published observations, our results suggest a dose-dependent role for Wnt3a in regulating the balance between renewal and selection of differentiation fates of axial progenitors in the epiblast. In the paraxial mesoderm, appropriate regulation of Wnt/??-catenin signaling was required not only for somitogenesis, but also for providing proper anterior-posterior polarity to the somites. Both processes seem to rely on mechanisms with different requirements for feedback modulation of Wnt/??-catenin signaling, once segmentation occurred in the presence of high levels of Wnt3a in the presomitic mesoderm, but not after permanent expression of a constitutively active form of ??-catenin. Together, our findings suggest that Wnt3a/??-catenin signaling plays sequential roles during posterior extension, which are strongly dependent on the target tissue. This provides an additional example of how much the functional output of signaling systems depends on the competence of the responding cells.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Jurberg</LastName>
                    <ForeName>Arnon Dias</ForeName>
                    <Initials>AD</Initials>
                    <Affiliation>Instituto Gulbenkian de Ci??ncia. Rua da Quinta Grande 6. 2780-156 Oeiras. Portugal.</Affiliation>
                </Author>
                <Author>
                    <LastName>Aires</LastName>
                    <ForeName>Rita</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Instituto Gulbenkian de Ci??ncia. Rua da Quinta Grande 6. 2780-156 Oeiras. Portugal.</Affiliation>
                </Author>
                <Author>
                    <LastName>N??voa</LastName>
                    <ForeName>Ana</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Instituto Gulbenkian de Ci??ncia. Rua da Quinta Grande 6. 2780-156 Oeiras. Portugal.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rowland</LastName>
                    <ForeName>Jennifer Elizabeth</ForeName>
                    <Initials>JE</Initials>
                    <Affiliation>Instituto Gulbenkian de Ci??ncia. Rua da Quinta Grande 6. 2780-156 Oeiras. Portugal.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mallo</LastName>
                    <ForeName>Mois??s</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Instituto Gulbenkian de Ci??ncia. Rua da Quinta Grande 6. 2780-156 Oeiras. Portugal. Electronic address: mallo@igc.gulbenkian.pt.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Dev Biol</MedlineTA>
            <NlmUniqueID>0372762</NlmUniqueID>
            <ISSNLinking>0012-1606</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Axial progenitors</Keyword>
            <Keyword MajorTopicYN="N">Mouse development</Keyword>
            <Keyword MajorTopicYN="N">Patterning</Keyword>
            <Keyword MajorTopicYN="N">Wnt signaling</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0012-1606(14)00403-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ydbio.2014.08.012</ArticleId>
            <ArticleId IdType="pubmed">25152336</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152335</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-3634</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Seminars in cell &amp; developmental biology</Title>
                <ISOAbbreviation>Semin. Cell Dev. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Activity dependent mechanisms of visual map formation From retinal waves to molecular regulators.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1084-9521(14)00244-4</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.semcdb.2014.08.008</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The refinement of neural connections requires activity-dependent mechanisms in addition to the genetic program initially establishing wiring diagrams. The well-understood organization of the visual system makes it an accessible model for analyzing the contribution of activity in the formation of connectivity. Prior to visual experience, patterned spontaneous activity in the form of retinal waves has an important role for the establishment of eye-specific and retinotopic maps by acting on the refinement of axon arborization. In the present review, which focuses on experimental data obtained in mice and ferrets, we highlight the features of retinal activity that are important for visual map formation and question whether synaptic release and Hebbian based competition rules apply to this system. Recent evidence using genetic tools that allowed the manipulation of different features of neural activity have clarified the controversy on whether activity is instructive or permissive for visual map formation. Furthermore, current evidence strongly suggests that different mechanisms are at play for different types of axons (ipsilateral vs. contralateral), maps (eye-specific vs. retinotopic) or targets. Many molecules that either modulate activity or are modulated by activity are important in the formation of the visual map, such as adenylate cyclase 1, serotonin, or molecules from the immune system. Finally, new players in the game include retrograde messengers signaling from the target cell to the retinal axons as well as microglia that could help to eliminate inappropriate synapses.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Assali</LastName>
                    <ForeName>Ahlem</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>INSERM U839, Institut du Fer ?? Moulin, Paris, France, UPMC, Paris, France. Electronic address: ahlem.assali@inserm.fr.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gaspar</LastName>
                    <ForeName>Patricia</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>INSERM U839, Institut du Fer ?? Moulin, Paris, France, UPMC, Paris, France. Electronic address: patricia.gaspar@inserm.fr.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rebsam</LastName>
                    <ForeName>Alexandra</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>INSERM U839, Institut du Fer ?? Moulin, Paris, France, UPMC, Paris, France. Electronic address: alexandra.rebsam@inserm.fr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>REVIEW</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Semin Cell Dev Biol</MedlineTA>
            <NlmUniqueID>9607332</NlmUniqueID>
            <ISSNLinking>1084-9521</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Activity</Keyword>
            <Keyword MajorTopicYN="N">Contralateral</Keyword>
            <Keyword MajorTopicYN="N">Development</Keyword>
            <Keyword MajorTopicYN="N">Ipsilateral</Keyword>
            <Keyword MajorTopicYN="N">Retinocollicular</Keyword>
            <Keyword MajorTopicYN="N">Retinogeniculate</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1084-9521(14)00244-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.semcdb.2014.08.008</ArticleId>
            <ArticleId IdType="pubmed">25152335</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152329</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-6351</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association</Title>
                <ISOAbbreviation>Food Chem. Toxicol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Role of Nrf2 activation and NF-??B inhibition in valproic acid induced hepatotoxicity and in diammonium glycyrrhizinate induced protection in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0278-6915(14)00381-0</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.fct.2014.08.009</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Diammonium glycyrrhizinate (DG), an active compound extracted and purified from liquorices root, has been reported to exhibit antioxidant and anti-inflammatory properties. The aim of this study was to investigate the effect and underlying mechanisms of DG on the hepatotoxicity induced by valproic acid (VPA). DG at the dose of 60 mg/kg was orally administered with VPA (100 mg/kg) to mice once daily for 14 consecutive days. DG treatment attenuated VPA-induced liver dysfunction, structural damage, glutathione depletion and decrease in antioxidant enzymes in BALB/C mice. DG prevented VPA-induced depletion of cytosolic nuclear factor E2-related factor 2 (Nrf2) and suppression of nuclear translocation of Nrf2, which, in turn, up-regulated phase II/antioxidant enzyme activities. The effects of VPA and DG on Nrf2 expression in HepG2 cells were in consistent with that of mice. Furthermore, an increase in the nuclear levels of nuclear factor-kappaB (NF-??B) was observed in the livers of VPA-treated mice that coincided with induction of inflammatory cytokines. In contrast, DG inhibited NF-??B translocation and that subsequently decreased inflammatory cytokines. Taken together, these results demonstrate that DG attenuates VPA-induced liver injury through increasing the expression of Nrf2 mediated phase II/antioxidant enzymes and simultaneously decreasing the expression of inflammatory mediators.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Jin</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, PR China. Electronic address: jinjing@mail.sysu.edu.cn.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xiong</LastName>
                    <ForeName>Tianqin</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>School of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou, 510006, P.R. China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hou</LastName>
                    <ForeName>Xiangyu</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sun</LastName>
                    <ForeName>Xiaozhe</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liao</LastName>
                    <ForeName>Jiayi</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>School of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou, 510006, P.R. China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Zhiying</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhao</LastName>
                    <ForeName>Zhongxiang</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>School of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou, 510006, P.R. China. Electronic address: zzx37@163.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Food Chem Toxicol</MedlineTA>
            <NlmUniqueID>8207483</NlmUniqueID>
            <ISSNLinking>0278-6915</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cytokines</Keyword>
            <Keyword MajorTopicYN="N">Diammonium glycyrrhizinate</Keyword>
            <Keyword MajorTopicYN="N">Hepatotoxicity</Keyword>
            <Keyword MajorTopicYN="N">NF-??B</Keyword>
            <Keyword MajorTopicYN="N">Nrf2</Keyword>
            <Keyword MajorTopicYN="N">Valproic acid</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0278-6915(14)00381-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.fct.2014.08.009</ArticleId>
            <ArticleId IdType="pubmed">25152329</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152324</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1878-1810</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Translational research : the journal of laboratory and clinical medicine</Title>
                <ISOAbbreviation>Transl Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhibition of the nucleotide-binding domain, leucine-rich containing family, pyrin-domain containing 3 inflammasome reduces the severity of experimentally induced acute pancreatitis in obese mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1931-5244(14)00278-3</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.trsl.2014.06.012</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Acute pancreatitis (AP), although most often a mild and self-limiting inflammatory disease, worsens to a characteristically necrotic severe acute pancreatitis (SAP) in about 20% of cases. Obesity, affecting more than one-third of American adults, is a risk factor for the development of SAP, but the exact mechanism of this association has not been identified. Coincidental with chronic low-grade inflammation, activation of the nucleotide-binding domain, leucine-rich containing family, pyrin-domain containing 3 (NLRP3) inflammasome increases with obesity. Lean mice genetically deficient in specific components of the NLRP3 inflammasome are protected from experimentally induced AP, indicating a direct involvement of this pathway in AP pathophysiology. We hypothesized that inhibition of the NLRP3 inflammasome with the sulfonylurea drug glyburide would reduce disease severity in obese mice with cerulein-induced SAP. Treatment with glyburide led to significantly reduced relative pancreatic mass and water content and less pancreatic damage and cell death in genetically obese ob/ob mice with SAP compared with vehicle-treated obese SAP mice. Glyburide administration in ob/ob mice with cerulein-induced SAP also resulted in significantly reduced serum levels of interleukin 6, lipase, and amylase and led to lower production of lipopolysaccharide-stimulated interleukin 1?? release in cultured peritoneal cells, compared with vehicle-treated ob/ob mice with SAP. Together, these data indicate involvement of the NLRP3 inflammasome in obesity-associated SAP and expose the possible utility of its inhibition in prevention or treatment of SAP in obese individuals.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Mosby, Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>York</LastName>
                    <ForeName>Jason M</ForeName>
                    <Initials>JM</Initials>
                    <Affiliation>Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, Ill. Electronic address: jmyork@uic.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Castellanos</LastName>
                    <ForeName>Karla J</ForeName>
                    <Initials>KJ</Initials>
                    <Affiliation>Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, Ill.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cabay</LastName>
                    <ForeName>Robert J</ForeName>
                    <Initials>RJ</Initials>
                    <Affiliation>Department of Pathology, University of Illinois at Chicago, Chicago, Ill.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fantuzzi</LastName>
                    <ForeName>Giamila</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, Ill.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Transl Res</MedlineTA>
            <NlmUniqueID>101280339</NlmUniqueID>
            <ISSNLinking>1878-1810</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1931-5244(14)00278-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.trsl.2014.06.012</ArticleId>
            <ArticleId IdType="pubmed">25152324</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152321</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1878-5646</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Vision research</Title>
                <ISOAbbreviation>Vision Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmacological inhibitions of glutamate transporters EAAT1 and EAAT2 compromise glutamate transport in photoreceptor to ON-bipolar cell synapses.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0042-6989(14)00181-3</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.visres.2014.07.020</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">To maintain reliable signal transmission across a synapse, free synaptic neurotransmitters must be removed from the cleft in a timely manner. In the first visual synapse, this critical task is mainly undertaken by glutamate transporters (EAATs). Here we study the differential roles of the EAAT1, EAAT2 and EAAT5 subtypes in glutamate (GLU) uptake at the photoreceptor-to-depolarizing bipolar cell synapse in intact dark-adapted retina. Various doses of EAAT blockers and/or GLU were injected into the eye before the electroretinogram (ERG) was measured. Their effectiveness and potency in inhibiting the ERG b-wave were studied to determine their relative contributions to the GLU clearing activity at the synapse. The results showed that EAAT1 and EAAT2 plays different roles. Selectively blocking glial EAAT1 alone using UCPH101 inhibited the b-wave 2-24 hours following injection, suggesting a dominating role of EAAT1 in the overall GLU clearing capacity in the synaptic cleft. Selectively blocking EAAT2 on photoreceptor terminals had no significant effect on the b-wave, but increased the potency of exogenous GLU in inhibiting the b-wave. These suggest that EAAT2 play a secondary yet significant role in the GLU reuptake activity at the rod and the cone output synapses. Additionally, we have verified our electrophysiological findings with double-label immunohistochemistry, and extend the literature on the spatial distribution of EAAT2 splice variants in the mouse retina.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Tse</LastName>
                    <ForeName>Dennis Y</ForeName>
                    <Initials>DY</Initials>
                    <Affiliation>Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA. Electronic address: ytse@bcm.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chung</LastName>
                    <ForeName>Inyoung</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA; Department of Ophthalmology, Gyeongsang National University, Jinju, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Samuel M</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Vision Res</MedlineTA>
            <NlmUniqueID>0417402</NlmUniqueID>
            <ISSNLinking>0042-6989</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">EAAT1</Keyword>
            <Keyword MajorTopicYN="N">EAAT2</Keyword>
            <Keyword MajorTopicYN="N">Electroretinogram</Keyword>
            <Keyword MajorTopicYN="N">GLT1</Keyword>
            <Keyword MajorTopicYN="N">Immunohistochemistry</Keyword>
            <Keyword MajorTopicYN="N">Retina</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0042-6989(14)00181-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.visres.2014.07.020</ArticleId>
            <ArticleId IdType="pubmed">25152321</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152298</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7573</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of ethnopharmacology</Title>
                <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Antidepressant-like effect of Butea superba in mice exposed to chronic mild stress and its possible mechanism of action.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0378-8741(14)00608-4</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jep.2014.08.014</ELocationID>
            <Abstract>
                <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Butea superba (BS) is a Thai medicinal plant that has been used as a folk medicine to improve physical and mental conditions and to prevent impaired sexual performance in middle-aged or elderly males. We have previously reported that this plant extract could improve cognitive deficits and depression-like behavior in olfactory bulbectomized mice, an animal model of dementia and depression.</AbstractText>
                <AbstractText Label="AIM OF THE STUDY" NlmCategory="OBJECTIVE">In this study we examined the effect of BS on depression-like behavior in mice subjected to unpredictable chronic mild stress (UCMS) to clarify the antidepressant-like activity of BS and the molecular mechanism underlying this effect.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">UCMS mice were administered BS daily (300mg of dried herb weight/kg, p.o.) or a reference drug, imipramine (IMP, 10mg/kg, i.p.), 1 week after starting the UCMS procedure. We employed the sucrose preference test and the tail suspension test to analyze anhedonia and depression-like behavior of mice, respectively. Serum and brain tissues of mice were used for neurochemical and immunohistochemical studies. The UCMS procedure induced anhedonia and depression-like behavior, and BS treatment, as well as IMP treatment, attenuated these symptoms. UCMS caused an elevation of serum corticosterone level, an index of hyper-activation of the hypothalamic-pituitary-adrenal (HPA) axis, in a manner attenuated by BS and IMP treatment. BS treatment also attenuated UCMS-induced decrease in the expression levels of brain-derived neurotrophic factor (BDNF) mRNA, cyclic AMP-responsive element binding protein (CREB) and a phosphorylated form of N-methyl-D-aspartate receptor subunit NR1, synaptic plasticity-related signaling proteins. Moreover, the UCMS procedure reduced doublecortin-positive cells in the dentate gyrus region of the hippocampus. BS administration reversed these UCMS-induced neurochemical and histological abnormalities.</AbstractText>
                <AbstractText Label="CONCLUSION:" NlmCategory="UNASSIGNED">These results suggest that BS can ameliorate chronic stress-induced depression-like symptoms and that the effects of BS are mediated by restoring dysfunctions of the HPA axis and synaptic plasticity-related signaling systems and neurogenesis in the hippocampus.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ireland Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Mizuki</LastName>
                    <ForeName>Daishu</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Matsumoto</LastName>
                    <ForeName>Kinzo</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194, Japan. Electronic address: mkinzo@inm.u-toyama.ac.jp.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tanaka</LastName>
                    <ForeName>Ken</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Le Thi</LastName>
                    <ForeName>Xoan</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fujiwara</LastName>
                    <ForeName>Hironori</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ishikawa</LastName>
                    <ForeName>Tsutomu</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Graduate School of Pharmaceutical Sciences, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba 260-8675, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Higuchi</LastName>
                    <ForeName>Yoshihiro</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Material Development Laboratories, Shiratori Pharmaceutical Co. Ltd., 6-11-24 Tsudanuma, Narashino, Chiba 275-0016, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Ethnopharmacol</MedlineTA>
            <NlmUniqueID>7903310</NlmUniqueID>
            <ISSNLinking>0378-8741</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Butea superb</Keyword>
            <Keyword MajorTopicYN="N">Depression-like symptoms</Keyword>
            <Keyword MajorTopicYN="N">Neurogenesis</Keyword>
            <Keyword MajorTopicYN="N">Synaptic plasticity-related signaling</Keyword>
            <Keyword MajorTopicYN="N">Unpredictable chronic mild stress</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0378-8741(14)00608-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jep.2014.08.014</ArticleId>
            <ArticleId IdType="pubmed">25152298</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152242</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-3072</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Tissue &amp; cell</Title>
                <ISOAbbreviation>Tissue Cell</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Immunohistochemical localization of Nox1, Nox4 and Mn-SOD in mouse femur during endochondral ossification.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0040-8166(14)00069-X</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.tice.2014.07.005</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Enzymes synthesizing reactive oxygen (Nox family) have recently been identified. Elucidation of the production mechanism has been initiated, and the involvement of reactive oxygen in metabolism, intracellular transport, signal transmission and apoptosis has been reported. We immunohistochemically investigated expression and localization of the Nox family in endochondral ossification using a normal mouse femur. Weakly positive reactions with Nox1, Noxa1, and Noxo1 were observed in the zones of proliferative and prehypertrophic chondrocytes at 3 weeks of age. Nox4 was widely positive from the resting over the hypertrophic cell zone. At 18 weeks of age, none of the Nox types was expressed in chondrocytes as the zones disappeared. On the other hand, positive reactions with Nox1, Noxa1, Noxo1, and Nox4 were observed in osteoblasts in the zone of ossification at 3 weeks of age, and each Nox was also positive in osteoblasts arranged on the bone marrow side in the epiphyseal cartilage at 18 weeks of age. In addition, a reactive oxygen-eliminating enzyme, Mn-SOD, was observed only in prehypertrophic chondrocytes at 3 weeks of age, and not detected in osteoblasts. It was suggested that the Nox family is closely associated with endochondral ossification of the mouse femur, and Nox1 and Nox4 are closely involved in the chondrocyte maturation process and bone matrix formation.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ambe</LastName>
                    <ForeName>Kimiharu</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Division of Oral Histology, Department of Morphological Biology, Ohu University School of Dentistry, Japan. Electronic address: k-ambe@den.ohu-u.ac.jp.</Affiliation>
                </Author>
                <Author>
                    <LastName>Watanabe</LastName>
                    <ForeName>Hiroki</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Division of Oral Histology, Department of Morphological Biology, Ohu University School of Dentistry, Japan. Electronic address: hi-watanabe@den.ohu-u.ac.jp.</Affiliation>
                </Author>
                <Author>
                    <LastName>Takahashi</LastName>
                    <ForeName>Shinya</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Oral and Maxillofacial Surgery, Ohu University School of Dentistry, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nakagawa</LastName>
                    <ForeName>Toshihiro</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Division of Oral Histology, Department of Morphological Biology, Ohu University School of Dentistry, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>1</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Tissue Cell</MedlineTA>
            <NlmUniqueID>0214745</NlmUniqueID>
            <ISSNLinking>0040-8166</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Endochondral ossification</Keyword>
            <Keyword MajorTopicYN="N">Mn-SOD</Keyword>
            <Keyword MajorTopicYN="N">NADPH oxidase</Keyword>
            <Keyword MajorTopicYN="N">Nox1</Keyword>
            <Keyword MajorTopicYN="N">Nox4</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0040-8166(14)00069-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.tice.2014.07.005</ArticleId>
            <ArticleId IdType="pubmed">25152242</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152235</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-4596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Free radical biology &amp; medicine</Title>
                <ISOAbbreviation>Free Radic. Biol. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>ROS-dependent Syk and Pyk2-mediated STAT1 activation is required for 15(S)-Hydroxyeicosatetraenoic acid-induced CD36 expression and foam cell formation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0891-5849(14)00383-9</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.freeradbiomed.2014.08.007</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">15(S)-Hydroxyeicosatetraenoic acid (15(S)-HETE), the major 15-lipoxygenase 1/2 (15-LO1/2) metabolite of arachidonic acid (AA), induces CD36 expression through xanthine oxidase and NADPH oxidase-dependent ROS production and Syk and Pyk2-dependent STAT1 activation. In line with these observations, 15(S)-HETE also induced foam cell formation involving ROS, Syk, Pyk2 and STAT1-mediated CD36 expression. In addition, peritoneal macrophages from Western diet-fed ApoE(-/-) mice exhibited elevated levels of xanthine oxidase and NADPH oxidase activities, ROS production, Syk, Pyk2, and STAT1 phosphorylation and CD36 expression compared to those from ApoE(-/-):12/15-LO(-/-) mice and these events correlated with increased lipid deposits, macrophage content and lesion progression in the aortic roots. Human atherosclerotic arteries also showed increased 15-LO1 expression, STAT1 phosphorylation and CD36 levels as compared to normal arteries. Together, these findings suggest that 12/15-LO metabolites of AA, particularly 12/15(S)-HETE might play a crucial role in atherogenesis by enhancing foam cell formation.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kotla</LastName>
                    <ForeName>Sivareddy</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Physiology, University of Tennessee Health Science Center, 894 Union Avenue, Memphis, TN 38163, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Singh</LastName>
                    <ForeName>Nikhlesh K</ForeName>
                    <Initials>NK</Initials>
                    <Affiliation>Department of Physiology, University of Tennessee Health Science Center, 894 Union Avenue, Memphis, TN 38163, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Traylor</LastName>
                    <ForeName>James G</ForeName>
                    <Initials>JG</Initials>
                    <Suffix>Jr</Suffix>
                    <Affiliation>Department of Pathology, Louisiana State University Health Science Center, 1501 King's Hwy, Shreveport, LA 71130, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Orr</LastName>
                    <ForeName>A Wayne</ForeName>
                    <Initials>AW</Initials>
                    <Affiliation>Department of Pathology, Louisiana State University Health Science Center, 1501 King's Hwy, Shreveport, LA 71130, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rao</LastName>
                    <ForeName>Gadiparthi N</ForeName>
                    <Initials>GN</Initials>
                    <Affiliation>Department of Physiology, University of Tennessee Health Science Center, 894 Union Avenue, Memphis, TN 38163, USA. Electronic address: rgadipar@uthsc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Free Radic Biol Med</MedlineTA>
            <NlmUniqueID>8709159</NlmUniqueID>
            <ISSNLinking>0891-5849</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CD36</Keyword>
            <Keyword MajorTopicYN="N">FOAM CELL</Keyword>
            <Keyword MajorTopicYN="N">ROS</Keyword>
            <Keyword MajorTopicYN="N">STAT1</Keyword>
            <Keyword MajorTopicYN="N">SYK</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0891-5849(14)00383-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.08.007</ArticleId>
            <ArticleId IdType="pubmed">25152235</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152234</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-4596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Free radical biology &amp; medicine</Title>
                <ISOAbbreviation>Free Radic. Biol. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Isotope Dilution Mass Spectrometry for the Quantification of Sulfane Sulfurs.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0891-5849(14)00377-3</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.freeradbiomed.2014.08.003</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Sulfane sulfurs are one type of important reactive sulfur species. These molecules have unique reactivity that can attach reversibly to other sulfur atoms and exhibit regulatory effects in diverse biological systems. Recent studies have suggested that sulfane sulfurs are involved in signal transduction processes regulated by hydrogen sulfide (H2S). Accurate and reliable measurements of sulfane sulfurs in biological samples are thus needed to reveal their production and mechanisms of actions. Herein we report a convenient and accurate method for the determination of sulfane sulfurs concentrations. The method employs a triphenylphosphine derivative (P2) to capture sulfane sulfurs as a stable phosphine sulphide product PS2. The concentration of PS2 was then determined by isotope dilution mass spectrometry, using a (13)C3-labelled phosphine sulfide PS1 as the internal standard. The specificity and efficiency of the method were proved by model reactions. It was also applied in the measurement of sulfane sulfurs in mice tissues including brain, kidney, lung, liver, heart, spleen, and blood.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Chunrong</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Chemistry, Washington State University, Pullman, WA 99164, USA; Research Institute of Science and Technology, Central China Normal University, Wuhan, 430079, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Faya</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences, Washington State University, Pullman, WA 99164, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Munske</LastName>
                    <ForeName>Gerhard</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Center for Reproductive Biology Molecular Biology and Genomics Core, Washington State University, Pullman, WA 99164, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Hui</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences, Washington State University, Pullman, WA 99164, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xian</LastName>
                    <ForeName>Ming</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Chemistry, Washington State University, Pullman, WA 99164, USA. Electronic address: mxian@wsu.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Free Radic Biol Med</MedlineTA>
            <NlmUniqueID>8709159</NlmUniqueID>
            <ISSNLinking>0891-5849</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Isotope dilution assay</Keyword>
            <Keyword MajorTopicYN="N">Mass</Keyword>
            <Keyword MajorTopicYN="N">Reactive sulfur species</Keyword>
            <Keyword MajorTopicYN="N">Sulfane sulfur</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0891-5849(14)00377-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.08.003</ArticleId>
            <ArticleId IdType="pubmed">25152234</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152233</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1367-4811</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Bioinformatics (Oxford, England)</Title>
                <ISOAbbreviation>Bioinformatics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>ExpTreeDB: web-based query and visualization of manually annotated gene expression profiling experiments of human and mouse from GEO.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">btu560</ELocationID>
            <Abstract>
                <AbstractText Label="MOTIVATION" NlmCategory="BACKGROUND">Numerous public microarray datasets are valuable resources for the scientific communities. Several online tools have made great steps to utilize these data by querying related datasets with users' own gene signatures or expression profiles. However, dataset annotation and result exhibition still need to be improved.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">ExpTreeDB is a database that allows for queries on human and mouse microarray experiments from Gene Expression Omnibus with gene signatures or profiles. Compared with similar applications, ExpTreeDB pays more attention to dataset annotations and result visualization. We introduced a multiple-level annotation system to depict and organize original experiments. For example, a tamoxifen-treated cell line experiment is hierarchically annotated as &quot;agent???drug???estrogen receptor antagonist???tamoxifen&quot;. Consequently, retrieved results are exhibited by an interactive tree-structured graphics, which provides an overview for related experiments and might enlighten users on key items of interest. Availability and implementation: The database is freely available at http://biotech.bmi.ac.cn/ExpTreeDB. Website is implemented in Perl, PHP, R, MySQL and Apache.</AbstractText>
                <AbstractText Label="CONTACT" NlmCategory="BACKGROUND">boxc@bmi.ac.cn SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.</AbstractText>
                <CopyrightInformation>?? The Author (2014). Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ni</LastName>
                    <ForeName>Ming</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Beijing Institute of Radiation Medicine, Beijing 100850, China, College of Life Sciences, Jilin University, Changchun 130012, China and Zhejiang University City Collage, Hangzhou 310015, China ni.ming@163.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ye</LastName>
                    <ForeName>Fuqiang</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Beijing Institute of Radiation Medicine, Beijing 100850, China, College of Life Sciences, Jilin University, Changchun 130012, China and Zhejiang University City Collage, Hangzhou 310015, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhu</LastName>
                    <ForeName>Juanjuan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Beijing Institute of Radiation Medicine, Beijing 100850, China, College of Life Sciences, Jilin University, Changchun 130012, China and Zhejiang University City Collage, Hangzhou 310015, China Beijing Institute of Radiation Medicine, Beijing 100850, China, College of Life Sciences, Jilin University, Changchun 130012, China and Zhejiang University City Collage, Hangzhou 310015, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Zongwei</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Beijing Institute of Radiation Medicine, Beijing 100850, China, College of Life Sciences, Jilin University, Changchun 130012, China and Zhejiang University City Collage, Hangzhou 310015, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Shuai</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Beijing Institute of Radiation Medicine, Beijing 100850, China, College of Life Sciences, Jilin University, Changchun 130012, China and Zhejiang University City Collage, Hangzhou 310015, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Bite</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Beijing Institute of Radiation Medicine, Beijing 100850, China, College of Life Sciences, Jilin University, Changchun 130012, China and Zhejiang University City Collage, Hangzhou 310015, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Han</LastName>
                    <ForeName>Lu</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Beijing Institute of Radiation Medicine, Beijing 100850, China, College of Life Sciences, Jilin University, Changchun 130012, China and Zhejiang University City Collage, Hangzhou 310015, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Yongge</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Beijing Institute of Radiation Medicine, Beijing 100850, China, College of Life Sciences, Jilin University, Changchun 130012, China and Zhejiang University City Collage, Hangzhou 310015, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Beijing Institute of Radiation Medicine, Beijing 100850, China, College of Life Sciences, Jilin University, Changchun 130012, China and Zhejiang University City Collage, Hangzhou 310015, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Fei</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Beijing Institute of Radiation Medicine, Beijing 100850, China, College of Life Sciences, Jilin University, Changchun 130012, China and Zhejiang University City Collage, Hangzhou 310015, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Shengqi</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Beijing Institute of Radiation Medicine, Beijing 100850, China, College of Life Sciences, Jilin University, Changchun 130012, China and Zhejiang University City Collage, Hangzhou 310015, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bo</LastName>
                    <ForeName>Xiaochen</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Beijing Institute of Radiation Medicine, Beijing 100850, China, College of Life Sciences, Jilin University, Changchun 130012, China and Zhejiang University City Collage, Hangzhou 310015, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Bioinformatics</MedlineTA>
            <NlmUniqueID>9808944</NlmUniqueID>
            <ISSNLinking>1367-4803</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">btu560</ArticleId>
            <ArticleId IdType="doi">10.1093/bioinformatics/btu560</ArticleId>
            <ArticleId IdType="pubmed">25152233</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152231</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1367-4811</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Bioinformatics (Oxford, England)</Title>
                <ISOAbbreviation>Bioinformatics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inter-species Inference of Gene Set Enrichment in Lung Epithelial Cells from Proteomic and Large Transcriptomic Data Sets.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">btu569</ELocationID>
            <Abstract>
                <AbstractText Label="MOTIVATION" NlmCategory="BACKGROUND">Translating findings in rodent models to humans has been a corner-stone of modern biology and drug development. However, in many cases a naive 'extrapolation' between the two species has not succeeded. As a result, clinical trials of new drugs sometimes fail even after considerable success in the mouse or rat stage of development. In addition to in-vitro studies, inter-species translation requires analytical tools that can predict the enriched gene sets in human cells under various stimuli from corresponding measurements in animals. Such tools can improve our understanding of the underlying biology and optimize the allocation of resources for drug development.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We developed an algorithm to predict differential gene set enrichment as part of the sbv IMPROVER Species Translation Challenge, which focused on phosphoproteomic and transcriptomic measurements of normal human bronchial epithelial (NHBE) primary cells under various stimuli and corresponding measurements in rat (NRBE) primary cells. We find that gene sets exhibit a higher inter-species correlation compared with individual genes, and are potentially more suited for direct prediction. Furthermore, in contrast to a similar cross-species response in protein phosphorylation states five and twenty-five minutes after exposure to stimuli, gene set enrichment 6 hours after exposure is significantly different in NHBE cells compared to NRBE cells. In spite of this difference, we were able to develop a robust algorithm to predict gene set activation in NHBE with high accuracy using simple analytical methods.</AbstractText>
                <AbstractText Label="AVAILABILITY" NlmCategory="BACKGROUND">Implementation of all algorithms are available as source code (in Matlab) at http://bhanot.biomaps.rutgers.edu/wiki/codes_SC3_Predicting_GeneSets.zip, along with the relevant data used in the analysis. Gene sets, gene expression and protein phosphorylation data is available upon request.</AbstractText>
                <AbstractText Label="CONTACT" NlmCategory="BACKGROUND">hormoz@kitp.ucsb.edu.</AbstractText>
                <CopyrightInformation>?? The Author(s) 2014. Published by Oxford University Press.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hormoz</LastName>
                    <ForeName>Sahand</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Kavli Institute for Theoretical Physics, Kohn Hall, University of California, Santa Barbara, CA 93106, USA hormoz@kitp.ucsb.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bhanot</LastName>
                    <ForeName>Gyan</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Physics and Department of Molecular Biology and Biochemistry, Busch Campus, Rutgers University, Piscataway, NJ 08854, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Biehl</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Johann Bernoulli Institute for Mathematics and Computer Science, University of Groningen, 9700 AK Groningen, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bilal</LastName>
                    <ForeName>Erhan</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>IBM T.J. Watson Research Center, Computational Biology, Yorktown Heights, NY 10003, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Meyer</LastName>
                    <ForeName>Pablo</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>IBM T.J. Watson Research Center, Computational Biology, Yorktown Heights, NY 10003, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Norel</LastName>
                    <ForeName>Raquel</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>IBM T.J. Watson Research Center, Computational Biology, Yorktown Heights, NY 10003, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rhrissorrakrai</LastName>
                    <ForeName>Kahn</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>IBM T.J. Watson Research Center, Computational Biology, Yorktown Heights, NY 10003, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dayarian</LastName>
                    <ForeName>Adel</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Kavli Institute for Theoretical Physics, Kohn Hall, University of California, Santa Barbara, CA 93106, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Bioinformatics</MedlineTA>
            <NlmUniqueID>9808944</NlmUniqueID>
            <ISSNLinking>1367-4803</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">btu569</ArticleId>
            <ArticleId IdType="doi">10.1093/bioinformatics/btu569</ArticleId>
            <ArticleId IdType="pubmed">25152231</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152212</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-3441</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</Title>
                <ISOAbbreviation>Eur J Pharm Biopharm</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sol-Gel transition of nanoparticles/polymer mixtures for sustained delivery of exenatide to treat type 2 diabetes mellitus.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0939-6411(14)00245-8</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.ejpb.2014.08.004</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The sol-gel transition of nanoparticles (NPs)/polymer mixture in aqueous medium was investigated for the sustained delivery of exenatide to treat type 2 diabetes mellitus. Exenatide-loaded multilayer NPs were prepared using a layer-by-layer approach which utilized the interaction between Pluronics and lipid bilayers as the main driving force for the construction of the multilayer. Pluronic F-127 was the polymer used, and it forms a gel at body temperature. Although the antidiabetic effects of exenatide-loaded multilayer NPs have been demonstrated previously in an animal model, in this work, the attempt was made to demonstrate the extended duration of antidiabetic effects, which was accomplished by localizing the exenatide-loaded NPs in muscular areas in the body through the gelation of Pluronic F-127. Transmittance electron microscopy and dynamic light scattering were used to examine the morphology of the multilayer NPs/polymer mixture. A change in the release pattern of exenatide was observed after gel formation at body temperature, and Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis was performed using native exenatide and a reference biomarker as control to observe whether exenatide extracted from the multilayer NPs and the multilayer NPs/Pluronic F-127 mixture degraded or not. We then observed the antidiabetic effect of exenatide-loaded multilayer NPs/Pluronic F-127 mixture by monitoring blood-glucose levels in db/db mice. In vitro and in vivo correlation was discussed regarding structural variation in the delivery vehicles.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Oh</LastName>
                    <ForeName>Keun Sang</ForeName>
                    <Initials>KS</Initials>
                    <Affiliation>College of Pharmacy, Korea University, 2511 Sejongro, Sejong 339-700, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Jae Yeon</ForeName>
                    <Initials>JY</Initials>
                    <Affiliation>College of Pharmacy, Korea University, 2511 Sejongro, Sejong 339-700, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yoon</LastName>
                    <ForeName>Byeong Deok</ForeName>
                    <Initials>BD</Initials>
                    <Affiliation>College of Pharmacy, Korea University, 2511 Sejongro, Sejong 339-700, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Minae</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>College of Pharmacy, Korea University, 2511 Sejongro, Sejong 339-700, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Heejoo</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>College of Pharmacy, Korea University, 2511 Sejongro, Sejong 339-700, Republic of Korea; Department of Physiology, McGill University 845 Rue Sherbrooke Ouest, Montreal, QC H3A 0G4, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Michelle</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>College of Pharmacy, Korea University, 2511 Sejongro, Sejong 339-700, Republic of Korea; Department of Biology, University of Washington, P.O. Box 351800, Seattle, WA 98195, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Seo</LastName>
                    <ForeName>Jae Hong</ForeName>
                    <Initials>JH</Initials>
                    <Affiliation>Biomedical Research Center, Korea University Guro Hospital, 148-1 Gurodong-ro, Guro-gu, Seoul 152-703, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yuk</LastName>
                    <ForeName>Soon Hong</ForeName>
                    <Initials>SH</Initials>
                    <Affiliation>College of Pharmacy, Korea University, 2511 Sejongro, Sejong 339-700, Republic of Korea; Biomedical Research Center, Korea University Guro Hospital, 148-1 Gurodong-ro, Guro-gu, Seoul 152-703, Republic of Korea. Electronic address: shyuk@korea.ac.kr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Eur J Pharm Biopharm</MedlineTA>
            <NlmUniqueID>9109778</NlmUniqueID>
            <ISSNLinking>0939-6411</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Exenatide</Keyword>
            <Keyword MajorTopicYN="N">Nanoparticles/polymer mixture</Keyword>
            <Keyword MajorTopicYN="N">Sol-gel transition</Keyword>
            <Keyword MajorTopicYN="N">Sustained delivery</Keyword>
            <Keyword MajorTopicYN="N">Type 2 diabetes mellitus</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0939-6411(14)00245-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejpb.2014.08.004</ArticleId>
            <ArticleId IdType="pubmed">25152212</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152205</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1600-0641</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of hepatology</Title>
                <ISOAbbreviation>J. Hepatol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Interferon Regulatory Factor 9 is a Key Mediator of Hepatic Ischemia/Reperfusion Injury.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0168-8278(14)00608-4</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jhep.2014.08.022</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">Hepatic ischemia/reperfusion (I/R) injury is characterised by anoxic cell injury and the generation of inflammatory mediators, leading to hepatic parenchymal cell death. The activation of interferon regulatory factors (IRFs) has been implicated in hepatic I/R injury, but the role of IRF9 in this progression is unclear.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We investigated the function and molecular mechanisms of IRF9 in transgene and knockout mice subjected to warm I/R of the liver. Isolated hepatocytes from IRF9 transgene and knockout mice were subjected to hypoxia/reoxygenation (H/R) injury to determine the in vitro effects of IRF9.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The injuries were augmented in IRF9-overexpressing mice that were subjected to warm I/R of the liver. In contrast, a deficiency in IRF9 markedly reduced the necrotic area, serum alanine amino transferase/aspartate amino transferase (ALT/AST), immune cell infiltration, inflammatory cytokine levels, and hepatocyte apoptosis after liver I/R. The sirtuin (SIRT) 1 levels were significantly higher and the acetylation of p53 was decreased in the IRF9 knockout mice. Notably, IRF9 suppressed the activity of the SIRT1 promoter luciferase reporter and deacetylase activity. The liver injuries were significantly more severe in the IRF9/SIRT1 double knockout (DKO) mice in the I/R model, eliminating the protective effects observed in the IRF9 knockout mice.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">IRF9 has a novel function of inducing hepatocyte apoptosis after I/R injury by decreasing SIRT1 expression and increasing acetyl-p53 levels. Targeting IRF9 may be a potential strategy for ameliorating ischemic liver injury after liver surgery.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Pi-Xiao</ForeName>
                    <Initials>PX</Initials>
                    <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Ran</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Ling</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhu</LastName>
                    <ForeName>Li-Hua</ForeName>
                    <Initials>LH</Initials>
                    <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jiang</LastName>
                    <ForeName>Ding-Sheng</ForeName>
                    <Initials>DS</Initials>
                    <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Hou-Zao</ForeName>
                    <Initials>HZ</Initials>
                    <Affiliation>National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tian</LastName>
                    <ForeName>Song</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Xiao-Fei</ForeName>
                    <Initials>XF</Initials>
                    <Affiliation>College of Life Sciences, Wuhan University, Wuhan, 430072, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Xiao-Dong</ForeName>
                    <Initials>XD</Initials>
                    <Affiliation>College of Life Sciences, Wuhan University, Wuhan, 430072, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>De-Pei</ForeName>
                    <Initials>DP</Initials>
                    <Affiliation>National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Hongliang</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China. Electronic address: lihl@whu.edu.cn.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Hepatol</MedlineTA>
            <NlmUniqueID>8503886</NlmUniqueID>
            <ISSNLinking>0168-8278</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Hepatic Injury</Keyword>
            <Keyword MajorTopicYN="N">IRF9</Keyword>
            <Keyword MajorTopicYN="N">Ischemia/Reperfusion</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0168-8278(14)00608-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jhep.2014.08.022</ArticleId>
            <ArticleId IdType="pubmed">25152205</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152168</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-3150</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicon : official journal of the International Society on Toxinology</Title>
                <ISOAbbreviation>Toxicon</ISOAbbreviation>
            </Journal>
            <ArticleTitle>First report of Interruption of mast cell degranulation and endothelial cells activation by anti-inflammatory drugs controlling the acute response provoked by Pseudoplatystoma fasciatum fish venom.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0041-0101(14)00236-0</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.toxicon.2014.08.007</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">This is the first report describing in mice the envenoming that possible to occur in humans provoked by P. fasciatum and evaluated the different class of mediators involved in the inflammatory injury, identifying important targets for drugs intervention. First we demonstrate that P. fasciatum venom induces an acute inflammatory response characterized by the recruitment of immune cells into peripheral tissues choreographed by chemoattractants including lipid mediators (LTB4 and PGE2), cytokines (IL-1?? and TNF-??), and chemokines (KC and MCP-1). Intravital microscopy studies showed that only high dose (60 ??g) of venom promoted hemodynamic changes inducing an abundant number of thrombi of varying sizes in venules leading to transient venular stasis with reduced blood flow. We found that serotonin, leukotrine and prostaglandin are involved in edematogenic and nociceptive responses, since a selective COX-2 inhibitor, a non-specific inhibitor for cytokines and COX-2, and a non-selective 5-HT receptor antagonist were able to reduce both symptoms. In conclusion, our data show that the main symptoms of acute inflammation as pain provoked by P. fasciatum fish venom could be well managed by available drugs as COX-2 inhibitors as well dexamethasone or non-selective 5-HT receptor antagonists.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lopes-Ferreira</LastName>
                    <ForeName>M??nica</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Immunoregulation Unit, Special Laboratory of Applied Toxinology (Cepid/Fapesp), Butantan Institute, S??o Paulo.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gomes</LastName>
                    <ForeName>Eduardo Martins</ForeName>
                    <Initials>EM</Initials>
                    <Affiliation>Immunoregulation Unit, Special Laboratory of Applied Toxinology (Cepid/Fapesp), Butantan Institute, S??o Paulo.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bruni</LastName>
                    <ForeName>Fernanda Miriane</ForeName>
                    <Initials>FM</Initials>
                    <Affiliation>Immunoregulation Unit, Special Laboratory of Applied Toxinology (Cepid/Fapesp), Butantan Institute, S??o Paulo.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ferreira</LastName>
                    <ForeName>Marcio Jose</ForeName>
                    <Initials>MJ</Initials>
                    <Affiliation>Immunoregulation Unit, Special Laboratory of Applied Toxinology (Cepid/Fapesp), Butantan Institute, S??o Paulo.</Affiliation>
                </Author>
                <Author>
                    <LastName>Charvet</LastName>
                    <ForeName>Patr??cia</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>SENAI, Departamento Regional do Paran??, Curitiba, Paran?? - Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lima</LastName>
                    <ForeName>Dr Carla</ForeName>
                    <Initials>DC</Initials>
                    <Affiliation>Immunoregulation Unit, Special Laboratory of Applied Toxinology (Cepid/Fapesp), Butantan Institute, S??o Paulo. Electronic address: carla.lima@butantan.gov.br.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Toxicon</MedlineTA>
            <NlmUniqueID>1307333</NlmUniqueID>
            <ISSNLinking>0041-0101</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Catfish</Keyword>
            <Keyword MajorTopicYN="N">acute inflammatory reaction</Keyword>
            <Keyword MajorTopicYN="N">anti-inflammatory drugs</Keyword>
            <Keyword MajorTopicYN="N">envenomation</Keyword>
            <Keyword MajorTopicYN="N">intravital microscopy</Keyword>
            <Keyword MajorTopicYN="N">thrombus</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0041-0101(14)00236-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.toxicon.2014.08.007</ArticleId>
            <ArticleId IdType="pubmed">25152168</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
